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Don't you remember when you first went to school? You went to kindergarten. And in 
kindergarten, the idea was to push along so that you could get into first grade, and 
then push along so that you could get into second grade, third grade, and so on, 
going up and up. 
And then you went to secondary school and now the pressure was being put on. You 
must get ahead. You must go up the grades and finally be good enough to get to 
university. And then when you got to university, you were still going step by step, step 
by step, up to the great moment in which you were ready to go out into the world. 
And when you finally got out into this famous world, then came the struggle for 
success in profession. And again, there seemed to be a ladder before you, 
something for which you were reaching all the time. 
And then, suddenly, in the middle of your life, you wake up one day and say "huh, 
I've arrived?”. And you feel pretty much the same as you've always felt. In fact you’re 
not so sure that you don't feel a little bit cheated. 
Because, you see, you were fooled. You were always living for somewhere where 
you aren't. And while it is of use for people to be able to look ahead and to plan, there 
is no use in planning for a future, for which when you get to and it becomes the 
present, you won't be there. You'll be living in some other future which hasn't yet 
arrived. 
And so in this way, one would never be able to actually inherit and enjoy the fruits of 
ones actions. 
You can't live at all, 
unless you can live fully now. 
Adapted from Alan Watts (1915 – 1973)
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An introduction to equine sarcoids 
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In the earliest report of an equine sarcoid, the lesion was described as a “locally 
invasive, fibroblastic tumour of skin found in horses, donkeys, and mules” (Jackson, 
1936). While at first this term was used along with other terms to address a broad 
range of tumours of fibroblastic origin, equine sarcoids were gradually acknowledged 
as a separate tumoural entity (Tarwid et al., 1985) and defined as benign, but locally 
aggressive fibroblastic tumours of the equine skin (Ragland, 1970). The occurrence of 
equine sarcoids is limited to the skin and they do not metastasize. They rarely show 
infiltrative growth, and if they do, this is limited to draining lymphoid tissues (Knottenbelt 
et al., 1995). Nevertheless, spread to other body sites due to contact of healthy skin 
with sarcoid tissue is common (Jackson, 1936) and affected horses are likely to have 
multiple tumours. 
The fact that equine sarcoids are considered benign tumours does not mean they don’t 
affect an animals welfare or value. Small sarcoids located at body sites where they 
don’t interfere with movement or riding gear do not cause any problems, but when they 
are larger, ulcerated or ill-located, they can cause serious discomfort or even prevent 
the use of the horse (Taylor and Haldorson, 2013). Because initial sarcoid stages are 
mostly harmless, they are often underdiagnosed or underestimated and are only being 
treated after they have started to grow. As larger tumours have a less favourable 
prognosis (Bergvall, 2013), it is important to gain more insight in the origin, 
development and treatment modalities of equine sarcoids. 
Below, the current knowledge on equine sarcoids is summarized, with an emphasis on 
clinical management. 
Etiopathogenesis 
To date, insights in how and why equine sarcoids develop are limited. Already from 
their first description, it was suggested that a virus could play a role in the development 
of equine sarcoids (Jackson, 1936), and early inoculation experiments in which lesions 
resembling equine sarcoids could be induced in horses by exposing them to cell-free 
extracts from bovine warts (Olson and Cook, 1951) seemed to confirm this suspicion. 
Similar inoculation experiments with more controlled inocula were carried out and 
evidence emerged that the bovine papillomavirus (BPV), which is known to cause 
warts in cattle, could play a causative role in equine sarcoid formation (Ragland and 
Spencer, 1969). Nevertheless, the lesions that were induced in these experiments 
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were not exactly equine sarcoids: while they histologically resembled equine sarcoids, 
they differed from naturally occurring tumours in that they remained limited in size and 
that they regressed spontaneously. Even in the most recent inoculation experiments, 
it was not possible to induce real equine sarcoids by inoculating horses with BPV 
(Hainisch et al., 2009; Hartl et al., 2011). 
After these inoculation experiments had made a strong case for a causative 
relationship between BPV and equine sarcoids, advances in biotechnology helped to 
crystallize this hypothesis. BPV DNA was now being detected in most equine sarcoid 
tissues by DNA-DNA hybridization (Lancaster et al., 1977) and southern blotting 
(Trenfield et al., 1985; Angelos et al., 1991). Polymerase chain reaction (PCR) 
techniques provided even more evidence (Bloch et al., 1994; Teifke et al., 1994) and 
further specified that only viruses of the genus Deltapapilomavirus (BPV type 1 and 2 
(Otten et al., 1993) and to a lesser extent type 13 (Lunardi et al., 2013)) are associated 
with equine sarcoids.  
Of course, the mere presence of BPV DNA in equine sarcoids is no proof of the virus 
actually causing these lesions. Nevertheless, there is evidence of expression of the 
main oncogenes in the majority of equine sarcoids (Nasir and Reid, 1999; Chambers 
et al., 2003b; Bogaert et al., 2007). Further, viral DNA load (ranging from 0.001 to 568.5 
copies per cell) seems to be associated with lesion severity (Haralambus et al., 2010) 
and m-RNA loads are highly correlated with DNA loads, which is an indication for stable 
gene expression in equine sarcoids (Bogaert et al., 2007). 
The non-enveloped BPV consists of nothing more than a capsid containing a circular 
dual strand DNA genome. The genome has a length of a little less than 8000 base 
pairs and consists of 8 open reading frames, containing 6 early genes (E1-E2; E4-E7) 
and 2 late genes (L1 and L2), and a long control region (LCR) which assists in 
replication and transcription (Campo, 2006) (Figure 1). 





Figure 1 - Linear representation of the BPV-1 and BPV-2 genome. Rectangles indicate open reading 
frames. (Campo, 2006) 
 
In cattle, after the virus has infected keratinocytes close to the basal layer through skin 
lacerations, the early genes come to expression first. E1, E2 and E4 regulate 
replication and transcription of the viral DNA, but their exact roles are not well known. 
The LCR is not being transcribed, but offers several binding sites for the E2 protein 
and binding of this protein to the LCR inhibits or promotes transcription of genes. E5, 
E6 and E7 induce transformation of the host cell and are better studied. The E5 protein 
is the main oncoprotein of the virus. When it comes to expression, it interferes with 
intercellular communication by inhibiting gap junctions between cells. By doing this, 
the host cell becomes isolated and cellular growth is no longer inhibited by the normal 
homeostatic processes. Concurrently, the E5 protein inhibits acidification of 
endosomes and by doing so, it causes the host cell to retain and recycle activated 
growth factors. It also directly activates the platelet derived growth factor receptor. 
These processes, combined with the inhibition of receptors for downregulation, results 
in uncontrolled cellular growth and mitosis (Campo, 2006; Venuti et al., 2011). The E6 
protein adds to the cellular transformation process by indirectly inhibiting the function 
of p53, which in normal cells is responsible for cell cycle arrest and apoptosis (Campo, 
2006). Both E5 and E6 are assisted by E7 in exerting their effect, but the exact role of 
E7 is not known (Campo, 2006). The combined effect of E5, E6 and E7 results in a 
fast growing and constantly dividing cell, which on a tissue scale leads to the formation 
of warts. Once an infected cell reaches the more superficial epidermal layers, the late 
genes L1 and L2 come to expression, leading to the formation of a major and minor 
viral capsid protein, respectively. Several copies of these proteins are then joined 
together to form a capsid and infectious viral particles are assembled and released. In 
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most cases, warts are benign and regress after the immune system has cleared the 
infection. 
Contrary to what is known for cattle, the exact mechanism of how BPV leads to the 
formation of equine sarcoids remains to be elucidated. In horses, the virus is mainly 
located in fibroblasts of the dermis (Teifke et al., 1994), although its DNA has also been 
detected in epidermal skin cells (Bogaert et al., 2010; Brandt et al., 2011b). How 
exactly the BPV reaches the dermal layers is unknown, but it seems to be common 
sense that skin lacerations up to the level of the dermis are needed. After infection, 
BPV leads to transformation of fibroblasts (Yuan et al., 2011a) through a largely 
unknown mechanism in which suppression of p53 functionality (Bucher et al., 1996; 
Martens et al., 2001b) and overexpression of p38 seem to play an important role (Yuan 
et al., 2011b). In horses, the viral infection is not cleared by the immune system, which 
is presumably the result of immune-evasion through major histocompatibility complex 
class 1 (called equine leucocyte antigen (ELA) in the horse) inhibition (Marchetti et al., 
2009), downregulation of toll like receptor 4 (Yuan et al., 2010) and an immune-
suppressed cytokine micro-environment (Mählmann et al., 2014; Wilson and Hicks, 
2016). Most researchers agree that equine sarcoid formation is the result of a localized 
infection, where BPV DNA is being confined in intracellular episomes (non-integrated 
DNA that can replicate independently of chromosomal DNA) (Lancaster, 1981), but the 
detection of BPV DNA in equine peripheral blood mononuclear cells (PBMCs) (Brandt 
et al., 2008a) has led to the suggestion that hosts might go through a viraemic phase 
before lesions occur (Brandt et al., 2009). This could be one possible explication for 
the observation that horses tend to have multiple sarcoids on different body sites. While 
expression of L1 and L2 DNA has been observed in some sarcoids (Nasir and Reid, 
1999; Wilson et al., 2013), inoculation of cattle with sarcoid extract failed to induce wart 
formation (Ragland and Spencer, 1969) and BPV infection in equine sarcoids is 
believed to be non-productive. 
Epidemiology 
Equine sarcoids occur in horses, donkeys and even zebra. They are the most common 
of all equine skin tumours, representing up to 90% of them (Scott and Miller, 2011). 
Their true population incidence is hard to estimate, because most reports are based 
on a referral clinic population and therefore biased. Reported incidences range from 




approximately 0.6% (Ragland, 1970; Mohammed et al., 1992) to about 12% (Studer et 
al., 2007). There is no strong evidence for equine sarcoid development being 
associated with demographic parameters, but several studies reveal certain 
tendencies, which are discussed below. 
The reported ages at which sarcoid incidence is the highest vary from 5.8 years to 15 
years (Mohammed et al., 1992; Reid et al., 1994; Torrontegui and Reid, 1994; Schaffer 
et al., 2013; Knowles et al., 2015). Researchers seem to agree that where other 
tumours are more likely to affect primarily older animals, equine sarcoids can occur at 
all ages. Nevertheless, the risk of developing other tumours than equine sarcoids 
increases with age (Knowles et al., 2015) and the risk of equine sarcoid diagnosis 
decreases above the age of 15 years (Mohammed et al., 1992), indicating that sarcoids 
are more likely to develop in relatively young horses. 
Some researchers observed the incidence of equine sarcoids to be significantly higher 
in geldings compared to stallions (Mohammed et al., 1992) and in geldings compared 
to mares (Reid et al., 1994). Others did not find a significant difference in incidence 
between sexes (Torrontegui and Reid, 1994; Schaffer et al., 2013) and this seems to 
be in agreement with what most experts believe (Scott and Miller, 2011). 
Equids of all breeds are susceptible to the development of equine sarcoids (Scott and 
Miller, 2011), but some breed predilections have been observed. Standardbreds were 
found to be less likely to have equine sarcoids than Thoroughbreds, while they in turn 
were less likely to have sarcoids compared to all other breeds (including Appaloosa, 
Quarter and Arabian breeds) (Mohammed et al., 1992). These observations are 
confirmed in another report where Quarter horses were at higher risk of equine sarcoid 
development and Standardbreds at lower risk, compared to Thoroughbreds (Angelos 
et al., 1988). There is no confirmed explanation for these observations, but as there is 
evidence of a certain genetic predisposition for equine sarcoid development, certain 
breeds might be genetically more vulnerable. 
After early observations that equine sarcoids occurred more frequently in certain 
families (Ragland et al., 1966; James, 1968), more specific evidence was discovered 
in support of the existence of a genetic predisposition. The occurrence of sarcoids has 
been associated with different alleles of the ELA gene (Lazary et al., 1985, 1994; 
Meredith et al., 1986; Brostrom, 1995), of which the product is responsible for antigen 
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presentation, an important step in initiating the immune response to (a viral) infection. 
More recently, a whole genome scan of a population of Swiss Warmblood horses 
presented evidence in favour of a polygenic inheritance for equine sarcoid 
susceptibility (Jandova et al., 2012). This suspicion was confirmed on a phenotypic 
level in a heritability study of a population of Franches-Montagnes, in which the 
heritability of equine sarcoids was estimated to be 8% to 21%, depending on the model 
(Christen et al., 2014). 
When all evidence is combined, it becomes clear that equine sarcoids can be 
considered a multifactorial disease in which the BPV is the etiological agent, but for 
which other factors also add to the developmental process. 
Transmission 
While it is now widely accepted that BPV infection is the main cause for equine sarcoid 
development, the question of how this virus, originating from cattle, is being transmitted 
to and possibly between horses, remains to be elucidated. Papillomaviruses are 
usually very species-specific and the BPV is the only member of the family that is 
known to spread and cause disease in other species than its natural host. The most 
evident way for the virus to spread would be by direct contact, but not all horses that 
develop equine sarcoids live together with or have been around cattle. BPV DNA has 
been identified in the surroundings of horses with and without sarcoids (Bogaert et al., 
2005), indicating that indirect transmission could be possible as well. It has been 
proposed by several authors that insects could act as a vector for BPV transmission 
(Knottenbelt and Kelly, 2000; Chambers et al., 2003a). This suspicion became even 
stronger when BPV DNA was detected by PCR in Musca autumnalis (Kemp-Symonds 
and Kirk, 2007) and several other fly species (Finlay et al., 2009) in proximity of 
sarcoid-bearing horses. It remains however unclear whether these findings were 
coincidental or whether flies actually transmit BPV. 
Because no certain proof of infective virus has ever been found in equine sarcoids, 
most authors believe BPV infection to be abortive in equids. Nevertheless, some 
evidence points in the direction of the production of infectious BPV virions in tumoural 
tissue. In an early transmission experiment, researchers were able to induce equine 
sarcoids by inoculating scarified skin of unaffected horses with a sarcoid suspension 
(Voss, 1969). Sarcoid outbreaks in populations of donkeys (Reid et al., 1994; Abel-
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Reichwald et al., 2016) and zebra (Nel et al., 2006) also suggest that infection could 
spread between equids. Of course, if it is assumed that insects act as a vector, these 
outbreaks could possibly also be de novo infections. Moreover, one study could not 
detect intact virion in any of the animals affected by the outbreak (Abel-Reichwald et 
al., 2016). On the other hand, in another study, donkeys were kept in pairs of one 
sarcoid-affected animal and one healthy animal. If healthy animals developed sarcoids, 
the BPV present in the lesions was of the same genotypic variant as the sarcoid 
affected animal in the same stable, but differed from other animal pairs (Nasir and 
Campo, 2008).  Further, as mentioned earlier, L1 and L2 DNA expression have been 
detected in equine sarcoids (Nasir and Reid, 1999; Wilson et al., 2013) and 
immunocapture PCR has demonstrated the presence of BPV DNA in association with 
L1 major capsid protein in equine sarcoids (Brandt et al., 2008b). In addition to this, 
one researcher published an electron microscopic image of a structure that resembles 
an intact BPV virion in an equine sarcoid (Wilson et al., 2013). 
The detection of DNA mutations specific to BPV originating from equine sarcoids 
(Chambers et al., 2003b; Nasir et al., 2007; Wilson et al., 2013; Trewby et al., 2014; 
Savini et al., 2015) is pointing towards another possible theory, in which separate 
strains of BPV exist. On the one hand there would be the wild type BPV originating 
from cattle, and on the other hand there would be an equine adapted strain able to 
produce infectious virions in sarcoids. The effect of these mutant gene sequences on 
viral replication were also tested. Transcriptional activity of virus containing an LCR 
variant was twice as high compared to virus containing the reference LCR in equine 
cells, but not in bovine cells (Nasir et al., 2007). Nevertheless, combined with the 
finding that variant E2 increased transcriptional activity more in bovine samples 
compared to equine samples, the authors suspected that the mutant E2 and LCR 
combination did not contribute to better replication and viral maintenance of variants in 
equine cells (Nasir et al., 2007). Despite these findings, BPV sequencing was mainly 
aimed at the LCR and E5 regions, whereas the complete BPV genome has rarely been 
sequenced. As it is not known at what location most mutations occur, it is very likely 
that when the genome would be sequenced at another location, more mutations will 
be discovered both in BPV originating from cattle wart tissue and from sarcoids and 
thus the importance of these mutations remains unclear. 





Equine sarcoids can occur anywhere on the skin, but are observed more often at the 
level of the head, ventral thorax and abdomen and in the paragenital region 
(Torrontegui and Reid, 1994). They are also observed quite frequently on distal limbs 
(Taylor and Haldorson, 2013), most likely because this region is more prone to skin 
lacerations. Indeed, sarcoid development is often associated with a history of non-
healing wounds (Torrontegui and Reid, 1994). Although some rare cases of mucosal 
involvement have been described, these were always complementary to a primary 
dermal equine sarcoid with local invasion of the mucosa (Knottenbelt, 2005; 
Knottenbelt and Kelly, 2011). 
Morphologically, equine sarcoids can have very different appearances ranging from 
small hairless hyperkeratotic spots on the skin with little clinical importance, to large 
ulcerated masses that impede movement and cause discomfort to the horse. Because 
of this variety in clinical presentation, a clinical classification system has been 
developed to better describe these tumours (Pascoe and Knottenbelt, 1999). Despite 
this system, equine sarcoids can change morphology and horses often have multiple 
tumours of the same or different type at different body locations. 
Occult equine sarcoids (Figure 2) appear as hairless spots on intact skin, with a 
rough or mildly hyperkeratotic aspect, and with or without slight skin thickening (Pascoe 
and Knottenbelt, 1999). They often are very small and because the changes to the skin 
can be very subtle (Knottenbelt, 2005), they are easy to miss if one does not know 
what to look for. They can range in size from very small circular lesions to large 
irregularly shaped patches and are often mistaken for dermatophytosis (Pascoe and 
Knottenbelt, 1999). Although they are slow growing or even stable most of the time, in 
some cases they can change to verrucous sarcoids (see further) or even show quick 
and aggressive growth towards fibroblastic sarcoids (see further), usually following 
trauma (Knottenbelt, 2005). 
Verrucous equine sarcoids have a more wart-like appearance (Figure 3). The skin 
is dry, thickened and hyperkeratotic to scaly (Pascoe and Knottenbelt, 1999) in a more 
pronounced way compared to occult sarcoids. Lesions can be pedunculated or 
stalkless (Knottenbelt, 2005) and as with occult sarcoids, sizes range from almost 
imperceptibly small to dozens of square centimetres of affected skin. If small they are 




easily mistaken for papillomas or “warts” (Knottenbelt, 2005) and are mostly harmless 
and stable. They can however grow larger and change into tumours of the fibroblastic 
type (see further), often starting from small tissue nodules, located within the area of 
verrucous sarcoid (Knottenbelt, 2005). 
Nodular equine sarcoids (Figure 4) are the only type of sarcoid where no changes to 
the epidermis can be seen. They consist of spherically shaped nodules which are very 
hard on palpation and lie directly under the skin (Pascoe and Knottenbelt, 1999). This 
category of sarcoids is further divided into type A nodular sarcoids, where the skin is 
not attached to the mass and freely moveable, and type B nodular sarcoids, where the 
skin is attached to the mass and cannot be moved independently (Knottenbelt, 2005). 
Nodule sizes range from 0.5 to over 20 cm in diameter (Knottenbelt, 2005) and these 
masses can easily be misdiagnosed as other nodular tumours like (neuro)fibroma, 
melanoma (Pascoe and Knottenbelt, 1999) and mastocytoma. Nodular sarcoids often 
show slow but steady growth, but can ulcerate and quickly develop into fibroblastic 
tumour types (see further). They can occur at any body site but are often seen in the 
upper eyelid (Pascoe and Knottenbelt, 1999). While they are harmless at first, they can 
grow into larger nodules, interfering with eyelid movement or even preventing the eye 
from opening, with obvious implications for the animal’s sight. 
Fibroblastic equine sarcoids (Figure 5) have a somewhat misleading name, because 
all sarcoids actually are of fibroblast cell origin. They appear as ulcerated, proliferative 
masses (Pascoe and Knottenbelt, 1999) and have been divided further into 3 
categories (Knottenbelt, 2005). Type 1A fibroblastic sarcoids are pedunculated and 
their stalk is thin and consists of macroscopically normal skin. Type 1B fibroblastic 
sarcoids are also pedunculated, but the stalk is thicker and a substantial part of the 
tumour is present in the skin at the base of the stalk. Type 2 fibroblastic sarcoids are 
sessile. The fibroblastic sarcoid is associated in particular with a history of chronic 
wounds or trauma to or unsuccessful treatment of other sarcoid types (Knottenbelt, 
2005), but can also develop spontaneously. This type of sarcoid rarely changes to 
other sarcoid types and often causes discomfort, because it bleeds, is mechanically 
hindering and attracts flies, which in turn can cause myiasis. Fibroblastic sarcoids are 
often mistaken for hypergranulation tissue if occurring at wound sites, and it is therefore 
important to check if non-healing wounds do not consist of sarcoid tissue (Knottenbelt, 




2005) (see diagnosis). Other common misdiagnoses are fibrosarcoma and squamous 
cell carcinoma (Pascoe and Knottenbelt, 1999). 
Two or more (or even all) of the previously mentioned sarcoid types can co-occur in 
the same lesion. When this is the case, the tumour is called a mixed equine sarcoid 
(Figure 6) (Pascoe and Knottenbelt, 1999). They probably represent a transient state 
between the abovementioned types (Knottenbelt, 2005). 
In one paper, an additional type of sarcoid is reported, called the malevolent equine 
sarcoid (Knottenbelt et al., 1995). This form distinguishes itself from the other forms 
in that it infiltrates in lymphoid vessels and lymph nodes, resulting in a strand of 
tumours along those tracts. There have not been other reports of this type of tumour 
and the question has been raised whether these tumours are actually sarcoids 
(Wobeser, 2017). 












Figure 2 - An occult equine sarcoid at the inner side of the 
thigh. 
Figure 3 - A verrucous equine sarcoid at the level of the left 
shoulder. 
Figure 4 - Type B nodular equine sarcoid at the level of the 
left upper eyelid. 









Figure 6 - Mixed (occult-verrucous-fibroblastic) equine sarcoid at 
the level of the right shoulder. 
Figure 5 - Type 2 fibroblastic equine sarcoid at the 
level of the left axilla. 





In a recent guest editorial, the author states that in theory, the diagnosis of equine 
sarcoids should be easy: “Similar to how US Supreme Court Justice Potter Stewart 
described pornography: ‘I know it when I see it.’” (Wobeser, 2017). Indeed, the clinical 
image of a relatively young horse with multiple skin tumours of different types at typical 
body sites is pathognomonic to the experienced clinician. However things become 
more complicated if one or more of these typical characteristics are absent or if the 
clinician does not have adequate experience with sarcoids. There are currently no 
scientifically confirmed guidelines for making a clinical diagnosis, and research for the 
reliability of such diagnosis is lacking. 
 
 
Figure 7 - Histological preparation of an equine sarcoid (H&E). At the dermo-
epidermal junction fibroblasts are arranged perpendicular to the basement 
membrane (picket-fence formation) (arrow) and dermal fibroblasts in the tumour 
mass are organized in whorls and bundles. 





Figure 8 - Histological preparation of an equine sarcoid (H&E). There are long, 
sharp rete ridges (arrows) and the dermal fibroblasts are organized in bundles 
and whorls. At the left of the image, dermal infiltration by lymphocytes and 
plasma cells is visible. 
Histopathological examination of tumoural tissue is still the gold standard for equine 
sarcoid diagnosis (Scott and Miller, 2011; Taylor and Haldorson, 2013). Equine sarcoid 
tissue typically shows a thickened dermis with increased fibroblast density and spindle-
shaped, hyperchromatic neoplastic cells embedded in a matrix of collagen fibers, 
which can be arranged in whorls, tangles or fishbone configurations (Figure 7 and 8). 
At the dermo-epidermal junction, fibroblasts often arrange perpendicularly to the 
basement membrane in a “picket fence” configuration (Figure 7) (Scott and Miller, 
2011). Epidermal changes can consist of hyperkeratosis, hyperplasia and the 
formation of long, sharp rete ridges (Figure 8) (Scott and Miller, 2011). Although 
epidermal hyperplasia and rete ridges are most often seen in verrucous sarcoids, and  
ulceration in fibroblastic lesions, all these characteristics can be present in any given 
sarcoid (Martens et al., 2011). The only constant between different equine sarcoids is 
an increased fibroblast density (Martens et al., 2000). This makes it particularly difficult 
to histologically differentiate equine sarcoids from other fibromatous tumours such as 
schwannomas (Scott and Miller, 2011). Immunostaining for the S-100 protein which 
should be present in schwannomas has been suggested to differentiate said tumours 




from equine sarcoids (Bogaert et al., 2011), although this is debated by others 
(Epperson and Castleman, 2017). 
Because BPV DNA has been shown to be present in up to 100% of tested equine 
sarcoids (Chambers et al., 2003a) and because PCR techniques are becoming more 
widely available and cheap, PCR detection of BPV DNA in tumoural tissue is gaining 
popularity as a diagnostic method for equine sarcoid. Nevertheless, BPV DNA has also 
been detected in normal equine skin (Bogaert et al., 2005, 2008), hoof canker lesions 
(Brandt et al., 2011a) and other inflammatory skin conditions (Wobeser et al., 2012), 
which makes PCR detection somewhat less specific as a diagnostic method. That 
being said, when a lesion has the clinical appearance of a sarcoid and is positive for 
the presence of BPV DNA, chances are high that it is indeed an equine sarcoid. 
Taking a biopsy can cause a previously stable equine sarcoid to start growing more 
aggressively or change into a fibroblastic lesion (Scott and Miller, 2011), making it 
necessary that owners are committed to treatment before biopsying. When technically 
feasible, it is also possible to do a full excision first, taking into account some 
precautions (see treatment), and perform histopathology on the excised tumour 
afterwards. Another possible approach is to perform PCR for BPV DNA on a swab 
taken from the suspected lesion (Martens et al., 2001b), which does not damage the 
tissues and limits the risk of activation of the tumour. While BPV DNA could be detected 
in the vast majority of swabs taken from fibroblastic and verrucous sarcoids, sensitivity 
was lower in occult and nodular sarcoids where the skin surface is completely intact 
(Martens et al., 2001b). Nevertheless, as the PCR protocol yields quick results, a good 
approach might be to analyse a swab sample first and only take a biopsy when the 
result of the PCR is negative. By doing so, the necessity for biopsy and therefore the 
risk of tumour activation are reduced to a minimum. 
Treatment 
Spontaneous regression of equine sarcoids is traditionally believed to be rare (Scott 
and Miller, 2011), although it has been reported in up to 48% of cases (Brostrom, 1995; 
Martens et al., 2001c; Berruex et al., 2016). When spontaneous regression occurred, 
this was mainly in young horses (age 3 or younger) with small, occult or verrucous 
sarcoids (Berruex et al., 2016). Equine sarcoids are prone to recurrence after any 
treatment and tend to become more aggressive after treatment failure (Scott and Miller, 




2011). Therefore, for small, stable sarcoids, benign neglect with careful monitoring of 
tumoural behaviour is defendable. Nevertheless, sarcoids are notorious for their 
unpredictable behaviour (Wobeser, 2017) and can, even without external stimulus, 
quickly turn into large, ulcerated masses that are hard to treat. Several treatments with 
varying success rates have been described, but to date, no treatment exists that can 
cure and/or prevent all equine sarcoids. It is therefore important that in the prognosis, 
it is made clear to owners that a successful treatment can never be guaranteed and 
that tumours can recur or new lesions can appear at other body locations. 
Sharp surgical excision is perhaps the most commonly performed equine sarcoid 
treatment in clinical practice. Because this treatment technique has been associated 
with a recurrence rate of up to 82% (McConaghy et al., 1994; Brostrom, 1995; 
Knottenbelt and Kelly, 2000), some authors discourage it (Pilsworth and Knottenbelt, 
2007; Tupper, 2017). Nevertheless, with a careful tumour selection and the application 
of an adequate surgical technique, success rates of up to 82% can be achieved 
(Martens et al., 2001c). Precautions which can be taken during surgery to prevent 
recurrence include a strict non-touch surgical protocol (Martens et al., 2001c), isolating 
the tumour from the surgical field by adequate draping (Tupper, 2017), performing the 
procedure under general anaesthesia (Brostrom, 1995) and the excision of wide 
margins of apparently normal skin (McConaghy et al., 1994; Martens et al., 2001c). 
The suggested width of these margins is variable and ranges from 0.5 to 2 centimetres  
(McConaghy et al., 1994; Martens et al., 2001c; Scott and Miller, 2011; Tupper, 2017). 
Recurrence of equine sarcoids after excision is suggested to be significantly higher 
when BPV DNA is present in the surgical margins (Martens et al., 2001c), although 
other evidence contradicts this finding (Taylor et al., 2014). A surgical margin of 12 mm 
seems to be the optimum between surgical practicality and detection rate of BPV DNA 
(Martens et al., 2001a). After sharp excision, wounds are sutured whenever possible 
and are otherwise left open to heal by second intention. 
As an alternative for sharp surgical excision, laser surgery has been used to treat 
equine sarcoids. Carbon dioxide (Carstanjen et al., 1997; Martens et al., 2001c; 
McCauley et al., 2002), diode (Compston and Payne, 2013; Compston et al., 2013, 
2016) or Nd:YAG (Compston et al., 2016) lasers can be used. As with conventional 
excision, more or less wide margins are being treated, but the wound bed is usually 
vaporized and the wound left open to heal by second intention. In a recent review, 




success rates are reported to be “significantly better” compared to conventional 
excision (Tupper, 2017), but there is no research supporting this statement. Reported 
success rates are similar to conventional excision (62% - 71%) (Carstanjen et al., 1997; 
Martens et al., 2001c; Hawkins and McCauley, 2005; Compston et al., 2016) and one 
author even formally tested the above hypothesis, finding that success rates between 
conventional and laser excision were not significantly different (Martens et al., 2001c). 
For cryosurgery, equine sarcoids are first debulked if necessary and then frozen. 
Multiple freeze-thaw cycles until at least -20 °C are used to efficiently induce cell death 
in tumour cells (Diehl et al., 1987; McConaghy et al., 1994; Martens et al., 2001c). 
Monitoring of tissue temperatures by thermocouple needles is advisable (Carr, 2012) 
to confirm adequate freezing of tumoural tissue and at the same time avoid unintended 
damage to other tissues. To obtain these low tissue temperatures, liquid nitrogen is 
mostly used, either by direct application or in the form of a contact probe (Diehl et al., 
1987; McConaghy et al., 1994; Martens et al., 2001c). Because the freezing process 
is difficult to control, cryosurgery can have serious consequences when carried out in 
proximity of vulnerable structures such as the eye, nerves, blood vessels or synovial 
structures (Knottenbelt et al., 1995). After the procedure, a cryogenic crust gradually 
forms and falls off as the cells become necrotic and are being sloughed by the body. 
The remaining wound is left to heal by second intention. Success rates are said to 
range from 60% to 100% (Carr, 2012), although reports were published with lower 
success rates of 42% or even 9% in specific cases (McConaghy et al., 1994; 
Knottenbelt and Kelly, 2000). One study reports the use of hyperthermia for treating 
equine sarcoids (Hoffman et al., 1983), but there are too few reported cases to allow 
evaluation of the effectiveness of this treatment. 
Local chemotherapy can be used as a stand-alone treatment, or as an adjuvant 
therapy after excision or cryosurgery. A cytotoxic agent is applied topically in the form 
of an ointment or is injected intralesionally, resulting in cell death of exposed cells. 
Because the cytotoxic agent is applied locally, systemic side-effects are avoided and 
high local concentrations can be achieved at the level of the tumour cells (Théon, 
1998). Because the cytotoxic agents pose a hazard for the operator, appropriate 
precautions need to be taken to avoid any contact with skin or eyes. Measures can 
include, but are not limited to, wearing a face mask, long impermeable sleeves, special 
gloves and the preparation and administration through a specialised no-spill system. 




For intralesional chemotherapy, cisplatin is the most frequently used agent. Because 
the product is easily absorbed and eliminated by the body, it is injected in the form of 
an emulsion with sterile sesame oil, which helps to keep it in place as a controlled-
release (Théon et al., 1993). Injections aiming at saturating tumoural tissues are 
repeated at 2 week intervals for a total of 4 injections (Théon et al., 1993) or until the 
desired effect is reached. The dosage was estimated at 1mg of cisplatin / cm³ of tissue 
(Théon et al., 1994). There are no systemic side effects and local side effects are 
limited (Théon et al., 2007). Adjuvant cisplatin treatment can be initiated during surgical 
excision, does not interfere with primary wound closure (Théon et al., 1994, 2007) and 
cisplatin can even be administered in the form of intralesionally implanted 
biodegradable beads (Hewes and Sullins, 2006). Nevertheless, there are no benefits 
compared to starting the adjuvant treatment postoperatively (Théon et al., 1999). For 
intralesional chemotherapy with cisplatin, success rates of up to 93% are reported 
(Théon et al., 2007). Other cytotoxic drugs that can be injected intralesionally include 
bleomycin (Scott and Miller, 2011), mitomycin-C (McKane and Coomer, 2013) and 
carboplatin, but there is limited information available on the use of these agents and 
their success rates. Intralesional chemotherapy can be combined with electroporation 
to increase intracellular drug concentrations, and beneficial effects of 
electrochemotherapy have been described in vitro (Souza et al., 2016) and in vivo 
(Tamzali et al., 2012; Tozon et al., 2016). Nevertheless, administering a high voltage 
electrical shock requires the horse to be in general anaesthesia, which is not always 
practical or wanted. 
Small occult or verrucous sarcoids can be treated topically by applying a 5% 5-
fluorouracil ointment twice daily (Knottenbelt et al., 1995; Tupper, 2017). Another 
cytotoxic topical treatment which has been described for equine sarcoids is the so 
called “AW-3-lude” or “AW-4-lude”. The ointment consists of a mixture of “a number of 
heavy metal salts and antimitotic compounds” (Knottenbelt and Walker, 1994), but the 
exact formulation remains undisclosed and the treatment is only available through one 
equine clinic. Nevertheless, an 80% success rate has been described (Knottenbelt and 
Walker, 1994).  
Because the horse’s immune system does not adequately react to BPV infection and 
sarcoid formation, immunotherapy is since long considered as a logical treatment. 
Bacillus Calmette-Guérin (BCG) is an attenuated strain of Mycobacterium bovis which 




was used as a vaccine for tuberculosis in humans. Later, it was discovered that the 
vaccine has antitumoural properties and it is nowadays in use as an intravesical 
treatment for bladder cancer. Equine sarcoids are saturated by intralesional injection 
of a solution containing either BCG cell wall extract or inactivated or attenuated BCG 
bacteria. Injections are repeated every 2-3 weeks for a total of 4 injections or until 
tumoural regression occurs (Klein et al., 1986; Knottenbelt et al., 1995; Martens et al., 
2001c; Tupper, 2017). Severe side effects, including anaphylactic shock and sudden 
death, have been described (Knottenbelt et al., 1995; Théon, 1998), but these are rare. 
Common side effects are limited to local swelling, abscess formation and a slight fever 
(Théon, 1998; Martens et al., 2001c). The exact mechanism of action of BCG is not 
known, but it induces a local unspecific primarily cellular immune response which kills 
tumour cells as bystanders in the inflammatory process. When this happens, tumoural 
antigens are probably being exposed, which can result in a specific immune response 
against tumoural cells (Théon, 1998). Success rates up to 100% are reported (Théon, 
1998), but vary heavily between locations and tumour types (Knottenbelt et al., 1995; 
Martens et al., 2001c). Best results are obtained for periocular nodular or fibroblastic 
sarcoids and success rates are drastically lower for other sarcoid types and at other 
locations (Knottenbelt et al., 1995; Théon, 1998; Tupper, 2017). 
For smaller equine sarcoids, topical treatment has been described with a cream 
containing 5% imiquimod (Nogueira et al., 2006). Imiquimod is being used in humans 
to treat genital warts and superficial basal cell carcinoma. While the exact mechanism 
of action is not entirely understood, it is known that imiquimod stimulates the production 
of cytokines which in turn initiates a nonspecific cellular immune response and 
activates natural killer cells and macrophages (Sauder, 2000). For the treatment of 
equine sarcoids in horses, there is only one study available, reporting complete tumour 
regression in 9/15 (60%) of cases and 75% reduction in tumour size for an additional 
3 lesions (Nogueira et al., 2006). The cream is applied three times a week for a total 
duration of up to 32 weeks, but all tumours that completely disappeared did so within 
16 weeks (Nogueira et al., 2006). Side effects are very common and include exudation, 
erythema, erosions, depigmentation and alopecia (Nogueira et al., 2006). Some topical 
creams commercialised to treat equine sarcoids contain bloodroot, which is also said 
to have immunostimulating qualities, but apart from a study based on owner perception 
(Wilford et al., 2014), scientific proof of its effectiveness is lacking. 




In cattle, both prophylactic and curative vaccination can be used to prevent or treat 
BPV-2 induced papillomas (Campo, 1997) and in several species, papillomavirus-
induced warts are often treated by autogenous vaccination (Nicholls and Stanley, 
2000). Similarly, autogenous vaccination can be used to treat equine sarcoids with 
studies reporting full tumoural regression in 16 out of 21 (Kinnunen et al., 1999), 12 
out of 15 cases (Espy, 2008) and 11 out of 16 cases (Rothacker et al., 2015). Others 
report little effect or even worsening of the condition (Knottenbelt et al., 1995). Recent 
research has focussed on developing a prophylactic vaccine for equine sarcoids, 
based on virus-like particles (VLP’s) containing L1 and L2 capsid proteins. These 
vaccines were well tolerated, induced high neutralizing antibody titres (Hainisch et al., 
2012) and prevented horses from developing sarcoid-like lesions which are normally 
induced upon intradermal BPV injection of non-vaccinated horses (Hainisch et al., 
2016). Nevertheless, these pseudo-sarcoids are known to remain small and 
spontaneously disappear over time in non-vaccinated horses (Hartl et al., 2011). They 
are therefore not representative for true equine sarcoids. Curative treatment of equine 
sarcoids with BPV VLP-based vaccines has been unsuccessful to date (Ashrafi et al., 
2008; Mattil-Fritz et al., 2008). 
During radiotherapy, ionising radiation is used to cause fatal DNA damage to tumoural 
cells, resulting in cell death and tumour remission. While teletherapy (radiation from a 
distant source) has been used to treat equine sarcoids (Henson and Dobson, 2004), 
interstitial brachytherapy is far more common. Interstitial brachytherapy consists of 
intratumoural implantation of radioactive iridium-192 with the obvious advantage that 
radiation doses can be maintained for a prolonged time in tumoural tissues. The 
technique is very successful with reported success rates consistently high (87% to 
98%), especially for periocular sarcoids (Théon and Pascoe, 1994; Knottenbelt and 
Kelly, 2000; Byam-Cook et al., 2006). Nevertheless, radiotherapy is not widely 
available, due to the need for a specialised infrastructure and the inherent danger for 
operators and caretakers. 
Other treatments for equine sarcoids have been described. Mistletoe extracts were 
able to inhibit equine sarcoid cell proliferation in vitro (Felenda et al., 2015), but in vivo 
trials revealed a success rate of only 38% (Christen-Clottu et al., 2010). Topical 
application of acyclovir yields a success rate of 68% (Stadler et al., 2011), but raises 
questions as to how it can affect replication of the BPV, which is not a member of the 




herpesviridae and therefore does not stimulate infected cells to produce the enzyme 
necessary to activate the drug.
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Equine sarcoids are common and their treatment is difficult. Since it became widely 
accepted that the BPV plays an important role in disease onset, scientific interest has 
increased because the BPV, which causes harmless warts in cattle but cancerous 
lesions in horses, is one of the few papillomaviruses to cross the species-barrier. The 
pathogenesis and mode of transmission of equine sarcoids are not fully understood 
and further insights are needed to find better ways to prevent and cure the disease. 
The general aim of this research project was therefore to fill some of these gaps in the 
current knowledge which will eventually lead to a better clinical management of the 
disease and to a better understanding of disease transmission. 
Because equine sarcoids are causally linked to the BPV, one way to prevent the 
disease would be to prevent exposure to the virus. While the mode of viral transmission 
remains unclear, recent research indicates that flies could play a role in this process 
and a biting fly would be an excellent vector. The first aim was to establish if and for 
how long a biting fly can become positive for BPV DNA after exposure to cattle warts 
or equine sarcoids under controlled experimental conditions. 
Currently, a paradox exists in equine sarcoid diagnosis: histopathological examination 
stands as the gold standard, but a biopsy is needed, which can lead to quick 
exponential tumour growth. While PCR techniques can solve part of this issue, they 
are not widely available to practitioners. Clinical diagnosis of equine sarcoids is cheap 
and requires no additional tests, but is said to be non-specific, although substantial 
research on this subject is lacking. Therefore, the second aim was to validate clinical 
diagnosis of equine sarcoids against histopathological examination. 
Many treatments for equine sarcoids have been described, but there is no agreement 
on how to decide which treatment to use in order to optimise the outcome. The third 
aim was to establish a standardized treatment selection protocol and evaluate its use. 
Because many of these treatments are expensive, time-consuming or invasive, topical 
treatments are gaining popularity. Topical treatment with acyclovir has been described, 
but did not prove to be very successful in our hands and controlled studies were 
missing. The fourth aim was to find out if topically administered acyclovir reaches the 
dermal layers of the skin, where it should exert its effect, and if acyclovir is better at 
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The association between the bovine papillomavirus (BPV) and equine sarcoids is well 
established, but it is unclear how the virus spreads. Although evidence in support of 
viral spread through direct animal contact exists, this does not explain sarcoid 
development in isolated equids. BPV DNA has been detected in flies, which could 
indicate that these insects serve as a vector. This study aimed to investigate whether 
BPV-negative stable flies (Stomoxys calcitrans) become positive for BPV DNA after 
exposure to equine sarcoid or bovine papilloma tissue under experimental conditions 
and if so, for how long. 
A total of 420 stable flies were caught alive and exposed to BPV positive equine sarcoid 
or bovine papilloma tissue. During the following week, dead flies were collected daily 
and BPV loads were determined by quantitative PCR. 
There was a significant rise in BPV load after tissue exposure both in sarcoid and 
papilloma exposed flies, but the viral load was higher and remained high for a longer 
time after exposure to papilloma tissue compared to sarcoid tissue. Within days, viral 
loads decreased again and became indifferent from loads before exposure. 
The results of these experiments indicate that BPV transmission by Stomoxys 
calcitrans seems possible and is more likely to occur after contact with bovine 
papillomas than with equine sarcoids. Transmission seems only possible shortly after 
tissue exposure. Further research could include experimental induction of sarcoids 









Equine sarcoids are common tumours of the equine skin. While they do not affect the 
general health of equids, they can be mechanically, hygienically and cosmetically 
compromising and treatment is difficult, costly and often unrewarding (Martens et al., 
2001; Haspeslagh et al., 2016). An association between equine sarcoids and the 
bovine papillomavirus (BPV) is well established (Chambers et al., 2003a; Nasir and 
Campo, 2008) and BPV DNA is present in most (if not all) equine sarcoids. Inoculation 
experiments demonstrated that sarcoid-like lesions can be induced in young, healthy 
horses by injecting cattle-derived BPV-1 virion intradermally (Hartl et al., 2011). The 
lesions histologically resembled equine sarcoids and expressed the E5 oncoprotein, 
but spontaneous regression occurred in all cases, probably due to a cellular immune 
response (Hartl et al., 2011). Interestingly, intradermal inoculation of sarcoid-derived 
fibroblasts or naked BPV-1 DNA failed to induce such lesions, confirming that an intact 
virus is necessary for sarcoid formation (Hartl et al., 2011). 
The mechanism of transmission of the virus from cattle to equids is not currently 
understood. Furthermore it has not been established whether an infective virus 
production occurs in equine sarcoids, that is capable of spreading from horse to horse. 
BPV DNA has been found on the skin and in the surroundings of healthy horses living 
in contact with sarcoid-affected equids or cattle suffering from papillomatosis (Bogaert 
et al., 2005). Early transmission experiments demonstrated that equine sarcoid 
formation could be triggered in healthy horses by inoculating scarified skin with minced 
sarcoid suspension (Voss, 1969) or bovine papilloma extract (Olson and Cook, 1951). 
These findings suggest that viral transmission through direct animal contact could be 
possible, but imply that, except for horses living in close contact with cattle, infective 
virus has to be produced in equine sarcoids. BPV DNA was also found in several fly 
species surrounding horses with and without equine sarcoids (Kemp-Symonds and 
Kirk, 2007; Finlay et al., 2009). This could indicate that insects may act as a vector for 
the spread of BPV from cattle to horses or between equids. 
Some observations point to the possibility that equine sarcoids are a source of infective 
BPV. Epidemic outbreaks of equine sarcoids have been observed in horses (Ragland, 
1970), donkeys (Reid et al., 1994) and an isolated group of zebra (Nel et al., 2006). In 
BPV DNA originating from equine sarcoids, several sequence variants have been 
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reported to differ from the reference sequence originating from cattle (Chambers et al., 
2003b; Nasir et al., 2007; Wilson et al., 2013; Trewby et al., 2014; Savini et al., 2015). 
This could indicate that an equine specific BPV subtype exists. Further findings include 
the detection of BPV DNA in a complex with L1 major capsid proteins in about half of 
investigated sarcoids (Brandt et al., 2008) and an electron microscopic image of 
putative intact BPV virions in an equine sarcoid section (Wilson et al., 2013). 
The present study investigates whether BPV-negative stable flies (Stomoxys 
calcitrans) become positive for the presence of BPV DNA after exposure to equine 
sarcoid or bovine papilloma tissue under experimental conditions and if so, for how 
long. 
Materials and methods 
Fly collection and maintenance 
Preliminary experiments (results not included) revealed that Stomoxys calcitrans was 
by far the most common fly at the stables used in this experiment (96% of all caught 
flies) and that none of the wild caught flies were positive for the presence of BPV DNA. 
At the time of fly collection, no horses with sarcoids or papilloma-bearing cattle were 
present. 
Flies used for the experiment were caught alive between June and September 2015 in 
the stables of the Faculty of Veterinary Medicine, Ghent University, under the same 
conditions as during the preliminary experiment. This was done using a handheld 
vacuum cleaner with filter and transparent container (FC6093, Philips). Stomoxys 
calcitrans were positively identified by examination of their proboscis. Twenty-seven 
batches of around 40 flies in each batch were captured. After capturing, the container 
with the flies was detached from the motor unit of the vacuum cleaner and put into a 
dark freezer at -20°C for seven minutes to immobilize the flies temporarily. Three flies 
from each batch were transferred into separate Eppendorf containers to serve as 
controls before the remaining flies were exposed to sarcoid or papilloma tissue. They 
were kept at -20°C until further processing. The rest of the flies were moved to specially 
made plastic containers which allowed for easy handling, feeding and sampling. A new, 
disinfected container was used for every new batch of flies. Immediately after 
transferring the flies, a sterile polystyrene petri dish (SPL Life Sciences) with a surface 
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area of 21.50 cm², containing either equine sarcoid tissue from a fibroblastic equine 
sarcoid or bovine papilloma tissue at room temperature, was placed in the container 
with the flies. The tissue was defrosted and sliced approximately 2 mm thick, and 
covered the complete bottom of the petri dish. The petri dish was left inside the 
container for 24 h and then removed. Equine sarcoid or bovine papilloma tissue was 
alternated between batches. During the entire experiment, flies were fed daily through 
an adapted disposable plastic pipette with citrated BPV negative equine blood. 
Every 24 h, dead flies were collected from the containers, transferred into separate 
labeled Eppendorf tubes and kept at -20°C until further processing. If after 7 days flies 
were still alive, the experiment was stopped and flies were killed by freezing them at -
20°C during 24 h before transferring them into separate labeled Eppendorf tubes kept 
at -20°C until further processing. The whole procedure was repeated until 30 flies were 
collected for each sampling point (24, 48, 72, 96, 120, 144 and 168 h after capture), 
both for batches exposed to equine sarcoid tissue and bovine papilloma tissue. 
PCR procedures 
DNA from all samples (flies, sarcoid, equine blood and papilloma tissue) was extracted 
using a commercial kit (DNeasy blood and tissue kit, Kiagen) following the tissue 
protocol supplied by the manufacturer. 
Details on PCR procedures can be found in Table 1. Quantitative real-time PCR for 
the presence of BPV DNA was performed on all samples. With each run, previously 
established quantified dilution series of BPV-1 and BPV-2 DNA, harvested from a mix 
of several equine sarcoids were included. They served as positive controls and as a 
reference for quantification of the viral load of the sample. To allow for absolute 
quantification of the viral load and to confirm successful DNA extraction, all samples 
were also analysed for the presence of a single copy housekeeping gene (equine, 
bovine or fly) (primers listed in Table 1). For equine sarcoid tissue samples, this was a 
unique sequence in the equine interferon beta gene (GenBank M14546) (Haralambus 
et al., 2010). Bovine tissue samples were analyzed for the presence of a unique 
sequence in the 8th bovine chromosome and for flies, a unique sequence in the ORCO 
gene (GenBank JX996042.1) was used. Quantified dilution series with known cell 
quantities were included in all runs, which allowed to determine the number of cells 
present in the samples. The viral load per cell could then be calculated as the number 
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of BPV copies in a sample divided by the number of equine, bovine or fly cells in the 
sample, respectively. All samples were analyzed in duplicate on the same plate and 
when the difference between the threshold cycle of both replicates was greater than 
one, the analysis of that sample was repeated in duplicate. For further calculations, the 
mean of the 2 measurements was used. 
 
Table 1 - Primers and cycling programs used for real time quantitative PCR detection of the 
targets. (BPV = bovine papillomavirus; IFNb = interferon beta; ORCO = odorant receptor 




Primer Cycling program 
BPV f-AATCGGGTGAGCAACCTTT 95°C – 3 min 
45 cycles: 
95°C – 20 s ; 60°C – 40 s 
r-TGCTGTCTCCATCCTCTTCA 
BPV-1 probe FAM-CGTCAAtCAGGTCTAAaCGCCC-BHQ1 
BPV-2 probe TexasRed-TCAAcCAGGTCTAAgCGCCC-BHQ2 
Equine IFNb f-AGGTGGATCCTCCCAATGG 95°C – 3 min 
45 cycles: 
95°C – 20 s ; 60°C – 40 s 
r-CGAAGCAAGTCATAGTTCACAGAAA 
IFNb probe FAM-CCTGCTGTGTTTCTCCACCACGGC-BHQ 
Fly ORCO 
(SYBR Green) 
f-TGACAAGGAGACAAACTCAACCATT 95°C – 3 min 
40 cycles: 




f-ACTCCCTGATTCTATTACCCATGT 95°C – 3 min 
40 cycles: 
95°C – 20 s ; 65°C – 60 s 
r-TTTGGTGCTTGTTCCTCTCA 




All analyses were performed using commercial statistical software (SPSS 23, IBM). To 
allow for a clear interpretation, abstraction was made from the BPV type (1 or 2) and 
viral load was defined as number of BPV copies per cell. Extreme values were 
identified in each group (sarcoid or papilloma tissue) and at each time point (0, 24, 48, 
72, 96, 120, 144 and 168 h), by drawing boxplots and calculating the means and 5% 
trimmed means. If an explanation could be found for the observed extreme values, 
they were eliminated from the database. When no explanation could be found, they 
were considered genuine data and included in all further analyses. At each time point, 
a generalized linear mixed model with a gamma distribution and a logarithmic link 
function was used to determine if BPV loads were higher in flies exposed to papilloma 
or to sarcoid tissue. BPV load was used as the dependent variable, while the tissue 
type (papilloma or sarcoid) was used as a fixed effect in the model. To correct the 
model for grouping by batch, a random effect of batch number was also included. In 
order to determine if BPV loads differed significantly between different sample times 
within exposure groups, for both tissue types (papilloma and sarcoid), a generalized 
linear mixed model with gamma distribution and logarithmic link function was used. 
BPV load was the dependent variable and sample time (0, 24, 48, 72, 96, 120, 144 or 
168 h) the fixed effect. Batch number was also included as a random effect to correct 
the model for the effect of grouping. If multiple comparisons were made, a Bonferroni 
correction was applied. Significance was set at P ≤ 0.05. 
Results 
In total, 210 flies in 13 batches were collected after exposure to bovine papilloma tissue 
and 210 flies in 14 batches after exposure to equine sarcoid tissue. Nine fly samples 
were eliminated from the analysis, six because no fly DNA was detected in the 
samples, which indicates a problem with extraction, and three because they were 
considered extreme values (because the detected fly DNA was unusually low, 
extremely high BPV loads were obtained). Mean BPV loads of bovine papilloma tissue 
and equine sarcoid tissue were 227921,27 copies/cell and 18,49 copies/cell, 
respectively. Table 2 summarizes the number of samples and the mean BPV load in 
each group at the different sample times. 
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Table 2 - The total and included number of samples and the mean bovine papillomavirus (BPV) load 
(copies/cell) for each exposure group at all sampling times (T0, T24, T48, T72, T96, T120, T144, T168). 
An asterisk indicates a BPV load significantly higher compared to the load at T0 within the exposure 
group (papilloma or sarcoid). 








 Samples total 39 30 30 30 30 30 30 30 
Samples Included 38 30 30 28 29 30 30 30 
Mean BPV Load 






















 Samples Total 42 30 30 30 30 30 30 30 
Samples Included 41 30 29 29 29 30 30 29 
Mean BPV Load 


















Before exposure to sarcoid or papilloma tissue (at T0), no significant difference was 
present in BPV load (P > 0.05) between both groups. Statistical analysis revealed that 
fly BPV load was significantly higher after exposure to bovine papilloma tissue 
compared to exposure to sarcoid tissue at all sample times (P < 0.05).  
Flies that were exposed to bovine papilloma tissues had a significant increase in BPV 
load between T0 and T24 (P < 0.01). At T48, the BPV load had decreased, but not 
significantly (P > 0.05) and was still significantly higher compared to T0 (P < 0.05). At 
T72, the load had become significantly smaller compared to T24 (P < 0.05) and was 
no longer significantly different from the load at T0 (P > 0.1). From T72 until T168, the 
fly BPV load was not significantly different from the load at T0 (P > 0.1), except for at 
T120, where a peak in fly BPV load was observed which was significantly different from 
the load at T0 (P < 0.05). 
Flies exposed to equine sarcoid tissue also showed a significant increase in BPV load 
between T0 and T24 (P < 0.01). At T48, the BPV load decreased again significantly 
compared to T24 and was no longer significantly different compared to the BPV load 
at T0. At all further sample points, the BPV load remained more or less stable and 
there was no significant difference compared to the load at T0. 
 




If it is assumed that BPV infection is not productive in equine sarcoids, there has to be 
a vector involved in the spread of BPV from cattle to isolated equids or groups of 
equids. Equine sarcoids most often occur in the inguinal region, in the axilla and on the 
head (Taylor and Haldorson, 2013; Haspeslagh et al., 2016). The skin is less thick in 
these regions (Nel et al., 2006; Scott and Miller, 2011), which makes them more 
preferred and vulnerable for stable fly bites. The detection of BPV DNA in flies 
surrounding horses with and without equine sarcoids (Kemp-Symonds and Kirk, 2007; 
Finlay et al., 2009) further incriminates these insects. 
In this study, Stomoxys calcitrans was selected because it was found to be by far the 
most common fly species around horses and cattle and because of its ability to pierce 
the skin. Nevertheless, BPV DNA has also been identified in Musca autumnalis (Kemp-
Symonds and Kirk, 2007), Fannia carnicularis (Finlay et al., 2009) and Musca 
domestica (Finlay et al., 2009). While none of these species are biting flies, they are 
known to feed on already existing wounds. Other possible biting vectors could be 
Haematobia irritans, which lives almost exclusively around cattle but is known to feed 
on horses living in close proximity to cattle as well, or different tabanid species, in which 
BPV DNA has been identified previously (Abel-Reichwald et al., 2016). 
The results of this research show that stable flies can become positive for the presence 
of BPV DNA both after exposure to equine sarcoid tissue and bovine papilloma tissue. 
The mean viral load was over 10 times higher immediately after papilloma exposure 
compared to after sarcoid exposure and remained significantly higher during the entire 
experiment. This difference could be explained by the fact that the viral load of the 
papilloma tissue was many times higher compared to the sarcoid tissue. Nevertheless, 
this would also be the case in real life and the results from this study indicate that viral 
spread from cattle to equids may be more likely than between equids. Only fibroblastic 
sarcoid tissue was used here, but there does not seem to be a relationship between 
sarcoid type and viral load (Haralambus et al., 2010) although BPV DNA in a complex 
with L1 major capsid proteins was predominantly detected in fibroblastic sarcoids 
(Brandt et al., 2008). Nevertheless it would be interesting to see if flies become positive 
for BPV DNA after contact with sarcoid types with intact skin, as BPV DNA has been 
detected in the epidermis of such lesions (Bogaert et al., 2010). 
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Since fly BPV load rapidly decreased after initial exposure, and if BPV DNA measured 
in this study would originate from intact virion, the window of opportunity for BPV 
transmission by flies is limited in time and therefore distance. If flies are responsible 
for BPV transmission and transmission only occurs from cattle to equids, horses could 
be protected by keeping them at sufficient distance from cattle. For other viruses that 
have blood feeding arthropods as a vector, a separation of 200 m between affected 
and healthy horses is sufficient to prevent disease spread (Issel and Foil, 2015).  
At T120 after papilloma exposure, there was an apparent peak in fly BPV load. There 
is no biological explanation for this, but the peak in mean BPV load was caused by 
three out of 30 samples with extremely high BPV loads. These samples were not 
eliminated as extreme values because the high load was not related to an unusually 
low amount of fly DNA in the sample, but was due to truly elevated BPV loads. 
Currently, it is not known what viral concentration is required for infective transmission. 
One research group succeeded in producing sarcoid-like lesions by inoculating up to 
107 viral particles intradermally, but these lesions all regressed spontaneously due to 
a cellular immune response (Brandt et al., 2009; Hainisch et al., 2009; Hartl et al., 
2011). In the present study, detected fly viral loads per cell are relatively low, but the 
total amount of viral particles in a fly could be in the same range as what was used in 
the inoculation study. It is also likely that the virus is concentrated at the proboscis or 
legs of the fly, where tissue contact was intensive. If this is the case, the proboscis 
would make an excellent tool for transmission, as the virus is inserted directly at its 
target location when a stable fly pierces the equine skin. 
Many questions in the transmission and pathogenesis of equine sarcoids are still to be 
solved. While the evidence that flies may have a role in BPV transmission and sarcoid 
onset is increasing, the exact mechanisms remain to be elucidated. 
In conclusion, BPV transmission by Stomoxys calcitrans seems possible and is more 
likely to occur after contact with bovine papillomas than with equine sarcoids. 
Transmission seems only possible for a short time after tissue exposure. Further 
research could include analysis of flies for the presence and amount of intact virions 
using quantitative immunocapture PCR and transmission electron microscopy for 
screening of microdissected fly segments such as the proboscis and intestine, and 
experimental induction of sarcoids in equids with BPV positive stable flies. 
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Equine sarcoids are common tumours of the equine skin that are difficult to treat. 
Correct diagnosis of these tumours is paramount for treatment selection and for 
scientific research. The gold standard for equine sarcoid diagnosis is histopathological 
examination, but this requires a tissue biopsy, which can cause lesion exacerbation 
and can interfere with the outcome of clinical trials. Because equine sarcoids have a 
typical clinical appearance for the experienced eye, clinical diagnosis can be a good 
alternative, but has not been validated. To remediate this, 40 clinical cases of 
histologically confirmed equine skin lesions were compiled and put into an online 
examination. Care was taken that the selected lesions were a good representation of 
clinical occurrence of equine sarcoids. Fourteen equine sarcoid experts, 39 board 
certified equine specialists, 103 equine practitioners and 25 novices categorized the 
cases as equine sarcoid or not. The overall success rate was 82% while sensitivity and 
specificity were 83.3% and 79.6% respectively. Equine sarcoid experts were 
significantly better at diagnosing the lesions and felt more confident doing so, 
compared to all other expertise levels. Thanks to this research, clinical diagnosis of 
equine sarcoids can now be accepted as valid. There is room for improvement of 
clinical diagnosis by less experienced veterinarians and guidelines for making a correct 








Equine sarcoids are the most common skin tumours found in equids (Marti et al., 1993; 
Scott and Miller, 2011). The exact aetiology of equine sarcoids is still not understood, 
but occurrence and clinical course of the disease are likely influenced by viral, host, 
and environmental factors (Marti et al., 1993; Taylor and Haldorson, 2013; Wilson and 
Hicks, 2016). Clinically, equine sarcoids are responsible for a wide spectrum of disease 
manifestations ranging from small, quiescent solitary tumours to voluminous, multiple, 
rapidly growing tumours that affect large surfaces of the integument. Lesion 
morphology is highly variable and comprises four principal forms, i.e. occult, verrucous, 
nodular, fibroblastic, or mixtures thereof (Knottenbelt et al., 1995). Sites of predilection 
include the face, neck, axilla, ventral abdomen, paragenital region and distal extremity, 
as well as areas of previous injury or scarring (Marti et al., 1993). Given this 
heterogeneity of clinical features and their impact on the use and welfare of the affected 
equid, many forms of treatment for equine sarcoids have been described. However, 
no specific treatment is universally effective (Haspeslagh et al., 2016b) and these 
tumours remain notorious for a high rate of recurrence.  
As with any form of neoplasia, the definitive diagnosis is based on histological 
examination. However, in equine practice histology is often not performed to confirm 
the clinical suspicion of equine sarcoid. This is explained by the high index of clinical 
suspicion in cases with typical clinical and morphological features of equine sarcoid, 
and by the fear of lesion exacerbation (Knottenbelt and Kelly, 2000). Especially for 
milder manifestations of the disease, including occult and verrucous lesions, the 
surgical stimulus of taking biopsies is believed to carry a significant risk of transforming 
quiescent lesions into more aggressively growing tumours (Ragland, 1970; Pascoe 
and Summers, 1981; Howarth, 1990; Knottenbelt, 2009). Furthermore, in many clinical 
situations, treatment or a definitive diagnosis are deemed unnecessary and are thus 
not pursued by the owner or attending veterinarian. 
Nonetheless, without confirmation of the clinically suspected diagnosis, it is difficult to 
draw reliable conclusions from experiments or interpret findings of clinical studies on 
equine sarcoid. Therefore, representative analyses that assess the agreement 
between clinical diagnosis and histology of cutaneous tumours thought to be equine 
sarcoids, will improve our understanding of different epidemiological and clinical 
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aspects of the disease. The objective of this study was to assess the sensitivity, 
specificity, positive and negative predictive values and the influence of the level of 
expertise of the observer when diagnosing equine sarcoid lesions clinically.  
Materials and Methods 
Online examination 
In order to assess the ability to correctly identify equine sarcoids in as many equine 
veterinarians as possible, an online test was compiled, including 40 clinical cases with 
skin lesions for which equine sarcoid was considered a possible differential diagnosis 
and for which an unequivocal histological diagnosis was available.  Each case was 
carefully processed to provide all relevant information as concise as possible. This 
information always included patient data of the affected subject and, whenever 
available, when the lesion had first been observed, its growth behaviour, any previous 
treatments and response to treatment, and the presence and location of other lesions 
on the affected individual. No information relevant for the assessment of the lesion was 
intentionally withheld. However, the case information was filtered to some extent in 
order to present cases as uniformly as possible.  
For each case, respondents were asked if they thought the lesion in question was an 
equine sarcoid (“yes” or “no”), and how confident they were of their clinical diagnosis 
on a scale from 1 (not confident at all) to 6 (very confident). Furthermore, each 
respondent was asked to identify himself, specify how long he or she had been working 
in equine practice, and provide his or her email address. At the end of the exam, each 
respondent was also asked what 3 features they found to be most reassuring that a 
skin lesion was actually an equine sarcoid, with the following answers to choose from: 
(1) Lesion localization, (2) Lesion morphology (occult/ verrucous/ nodular/ fibroblastic/ 
mixed), (3) Multiple lesions in the same horse with typical sarcoid morphology, (4) Age 
of the animal, (5) Changing lesion morphology (e.g.: changing from occult to 
verrucous), (6) (Aggressive) recurrence after treatment. 
The online examination was made available using Google Forms and can be accessed 
under the following link: https://goo.gl/forms/I0iGWYq0mDbOrrZ83. Potential 
candidates were directly contacted by the first authors (C.K. and M.H.) via email and 
kindly requested to take part in the online examination. Furthermore, the study 
   Chapter 4 – Clinical diagnosis part I 
61 
 
objectives were clearly disclosed and all candidates were informed that results of the 
exam will be subjected to peer-review and publication in an anonymised format. 
Candidates were categorized as (1) “equine sarcoid expert”, if they had previously 
published on the topic of this tumour in peer-reviewed journals and had at least 2 years 
of clinical experience, (2) “board certified equine veterinarian”, if they were qualified 
specialists with Diplomate status of the American or European Colleges of 
Veterinary/Equine Surgery, Internal Medicine, or Dermatology, (3) “equine 
practitioner”, if they had at least 1 year of clinical experience in equine practice, or (4) 
“novice”, if they had less clinical experience, including veterinary medicine students (2 
final years of studies) and recent graduates. 
Once all required fields of the online examination had been filled in by a respondent, 
the responses were automatically recorded in an Excel-spreadsheet.  
Case-composition for the online examination 
To determine the proportion of equine sarcoid and non-equine sarcoid skin lesions to 
be included in the online examination, a preliminary analysis was carried out on the 
histological diagnoses of all equine skin lesions (including external submissions, and 
not just restricted to neoplastic lesions) to the histopathology diagnostic laboratory at 
the University of Berne between January 2011 and September 2016. To assess a 
representative proportion of diagnostically challenging cases, this data set was 
augmented with the histological diagnosis of skin lesions submitted to the histology 
diagnostic laboratories at the veterinary teaching hospital at the Universities of Ghent 
and Vienna (not including external submissions) between June 2011 and June 2016. 
For this analysis, the determining inclusion criterion was that the suspected clinical 
diagnosis had to be listed on the histology request form or could conclusively be 
deducted from the medical records. 
Cases of cutaneous masses and skin alterations that were seen by the first authors 
(C.K. at the ISME Equine Clinic Berne and M.H. at the Equine Hospital of Ghent 
University) between 2011 and 2016 were screened for completeness in 
documentation, including histopathologic examination and comprehensive written 
medical and digital photo documentation. All cases included in the pool for the online 
exam were clinical cases and an informed consent that case data may be used for 
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teaching and research purposes had been signed by the owners for each case. Cases 
for which photographic documentation of the relevant skin lesion was of inadequate 
quality or unclear and cases with an equivocal histological diagnosis were excluded.  
Clinical cases with adequate documentation to be included in the online examination 
were categorized as “equine sarcoid” or “non-equine sarcoid” cases, based on the 
results from histology, and furthermore as “typical” or “diagnostically challenging” 
cases. To differentiate between typical and diagnostically challenging cases, the 
authors adhered to a list of criteria summarized in Table 1. This resulted in a final case 
pool, in which cases were assigned to one of the following four categories: 1. “typical 
equine sarcoid”, with case features typical of equine sarcoid disease; 2. “diagnostically 
challenging equine sarcoid”, with case features that are less typical, or unspecific of 
equine sarcoid; 3. “typical non-equine sarcoid”, with case features that are highly 
suggestive and typical of another differential diagnosis; and 4. “diagnostically 
challenging non-equine sarcoid”, with case features that are also compatible with 
equine sarcoid. According to pre-determined proportions (equine sarcoid, non-equine 
sarcoid, diagnostically challenging or typical), the appropriate number of cases from 
each category was selected at random from this case pool to assemble the online 
examination consisting of 40 clinical cases (Figure 1), at the same time ensuring that 
lesions of all 4 basic morphologies and different localisations were included in the final 
version of the online examination. 
















Table 1 - Discriminatory criteria to differentiate “typical” and “diagnostically challenging” equine sarcoid (ES) cases. 
 
 typical ES case features 
features of diagnostically challenging cases and/or case features 
not typical of ES 
age 2 years and older < 2 years and > 15 years of age 
history of… 
observed changes from occult to verrucous, or 
verrucous to fibroblastic morphological appearance 
recent wounding 
tumour recurrence within 2 months after excision signs of pruritus 
lesion morphology and 
number 
several lesions clearly compatible with one or more 
typically described ES tumour morphologies (occult, 
verrucous, nodular, fibroblastic) 
solitary nodular mass 
hairless lesions with symmetrical distribution over the two body 
halves, or over surfaces exposed to rubbing or in direct contact with 
tack and blankets 
lesion localisation 
typical ES localisation (eyes, ears, axilla, chest, 
abdomen, medial proximal legs) 
lesion localised at (oral, ocular or genital) muco-cutaneous junction or 
at the base of the tail 
 





Figure 1 - Flow diagram of case selection and the resulting case composition of the online exam. 
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Descriptive statistics and calculations of success rate, sensitivity, specificity, positive 
predictive value and negative predictive value were carried out in a spreadsheet (Excel 
2013). Formal statistical analyses were carried out using commercially available 
software (SPSS 23). 
To check whether there was a difference in ability to differentiate between equine 
sarcoid and non-equine sarcoid lesions between different expertise levels of 
respondents or between typical and diagnostically challenging lesions, a generalized 
estimating equations (GEE) model with a binomial error distribution and a logit link 
function was fitted. The ability to correctly differentiate equine sarcoids from other 
lesions (Yes/No) was used as dependent variable and the expertise level (equine 
sarcoid Expert/Board certified veterinarian/Practitioner/Novice) and lesion difficulty 
(typical/diagnostically challenging) were used as independent variables. Because 
there were more than 2 levels of expertise, the estimated marginal means for this 
variable were calculated and pairwise comparisons were carried out, applying a 
Bonferroni correction. A second GEE model with a multinomial error distribution and a 
cumulative logit link function was fitted to test if there was a difference in confidence 
between different expertise levels of the respondents or between typical and 
diagnostically challenging cases. Confidence level (1 to 6) was used as the dependent 
variable and expertise level (equine sarcoid Expert/Board certified 
veterinarian/Practitioner/Novice) and lesion difficulty (typical/diagnostically 
challenging) as the independent variables. To test if confidence levels were higher if a 
lesion was correctly diagnosed, a third GEE with a multinomial error distribution and a 
cumulative logit link function was fitted, using confidence level (1 to 6) as the 
dependent variable and the ability to correctly differentiate equine sarcoid from other 
lesions (Yes/No) as the independent variable. All models were corrected for the fact 









Case composition for the online examination 
A total of 234 accessions to the histopathology diagnostic laboratory at the University 
of Berne were available for the preliminary analysis regarding the proportions of equine 
sarcoid and non-equine sarcoid cases to be included in the online examination (Figure 
2). Based on this proportion analysis, a case composition of 66% (26/40) of equine 
sarcoid cases, and 34% (14/40) other cases was aimed for. 
 
Figure 2 - Distribution of histology diagnoses from 234 accessions to the histopathology diagnostic 
laboratory at the University of Berne between January 2011 and September 2016 
 
60% equine sarcoids: 
- 53% (124) ES with unequivocal 
histology diagnosis 
- 7% (17) ES as main presumptive 
diagnosis on histology 
40% other skin associated tumours: 
- 12% (28) squamous cell carcinoma 
- 10% (24) dermatitis (including eosinophilic dermatitis) 
- 4% (10) melanoma 
- 2.5% (5) papilloma 
- 2% (4) mastocytoma 
- 1.5% (3) cutaneous lymphoma 
- 4% (9) unclear diagnosis (not including ES) 
- 4% (10) other (lipoma, hair follicle cyst, …) 
 
all other skin tumors (93)
equine sarcoids (141)
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The preliminary analysis of histopathology submissions regarding the prevalence of 
diagnostically challenging cases, revealed a larger proportion of diagnostically 
challenging non-equine sarcoid cases (skin lesions that were clinically suspected as 
equine sarcoid, but histologically diagnosed as other lesions) compared to 
diagnostically challenging equine sarcoid cases (skin lesions that were not suspected 
to be equine sarcoid, but histologically diagnosed as equine sarcoid). Overall, 50/235 
(21.3%) diagnostically challenging non-equine sarcoid cases were identified in all 
available data sets (5.6% (7/124) Berne; 28.6% (10/35) Vienna; 43.4% (33/76) Ghent). 
Here, it needs to be pointed out that the data from Ghent and Vienna is skewed by a 
strong selection bias, as only excised skin lesions with a doubtful clinical diagnosis (in 
Ghent 76 out of 600 clinical cases (12.7%)) were submitted for histology. The 
proportion of diagnostically challenging non-equine sarcoid cases identified at the 
University of Berne is likely the most representative, as it refers to a time period during 
which all excised and biopsied cutaneous masses were submitted for histology. Since 
February 2015, tumour tissue and case details including digital photographs of every 
case presented to the ISME Equine Clinic Berne for evaluation of a cutaneous mass 
are systematically archived in a tumour tissue bank.  Therefore, it was deemed 
appropriate to include a proportion of 10% diagnostically challenging non-equine 
sarcoid cases in the online examination.  Diagnostically challenging equine sarcoid 
cases, on the other hand, were identified in only 2/366 instances in 2 referral centres 
for which data was available over a 5-year period (0.8% (1/141) Berne; 0.4% (1/225) 
Ghent). Thus, only 1 diagnostically challenging equine sarcoid case was included in 
the online examination. The case selection process and proportions of case categories 
included in the online examination are shown in Figure 1.  
Examination respondents 
In total, 181 respondents completed the online examination between February 1st and 
April 15th, 2017. This included 156 veterinarians with more than one year of experience 
and active in equine practice in 17 different countries from the European, North 
American, and Australian continents. Furthermore, 4 recent graduates with less than 
one year of working experience and 21 veterinary students enrolled in the equine 
emphasis track and studying in their 2 final years at the University of Berne or Ghent. 
The overall response rate was 44.4%. Respondents from Switzerland and Belgium 
were overrepresented contributing 33.1% and 17.1% of respondents, respectively. 
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Fourteen respondents met the criteria of equine sarcoid experts, 39 respondents were 
board certified equine veterinarians, 103 were categorized as equine practitioners, and 
25 as novices. 
Examination results 
Table 2 summarizes the success rates, sensitivity, specificity, positive and negative 
predictive value and mean level of confidence for clinical diagnosis of equine sarcoid 
for all respondents and separately for the different levels of expertise. 
 
Table 2 - Success rate, sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV), and mean confidence levels for all respondents and for the different 
levels of expertise (SD = standard deviation; ES = equine sarcoid). 













82.0 83.3 79.6 88.4 72.0 4.24 (± 1.30) 
ES experts 
87.9 88.7 86.2 92.3 80.5 4.77 (± 1.19) 
Board certified 
81.7 82.5 80.2 88.6 71.2 4.25 (± 1.24) 
Practitioners 
82.0 82.9 80.4 88.7 71.7 4.25 (±1.28) 
Novices 
79.2 83.2 71.7 84.5 69.7 3.49 (± 1.31) 
 
Statistical analysis revealed that equine sarcoid experts were significantly better at 
distinguishing between equine sarcoid and other lesions compared to board certified 
veterinarians (OR = 1.67; P < 0.01), equine practitioners (OR = 1.64; P < 0.01) and 
novices (OR = 1.99; P < 0.001). Other differences between different levels of expertise 
were not significant. Equine sarcoid experts were also more confident compared to 
board certified equine veterinarians (OR = 2.25; P < 0.001), equine practitioners (OR 
= 2.21; P < 0.001) and novices (OR = 6.30; P < 0.001). The cases with a typical 
morphology were significantly more likely to be assessed correctly (OR = 4.92; P < 
0.001) then challenging cases, and respondents of all expertise levels also felt 
significantly more confident (OR = 1.78; P < 0.001) when assessing typical cases 
compared to challenging ones. 
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Equine sarcoid experts who correctly diagnosed a case were significantly more 
confident of their diagnosis compared to equine sarcoid experts who did not correctly 
diagnose the case (OR = 6.42; P < 0.001), but this was not the case for other levels of 
expertise and overall, there was no significant correlation between the ability to 
correctly differentiate equine sarcoid from other lesions and the level of confidence 
(OR = 4.79; P = 1.00). 
Both overall and within each expertise level, the 3 features that were most reassuring 
that a skin lesions was actually an equine sarcoid were (1) multiple lesions in the same 
horse with typical equine sarcoid morphology (84.0% of respondents), (2) typical lesion 
morphology (80.1% of respondents), and (3) lesion localization (71.8% of 
respondents). 
Discussion 
The present study describes the development of an online examination to critically 
assess the diagnostic accuracy of the clinical diagnosis of equine sarcoid. The 
conceptual design aimed to elaborate an examination with a representative proportion 
of skin lesions that are possible differential diagnoses for equine sarcoid and special 
consideration was given to the diverse clinical aspects of the disease that may 
influence the reliability of the clinical diagnosis. Based on the examination results from 
181 respondents, the clinical diagnosis of equine sarcoid is fairly reliable regardless of 
the level of expertise of the respondents, with an overall sensitivity and specificity of 
about 80% and positive predictive value of nearly 90% (Table 2).  
Previous publications have mentioned that equine sarcoid diagnosis based on clinical 
assessment of the lesions should be easy (Wobeser et al., 2010) and that a strong 
agreement between clinical diagnosis and histopathology of equine sarcoid exists 
(Lazary et al., 1994; Jandova et al., 2012). Nevertheless, there is no record of specific 
research focusing on this topic and future research would benefit from insights in the 
accuracy of the clinical diagnosis (Compston et al., 2016). While histopathology still 
remains the gold standard for the diagnosis of sarcoids and other skin tumours and 
should remain the mainstay for diagnosis whenever possible, the high specificity, 
sensitivity and positive and negative predictive values found in this study indicate that 
the clinical diagnosis of equine sarcoid may indeed serve as a reliable alternative with 
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a predictive margin of error. This knowledge is useful in many clinical situations where 
biopsies are often avoided for practical or economic reasons as well as the fear of 
possible lesion aggravation (Knottenbelt, 2009). In research settings, taking biopsies 
and performing histopathology are often incompatible with practical, economic and 
ethical considerations (Berruex et al., 2016) or deliberately avoided for the risk of 
interference with the outcome of clinical or experimental trials (Haspeslagh et al., 
2016a).  
Although widely accepted as the gold standard of diagnosis, it has to be pointed out 
that histopathology also has its limitations in sarcoid diagnosis. Histopathological 
characteristics are neither consistent (Martens et al., 2000) nor absolutely specific 
(Epperson and Castleman, 2017) in all equine sarcoids and the diagnosis depends 
heavily on the expertise and experience of the pathologist (Taylor and Haldorson, 
2013). A polymerase chain reaction (PCR) based screening for bovine papilloma virus 
(BPV) DNA may complement the diagnostic workup in some clinical settings (Martens 
et al., 2001).  
One of the possible pitfalls of designing a case-based study to investigate the 
diagnostic accuracy of a clinical assessment is that the selected cases need to be 
representative of the clinical population. For this study, careful preliminary analyses of 
histopathological and clinical caseloads of 3 equine hospitals in 3 different countries 
ensured a representative ratio of equine sarcoid and other cases and of typical and 
diagnostically challenging cases. The determined proportion of equine sarcoid cases 
versus non-equine sarcoid cases (66% and 34%, respectively) was within the range of 
published equine sarcoid prevalence (35% - 90% of all cutaneous neoplasms) (Scott 
and Miller, 2011). For the classification of typical versus diagnostically challenging 
cases, a unanimous agreement had to be reached between the first authors, who 
carefully assessed each case, guided by a list of objective criteria. The analysis of the 
test results clearly shows that cases thereby classified as ‘typical’ yielded a significantly 
higher respondent confidence score then cases classified as diagnostically 
challenging. This finding confirms that the case classification was representative and 
suggests that the objective discriminatory criteria (Table 1) may be of use for clinical 
applications. 
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The ability to correctly discriminate equine sarcoids from other lesions was high for all 
respondents, but was significantly higher for respondents fulfilling the criteria of equine 
sarcoid experts compared to all other levels of expertise (board certified veterinarians, 
practitioners and novices). Equine sarcoid experts were also significantly more 
confident of their diagnosis compared to all other respondents. Moreover, only for the 
group of equine sarcoid experts, the level of confidence correlated with the correct 
differentiation of an equine sarcoid versus a non-equine sarcoid case. Essentially, this 
means that clinicians with less expertise are more likely to be erroneous in their 
judgment, despite a deceivingly high level of confidence. Therefore, we argue that it is 
feasible and potentially useful to develop a diagnostic tool to guide (less experienced) 
veterinarians with their clinical diagnosis and provide a directive feedback of which skin 
lesions are better subjected to a biopsy. Ideally, this diagnostic tool would bring the 
diagnostic abilities of inexperienced veterinarians to the level of equine sarcoid 
experts. The case features that were identified to discriminate typical equine sarcoids 
from clinically challenging lesions (Table 1) could serve as starting point to develop 
such a tool. 
Several limitations of this study need to be pointed out. The initial case pool consists 
of cases seen at equine referral centres in Switzerland and Belgium. Thus, a potential 
selection bias for clinically challenging case material, skewed towards a higher 
proportion of aggressive skin tumours compared to first opinion practice needs to be 
considered. Furthermore, possible geographical differences in the characteristics of 
equine sarcoids that may exist between continental Europe and other regions of the 
world were not taken into account. The format of the examination only provides the 
test respondent with incomplete, filtered case information and impedes any interaction 
with the subjects, such as palpation of the lesions, or the possibility of asking the owner 
specific questions, for instance regarding pruritus or details about previous treatments. 
This may have negatively influenced the respondents’ ability to correctly discriminate 
between equine sarcoids and other lesions.  
In conclusion, the results of this study show that clinical diagnosis of equine sarcoids 
is reliable, especially when carried out by experienced observers. The clinical 
diagnosis of these tumours has an overall sensitivity and specificity of about 80% with 
a predictable margin of error. Less experienced veterinarians could benefit from a tool 
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to guide them in the correct diagnosis of skin lesions and help them decide for which 
cases diagnostic testing is highly recommended.
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While histopathology remains the gold standard for equine sarcoid diagnosis, previous 
research has demonstrated that clinical diagnosis could be a valuable alternative. 
Nevertheless, less experienced veterinarians were not as good as sarcoid experts in 
discriminating sarcoids from non-sarcoid lesions. Therefore, and because of the lack 
of standardized clinical parameters for clinical sarcoid diagnosis, the aim of this study 
was to develop and test a diagnostic protocol (DP) which could be used to guide 
veterinarians in the diagnostic process. The DP was designed based on clinical 
parameters typical of equine sarcoids and then refined by repeated testing on different 
cases. To assess the functionality of the DP, it was given to experienced and 
inexperienced equine veterinarians and veterinary students to use on 40 standardized 
clinical sarcoid and non-sarcoid cases. The respondents were asked to clinically 
diagnose these cases as sarcoid or non-sarcoid lesions. The scores of respondents 
using the DP were then compared to those of respondents not using the DP. Overall, 
respondents using the DP were significantly more likely to correctly diagnose a case 
compared to respondents not using the DP and felt significantly more confident of their 
diagnosis. This was mostly because novice respondents performed better when using 
the DP. For more experienced practitioners, there was no significant effect of the DP. 
In conclusion, the DP proved to be a reliable tool to increase clinical diagnostic 
performance and user confidence, although some alterations can be made to improve 
its functionality even more. By systematically applying the DP, less lesions will need 








Histopathology remains the gold standard for the diagnosis of equine sarcoids. 
Nevertheless, taking biopsies of sarcoids may aggravate these lesions and is therefore 
better avoided (Knottenbelt and Kelly, 2000). Earlier findings indicate that the clinical 
diagnosis of equine sarcoid has an overall high sensitivity and specificity (chapter 4). 
Given the high index of suspicion and the supposed risk of lesion aggravation, many 
clinicians elect not to take biopsies to confirm the suspected diagnosis prior to initiating 
treatment. Arguably, this may represent the most reasonable approach in many cases 
where lesion morphology and other clinical features of equine sarcoid disease are 
typical.  Nonetheless, the previous analysis revealed that even experienced equine 
practitioners still misdiagnosed 18.0% of clinical cases. Unsurprisingly, sarcoid experts 
were significantly more likely to correctly differentiate equine sarcoids from other skin 
lesions compared to less experienced respondents. Furthermore, novices and 
practitioners were significantly less confident of their diagnosis compared to experts in 
the field. This indicates that a diagnostic tool to aid in the differentiation between 
sarcoid and non-sarcoid lesions and guide less experienced veterinarians with their 
clinical diagnosis is desirable. Ideally, such a tool will increase the diagnostic accuracy 
of a clinician assessing a skin lesion and/or cutaneous mass in an equine subject, and 
guide the selection of lesions with less typical clinical features, for which a biopsy and 
histology is indicated.  
In order to design such a diagnostic tool, unmistakably identifiable case features that 
are characteristic and at the same time exclusive to a particular condition need to be 
defined. Unfortunately, such pathognomonic clinical signs are not readily identified for 
equine sarcoids, a condition with a highly heterogeneous clinical presentation 
(Knottenbelt, 2005). However, although none are exclusive to equine sarcoids, certain 
case features are typical for sarcoid cases and very commonly associated with this 
complex condition. These features include lesion morphology (Knottenbelt, 2005), the 
presence of multiple, similar lesions in different locations in the same horse, the 
notorious recurrence after treatment (Scott and Miller, 2011), growth spurts (Wobeser, 
2017) and being present in typical localizations (Torrontegui and Reid, 1994). All of 
these criteria were previously used for the triage of cases in typical and diagnostically 
challenging cases and some were identified as being important for clinical sarcoid 
diagnosis by a panel of respondents (chapter 4).  
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The working hypothesis was that the systematic review and weighting of these criteria, 
along with the animal’s demographic information would increase the discriminatory 
capacity of less experienced practitioners to correctly differentiate between sarcoid and 
non-sarcoid lesions. Furthermore, it was hypothesized that the use of a clinically 
applicable diagnostic tool would improve the level of confidence with which observers 
make their decision. The objective of the present study was to develop and validate a 
diagnostic protocol (DP) to guide clinicians in diagnosing equine sarcoids and to select 
potentially challenging cases for which taking a biopsy is highly advisable to confirm or 
rule out the differential diagnosis of equine sarcoid. 
Materials and Methods 
Development of the diagnostic protocol 
Case features typical for sarcoids regarding the subject’s particulars, medical history, 
number of lesions compatible with typical sarcoid morphologies, lesion localization and 
morphology were listed. A weighting coefficient was subjectively assigned to each of 
these case features to reflect the importance of the given feature in the overall 
diagnostic decision. This resulted in a preliminary DP that would produce a high score 
for lesions that were likely equine sarcoids and a low score for lesions that probably 
were not. This preliminary DP was then tested on all of the 73 histologically confirmed 
sarcoid and non-sarcoid cases that were pooled for the previous study (chapter 4) and 
clinical cases presented to the equine referral hospitals of the Universities of Berne 
and Ghent during the months of December 2016 – February 2017. Based on the 
resulting total scores, cut-off values were determined indicating either a high probability 
of equine sarcoid, a low probability of equine sarcoid or a grey area where further 
diagnostic techniques (biopsy or PCR) are recommended. The DP was then generated 
in an active Excel spreadsheet to automatically calculate the total score and advise the 
user of the diagnostic decision (Table 1).
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Table 1 - The diagnostic protocol used in this study, filled out for a fictional case. High final 
scores indicate a high likelihood of equine sarcoid while low final scores indicate a low 
likelihood of equine sarcoid. In this example, the final score of 10 indicates that further 







    
 < 1 year old    
-4  0 
2 - 7 years old   
2  2 
7 - 17 years old   
1  0 
18 years or older   
0  0 




no information (also: slow continous growth) 
1  0 
recurrence  
after therapy that was (at least temporarly) successful in 
reducing the lesion 
3  0 
growth 
behaviour 
rapid growth (spurts) observed 
2 2 
growth triggered by wounding 
2  0 
changes in morphology over time  
4  4 
 weighted subscore (weighting coefficient = 1) 
6 
3. number of lesions 
  
solitary no other lesions described/found 
1  1 
multiple 
2 - 10 lesions with similar (sarcoid-typical) morphology 
2  0 
> 10 lesions with similar (sarcoid-typical) morphology 
3  0 
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periocular or auricular 
2  0 
lip or cheek 
1  0 
neck: atlas/parotid region, jugular groove, lower neck 
1  0 
chest, axilla, antebrachium, shoulder 
2  0 
girth and ventrum near midline 
2  0 
inguinal region and inside of the thigh, fold of the knee 
3  0 
prepuce or teats/scrotum (but not shaft of the penis or 
glans) 
3  0 
fetlock or pastern 
1  0 
 atypical 
localisation 
back, saddle region, perineum, muco-cutaneous junctions, 
penile shaft, glans or clitoris, tail, crest of the neck,… 
-2  -2 
 weighted subscore (weighting coefficient = 2) 
-4 
5. lesion morphology 
  
occult 
flat ("thin-skinned"), circular, hairless lesion with 
hyperkeratotic surface and small (2mm) granules  
2  0 
verrucose 
wart-like, raised hairless cutaneous mass with variable 
hyperkeratosis 
2  0 
nodular spherical, firm subcutaneous or cutaneous mass 
1  1 
fibroblastic 
fleshy (pedunculated or sessile) proliferation with an 
ulcerated surface 
1  0 
mixed 
more than one morphological type (occult, verrucose, 
nodular, fibroblastic) is present, without one type clearly 
predominating 
3  0 
atypical 
ulcerated 
predominantly destructive/ulcerative process or chronic 
wound healing by second intention with finely granulated 
surface 
-2  0 
 weighted score (weighting coefficient = 2) 
2 
          total score 
10 
Biopsy highly recommended ( 5 > score < 15)  
very likely equine sarcoid--> total score = or > 15 
very likely not equine sarcoid --> total score = or < 5 
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Online examination to assess inter-observer agreement 
To ensure that the DP can be applied correctly and consistently, an online examination 
was conducted to test the inter-observer agreement. Ten cases were selected from a 
pool of 40 sarcoid and 30 non-sarcoid cases (chapter 4). It was ensured that both for 
sarcoid and non-sarcoid lesions, the entire spectrum of scores as determined for each 
case by the developers of the DP (M.H. and C.K.) was represented in the exam. For 
each case, photographs of the lesion and a brief case description in a standardized 
format were provided and made accessible online through the following link: 
https://goo.gl/forms/2j6JD4npXi2lAVPx2. 
Potential respondents had never been exposed to the DP before and were contacted 
by email and kindly asked to participate in the online examination. A copy of the DP in 
form of an automated Excel spreadsheet and supplementary illustrations depicting 
typical sarcoid morphologies and localisations (supplementary items 1 and 2) were 
attached to the invitation email. Furthermore, guidelines on how to correctly use the 
DP were provided and the study objectives were clearly disclosed so that all candidates 
were informed that results of the exam would be subjected to peer-review and 
publication in an anonymised format. For each case, respondents had to fill in the exact 
total score obtained by using the DP. 
Online examination to assess the clinical value of the decision protocol 
To assess the potential clinical value of the DP, an online examination designed to 
evaluate the clinical diagnosis of equine sarcoid was conducted as previously 
described in detail (chapter 4).  Briefly, this online examination consisted of 40 sarcoid 
and non-sarcoid cases out of a case pool of well-documented skin lesions with 
histologically confirmed diagnoses. The proportion of typical and diagnostically 
challenging cases (both sarcoid and non-sarcoid) aimed to reflect the distribution of a 
clinical population. Again, photographs of the lesion and a brief case description in a 
standardized format were provided for each case. The online examination was made 
accessible through the following link: https://goo.gl/forms/I0iGWYq0mDbOrrZ83.  
Candidates were grouped as (1) “sarcoid expert”, if they had previously published on 
the topic of equine sarcoid in peer-reviewed journals and had at least 2 years of clinical 
experience, as (2) “equine practitioners”, if they had at least 1 year of clinical 
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experience in equine practice, or as (3) “novices”, if they had less clinical experience, 
including veterinary medicine students (in their two final years of studies and tracking 
with an equine emphasis) and recent graduates.  
Potential respondents were contacted by email and kindly asked to participate in the 
online examination. Every other potential respondent in the randomly generated list of 
candidates for the group of “novices” and the group of “equine practitioners” was 
provided with the DP, including the appertaining illustrations of typical sarcoid 
morphologies and localizations. The invitational email also included the guidelines on 
how to use the DP and it was explained that the DP was intended to help complete the 
online examination successfully and that it only served as a guideline, not overruling 
their personal decision.  Furthermore, the study objectives were clearly disclosed and 
all candidates were informed that results of the exam would be subjected to peer-
review and publication in an anonymised format. 
For each case, respondents had to select whether they thought the lesion was an 
equine sarcoid or not and indicate how confident they were of this clinical diagnosis 
(on a scale of 1 to 6).  
Once a respondent had filled out all required fields of the online examination, the 
responses were automatically recorded in an Excel-spreadsheet. Results of 
respondents using the DP were then compared to results of their peers not using the 
DP and to results of a group of sarcoid experts, which were obtained in the previous 
study (chapter 4). 
Statistical Analyses 
Descriptive statistics were performed in a spreadsheet (Excel 2013). Formal statistical 
tests were carried out using commercially available software (SPSS 23). To assess 
the inter-observer agreement, the intraclass correlation coefficient (ICC) was 
calculated using a two way random model testing for absolute agreement. Normality 
of the data was assessed using probability-probability plots. To assess whether the 
use of the DP had a significant effect on the ability to correctly diagnose a case, a 
generalized estimating equations (GEE) procedure was used with a binomial error 
distribution and a logit link function. The ability to correctly diagnose the lesion (Yes/No) 
was used as the dependent variable and whether the respondent used the DP 
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(Yes/No) as the independent variable. Estimated marginal means were calculated and 
pairwise comparisons between groups (Expert, practitioner with and without DP, 
novice with and without DP) were carried out. To find out whether the use of the DP 
had a significant effect on the confidence of the respondents, a GEE with a multinomial 
error distribution and a cumulative logit link function was carried out, using the 
confidence level (1 to 6) as the dependent variable and whether the respondent used 
the DP (Yes/No) as the independent variable. All models were corrected for the fact 
that the same respondent scored multiple cases and when multiple comparisons were 
carried out, a Bonferroni correction was applied. Statistical significance was set at 
P≤0.05. 
Results 
The test to assess the inter-observer agreement was completed by 55 respondents 
(response rate 42.0%). The single measures ICC was 0.78 (95% confidence interval: 
0.62-0.92). 
The online examination to assess the clinical value of the DP was completed by 195 
respondents. Of the 195, 53 respondents (27.2%) used the DP as a practical tool to 
help in the decision making process of the online examination (response rate = 17.5%). 
Of these 53 respondents, 22 were practitioners with at least 1 year of working 
experience and 31 were novices. The results of these respondents were compared to 
those of the 142 respondents who completed the online examination without the help 
of a DP as described in chapter 4 (response rate 41.2 %). Of these 142 respondents,  
103 were equine practitioners, 25 were categorized as novices and 14 respondents 
met the criteria of sarcoid experts (chapter 4). The success rate, sensitivity, specificity, 
positive and negative predictive value, and mean confidence level for the different 
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Table 2 - Success rate, mean confidence, sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of the different groups of respondents (SD = standard deviation; DP = 
diagnostic protocol). 
 Novices Practitioners ES experts 










Success rate (%) 79.2 85.7 82.0 83.0 87.9 
Mean confidence (± SD) 3.49 (± 1.31) 4.37 (± 1.27) 4.25 (± 1.28) 4.45 (± 1.30) 4.77 (± 1.19) 
Sensitivity (%) 83.2 90.4 82.9 87.2 88.7 
Specificity (%) 71.7 77.0 80.4 75.0 86.2 
PPV (%) 84.5 87.9 88.7 86.6 92.3 
NPV (%) 69.7 81.3 71.7 76.0 80.5 
 
Overall, the odds for respondents using the DP to correctly diagnose a case were 1.2 
times higher compared to those for their peers not using the DP (OR=1.25; P=0.002). 
Novices using the DP were significantly more likely to correctly diagnose a case 
compared to novices not using the DP (OR=1.58; P=0.001) and practitioners not using 
the DP (OR=1.32; P=0.04), and there was no significant difference compared to 
sarcoid experts. Practitioners using the DP were not significantly more likely to 
correctly diagnose a case compared to practitioners not using the DP (OR=1.07; 
P=1.0) or sarcoid experts (OR=0.67; P=0.18). 
Respondents using the DP were 1.5 times more confident of their diagnosis compared 
to their peers who did not have access to the DP (OR=1.53; P<0.001). Novices using 
the DP were significantly more confident of their diagnosis compared to novices without 
DP (OR=3.34; P<0.001) and practitioners without DP (OR=1.19; P=0.002), but were 
significantly less confident compared to sarcoid experts (OR=0.54; P<0.001). Similarly, 
practitioners using the DP were significantly more confident compared to practitioners 
without DP (OR=1.37; P<0.001) and novices without DP (OR=3.85; P<0.001), but 
significantly less confident compared to sarcoid experts (OR=0.62; P<0.001). There 
was no significant difference in confidence between novices who used the DP and 
practitioners who used the DP. 




This is the first study to establish and test a DP to aid veterinarians and veterinarians 
in training with clinical sarcoid diagnosis. Similar score systems, as for example the 
modified sepsis score for equine neonates (Brewer et al., 1988) , are routinely being 
used in veterinary medicine. 
The ICC was good to excellent, indicating that the scores that were obtained when 
using the DP were consistent between respondents. While there is certainly room for 
improvement, the results indicate that by using the DP, all respondents became more 
confident of their diagnosis. Novices using the DP were better at discriminating 
sarcoids from non-sarcoid lesions compared to peers without DP and the success rates 
of their diagnostic decisions were statistically indistinguishable from those of sarcoid 
experts. In contrast, using the DP did not lead to better diagnostic decision in more 
experienced equine practitioners. A possible explanation is that these respondents 
may have adhered or referred less frequently to the DP for making their decision, but 
this suspicion could not be verified. 
Interestingly, using the DP mainly increased the sensitivity (Table 2). The specificity   
decreased when equine practitioners used the DP, but remained above 75% for all 
respondents using the DP (Table 2). Potentially, this can be adjusted by altering the 
weighting coefficients or the importance of certain characteristics in the total score. 
Furthermore, it was considered to include additional parameters to further improve the 
discriminatory accuracy of the DP. For example, special breeds and/or coat colors 
could be taken into consideration, as it has been shown that Haflingers (Lassaline et 
al., 2015) or pale-skinned horses like Appaloosa or Paint horses (Schaffer et al., 2013) 
are more likely to develop squamous cell carcinomas,  and grey horses are more likely 
to develop melanomas (Phillips and Lembcke, 2013). On the other hand, none of these 
horses are less prone to ES compared to other breeds or coat colors, so breed and 
coat color may not be very good discriminatory factors, and it was elected not to use 
these in the DP. 
Respondents using the DP did not only receive the DP, but also additional illustrations 
of typical sarcoid morphologies and locations. Therefore, the increased ability of 
respondents using the DP to correctly differentiate equine sarcoids from other lesions 
could also be due to a learning effect, induced by providing them with a correct 
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theoretical background on sarcoid characteristics of which they possibly were unaware 
before. 
The DP, as used here, suggests that taking a biopsy of the lesion is highly 
recommended if the final score falls within a certain range. PCR techniques on swabs 
are a reliable non-invasive alternative for histopathology, especially on lesions with 
ulcerated skin (Martens et al., 2001). This could be implemented in the DP by 
suggesting PCR tests to be carried out on cases that yield a final score within a high 
range, but not high enough to pass the threshold of 15 points. By doing so, suspected 
sarcoid cases will be further examined by a non-invasive technique first, avoiding 
biopsies and possible lesion aggravation. 
In conclusion, the routine use of the suggested DP by less experienced veterinarians 
will lead to a better and more confident clinical diagnosis, which in turn will result in 
less biopsies and thus decrease the risk of lesion exacerbation. The DP may still be 
improved by adjusting the weighting coefficients or adding new useful parameters, as 
more experience is gained with its application in equine practice. 
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Suplementary item 1 - Examples of typical equine sarcoid morphologies which were 
included with the diagnostic protocol. 
 








Suplementary item 1 (continued) 
 
Verrucous equine sarcoids 
 




Suplementary item 1 (continued) 
 
 Nodular equine sarcoids 
 




Suplementary item 1 (continued) 
 
 Fibroblastic equine sarcoids 
 




Suplementary item 1 (continued) 
 
 Mixed equine sarcoids 
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The objective of this study was to evaluate outcomes following treatment of sarcoids 
in equids and to identify risk factors for treatment failure in these patients. A 
retrospective case series was performed on 230 equids with 614 sarcoids that had 
been treated according to a standardized treatment decision protocol (electrosurgery, 
electrosurgery with intralesional placement of cisplatin-containing beads, topical 
administration of imiquimod or acyclovir, cryosurgery, Bacillus Calmette-Guerin 
vaccine injection, or intralesional injection of platinum-containing drugs) between 2008 
and 2013. Data regarding animal, tumour, treatment, and outcome variables were 
collected. Complete tumour regression without recurrence for ≥ 6 months was 
considered a successful outcome. Success rates were calculated; binary logistic 
regression analysis was used to identify risk factors for treatment failure and to 
compare effects of the 2 topical treatments. A 2 test was used to compare effects of 
the number of Bacillus Calmette-Guerin vaccine or cisplatin-containing drug injections 
on outcome. The overall success rate was 460 of 614 (74.9%). Electrosurgical 
excision resulted in the highest treatment success rate (277/319 [86.8%]); odds of 
treatment failure were significantly greater for intralesional injections of platinum-
containing drugs, cryosurgery, and topical acyclovir treatment. Odds of treatment 
failure were also significantly greater for sarcoids on equids with multiple tumours than 
for solitary lesions and significantly lower for sarcoids on equids that received 
concurrent immunostimulating treatment for another sarcoid than for patients that did 
not receive such treatment. While selection bias for treatments was inherent to the 
study design, results may assist clinicians in selecting treatments and in determining 









Sarcoids are locally aggressive, nonmetastatic tumours of the skin in equids (Pascoe 
and Knottenbelt, 1999). Bovine papillomavirus types 1 and 2 are causally associated 
with sarcoid development in equids (Chambers et al., 2003) but the environment and 
genetics of animals also have important roles. Sarcoids are the most common skin 
tumours in horses (Ragland, 1970), and many treatments have been developed 
(Taylor and Haldorson, 2013). However, no specific treatment is currently considered 
the standard of care, and therapy must be tailored according to characteristics of the 
patient and tumour, treatment availability, and owner preference. Because of the 
heterogeneity in tumour features and treatments used, determining an accurate 
prognosis is difficult. 
Most studies on sarcoid treatments in equids have focused on 1 or 2 selected 
treatments for specific sarcoid types, locations, or both, which makes it hard to 
estimate overall success rates for treatment of sarcoids. Reports describing a 
systematic approach to treatment selection are scarce. Diehl et al. (Diehl et al., 1987) 
published a report of 117 horses that were treated for sarcoids by means of CO2 laser 
surgery, cryosurgery, conventional excision, radiotherapy, or a combination of laser 
surgery and radiotherapy. The overall success rate was 86 of 117 (73.5%) horses, 
and the highest success rate was for laser surgery (48/59 horses [81.4%]). However, 
the number of horses was very low (< 15) for 3 treatment groups, and no specific 
information was included on how treatment was selected. Our research group 
previously described the use of 4 different treatments (conventional excision, CO2 
laser excision, BCG vaccination, and cryosurgery) for 197 sarcoids in 95 horses 
(Martens et al., 2001b). In that study, the overall success rate was 154 of 186 (82.8%) 
and the best results were also obtained with laser surgery. In that report (Martens et 
al., 2001b), a defined, systematic approach to treatment selection on the basis of 
tumour characteristics was described, but some treatment options (eg, use of topically 
applied medications) were not included. 
The objective of the study reported here was to retrospectively evaluate outcomes 
following treatment of sarcoids in equids at the authors’ institution, where treatments 
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were selected according to a standardized protocol. We also aimed to identify risk 
factors for treatment failure in these patients. 
Materials and Methods 
Case selection 
Electronic medical records of the surgery department at Ghent University were 
searched to identify equids treated for clinically diagnosed sarcoids between the first 
of January, 2008, and June 30, 2013. The minimal follow-up period for inclusion in the 
study was 6 months after the date of the last treatment. No equid that met these criteria 
and had treatment information available was excluded. 
Medical records review 
Data collected included breed or breed type, age at treatment, and sex of the patient; 
anatomic location, size and type of sarcoids (occult, nodular, verrucous, fibroblastic, 
or mixed)(Knottenbelt, 2005); presence and number of multiple tumours if applicable, 
whether sarcoids had been previously diagnosed and had recurred at the same site; 
and whether ulceration was present. The treatment selected, number of treatments, 
complications (when reported), and outcomes were recorded. When an equid 
underwent ≥ 1 treatment type for different tumours, this information was also collected, 
and the treatment types were assessed for potential immunostimulatory effects. Major 
complications were defined as complications being substantially hindering or painful 
to the horse or delaying healing after treatment. Full regression was defined as 
complete disappearance of the tumour with formation of normal skin, and partial 
regression was defined as a decrease in size, without complete disappearance; lack 
of change in tumour size or an increase in size was deemed a nonresponse to 
treatment. Only full regression without evidence of recurrence at follow-up evaluation 
≥ 6 months after treatment was considered to be a success; partial regression and 
nonresponse to treatment were considered treatment failure. Most information was 
collected from the medical records. Owners were contacted by phone for a long-term 
follow-up. 
 





During the study period, the following protocol was used to determine treatment 
choice. 
Sarcoids were excised by use of an electrosurgical scalpel (with or without placement 
of cisplatin-containing beads) whenever well-defined edges were present and the size 
and location allowed removal of a wide margin of normal skin and primary wound 
closure. Occult or slightly verrucous sarcoids that were not excised were treated 
topically with acyclovir cream or imiquimod cream; after explaining the differences in 
price, possible side effects, and application frequency for each product, treatment 
choice was at the owner’s discretion. Tumours that were ill-defined, inconveniently 
located for excision, or strongly attached to deeper tissues were treated by 
cryosurgery when the surgeon anticipated no risk of damaging underlying vital 
structures. Those that were unamenable for excision or cryosurgery owing to size or 
location were treated by means of local (intralesional) chemotherapy with cisplatin- or 
carboplatin-containing sterile sesame oil, except that periocular tumours were treated 
by intralesional BCG vaccine administration. Some patients underwent treatment by 
excision, intralesional chemotherapy, or topical acyclovir administration for 1 lesion, 
whereas another tumour on the same animal was treated by BCG vaccine injection, 
cryosurgery, or topical imiquimod application. The latter 3 treatment types were 
considered to have some degree of general immunostimulating effects that could 
influence results for the concurrently treated tumour. Protocols for sedation, general 
anaesthesia, and analgesic and antimicrobial administration were at the discretion of 
the attending surgeon and anaesthesiologist. 
Electrosurgical excision—All excisions were performed under general anaesthesia. 
Direct tumour contact was avoided during the skin preparation protocol and a 
perimeter of ≥ 12 mm of apparently normal skin (Martens et al., 2001a) around the 
tumour edge was marked with a sterile pen. Nodules or paler skin detected around the 
tumour were included within the excision margins. The monopolar electroscalpel (ICC 
300, ERBE) was used at a cutting setting of 120 Watts. A non-touch excision technique 
was used to avoid iatrogenic spread of tumour cells. Following tumour excision, gloves 
and instruments were changed, and the wound was rinsed with a 0.05% chlorhexidine 
solution and closed in 2 layers with size 1 polyglactin 910. Excessive tension on wound 
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edges was relieved by placement of additional stented sutures in a horizontal mattress 
pattern. Until May, 2012, cisplatin-containing beads (Matrix III cisplatin beads, Royer 
Biomedical) (1.6 mg/bead at 2 cm intervals) were placed in the wound bed prior to 
closure for patients with recurrent tumours or for those in which tumour margins were 
subjectively difficult to identify (Hewes and Sullins, 2006). After this time, the beads 
were no longer available, and the adjunctive chemotherapeutic treatment of these 
patients was discontinued. Sarcoids treated by the combination of excision and 
cisplatin-containing bead placement were analysed as a separate treatment group. 
Topical treatments—When selected, a 5% acyclovir cetomacrogol cream (generic 
preparation) was applied every 12 hours (Stadler et al., 2011) until full tumour 
regression occurred or until no changes could be seen after 2 months of treatment. 
The alternate treatment of 5% imiquimod cream (Aldara, 3m) was applied 3 
times/week after washing the skin with a mild soap solution. The imiquimod cream 
was left on for 8 hours and then washed off to avoid excessive skin irritation, and the 
treatment was performed until full tumour regression or until no changes could be seen 
after ≥ 3 weeks of treatment (Nogueira et al., 2006). 
Cryosurgery—Sarcoids were surgically reduced to the level of the surrounding skin 
with an electrosurgical instrument in patients under general anaesthesia. One 
thermocouple probe needle (BAT-10, Physitemp) was then inserted in the tumour 
base and another was inserted into tissue underneath the base of the tumour to 
monitor temperature during the freeze-thaw cycles. The tumour base and 
approximately 5 mm of surrounding skin were frozen (≥ 1 minute at –25 oC) with liquid 
nitrogen. The nitrogen was applied by use of continuous circulation contact tips 
(DFS30, Spembly Medical) or by placement of a plastic ring fitted around the tumour 
into which liquid nitrogen was directly administered in small amounts at a time to allow 
for temperature control. The temperature measured by the deep tissue probe was kept 
> 0oC to avoid damage to underlying tissues. Two freeze-thaw cycles were applied. 
Between cycles, tissues were allowed to thaw spontaneously until the probes 
measured temperatures of ≥ 20 oC. 
BCG vaccine treatment—Periocular tumours were treated with BCG (Onco-Tice, 
Organon) (0.5 X 108 to 2 X 108 colony forming units/dose) vaccine administration in 
standing sedated equids. When necessary, ulcerated masses were first debulked to 




the level of the surrounding skin as previously described. Sarcoid tissue was saturated 
with the vaccine by injecting approximately 0.3 ml/cm³ in different planes and 
directions via a Luer-lock syringe with a 23-gauge needle. Four local injections were 
scheduled to be given at 2- to 3- week intervals (Martens et al., 2001b). Two months 
after the 4th injection, patients were re-evaluated; in patients with partial tumour 
regression, a new cycle of injections was started. 
Intralesional injection of chemotherapeutic drugs—A cisplatin (Cisplatine Sandoz, 
Sandoz) containing emulsion was used for intralesional injections until February, 2012, 
and a carboplatin (Carbosin, Teva) containing emulsion was used afterward. 
Fibroblastic tumours were debulked prior to the treatment in general anaesthesia using 
an electroscalpel as previously described. The chemotherapeutic agent was mixed 
with sterile sesame oil to a final concentration of 3 mg/mL (cisplatin) (Théon et al., 
1993) or 5 mg/mL (carboplatin). The technique of saturation was comparable to that 
used for BCG vaccine administration but a 21-gauge needle was used for delivery. 
Injections were repeated every 4 weeks until full tumour regression unless the owner 
declined continuation of the treatment or no progress was made after 3 consecutive 
injections. 
Statistical analysis 
Data were explored with commercially available software (Excel, Microsoft) and 
subsequently analyzed with a statistical program (SPSS 20, IBM). All model 
assumptions were met. Outcome after treatment (success vs failure) was modeled as 
a dependent variable. Nine independent variables (treatment type; presence of 
multiple sarcoids [yes or no]; whether treatments with immunostimulating effects were 
used on another sarcoid in the same animal; tumour location, tumour type, and 
whether ulceration was present; age and sex of the animal; and whether sarcoids had 
been previously diagnosed and had recurred) were assessed for associations with 
outcome.  
For each categorical independent variable (ie, all except age), the variable with the 
highest success rate was used as referent. Age was treated as a continuous 
independent variable in all models. First, univariable binary logistic regressions were 
carried out to estimate the general effects of each independent variable on the 
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outcome after treatment. A multivariable binary logistic regression model was then 
built by selecting independent variables with a univariable P value ≤ 0.20 for inclusion, 
except for tumour type and location, which were considered confounding variables for 
treatment and therefore forced into all models. Values of P ≤ 0.05 were considered 
significant in all further models. The multivariable model was corrected for clustering 
by animal, and equids with missing data for any of the independent variables were 
excluded. The model was then refined by repeatedly eliminating the independent 
variable with the highest nonsignificant P value (except that tumour type and location 
were retained in the model as described). Odds ratios for treatment failure (as 
compared with that for the referent categories [those with the highest success rate for 
a given comparison]) were calculated together with Wald 95% confidence intervals 
(CIs) for significant independent variables in the final multivariable model. 
The choice between acyclovir and imiquimod for topically treated tumours was a result 
of owner preference, and the number of sarcoids in each group was almost equal. 
Because some patients had multiple lesions, a binary logistic regression with 
correction for clustering by animal was performed to compare effects of the 2 topical 
treatments on outcome. For BCG and intralesional chemotherapy (cisplatin or 
carboplatin emulsion) treatments, the effect of the number of injections on the outcome 
was tested by means of a 2 test. 
Results 
Medical records review identified 317 equids with 879 sarcoids. Eighty-seven horses 
(with 265 sarcoids) were lost to follow-up, resulting in 230 horses with 614 sarcoids 
that were included in the analyses. There were 96 sexually intact females, 22 sexually 
intact males, and 112 castrated males in the study, including 10 Thoroughbreds, 3 
French Trotters, 149 warmblood type horses, 5 half-breed horses, 4 draft type horses, 
24 ponies and 6 donkeys. Breed identification was missing for 29 horses. Median age 
at treatment was 7.9 years (range, 0.5 to 26.9 years) and the median follow-up period 
was 815 days (range, 167 to 2,256 days). 
Overall, 460 of 614 (74.9%; 95% CI: 71.3% - 78.2%) sarcoids were recorded as having 
a successful outcome after treatment. Although no reliable quantitative data were 
available regarding complications following treatment, reported major complications 




included wound dehiscence after excision by electrosurgery, severe skin irritation after 
imiquimod application, and abscess formation following BCG vaccine injection. No 
major complications were reported after cryosurgery, acyclovir application, or 
intralesional chemotherapy with cisplatin- or carboplatin-containing emulsions. 
Treatment success rates for sarcoids, categorized by biological variables of interest 
and treatment type, were tabulated (Table 1). 
Sarcoids were most frequently located in the inguinal region (228/614 [37.1%]) or on 
the head (120 [19.5%]); the least common site was at the distal aspect of the limbs 
(18 [2.9%]). Tumours of the inguinal area and head were most often treated by 
electrosurgery (147/228 [64.5%]) and by BCG vaccine injection (47/120 [39.2%]), 
respectively, whereas those in distal limb regions most commonly underwent topical 
imiquimod treatment (6/18 [33.3%]). A summary of lesions treated by each method 
and grouped according to anatomic location and sarcoid type is provided (Table 2). 
Measurements were available for 286 sarcoids in 105 equids. The median sarcoid 
surface measurement was 6.6 cm² (range, 0.04 to 600 cm²). Because the size was 
not recorded for most sarcoids, this variable was not included in the statistical analysis. 
Sarcoids treated with BCG vaccine injection were injected a median of 4 times (range 
1 to 7]). There was no significant (P = 0.35) difference in the number of injections 
between tumours with a successful outcome and those that were nonresponsive to 
BCG vaccination. Sarcoids treated by intralesional chemotherapy with cisplatin- or 
carboplatin-containing emulsions underwent a median of 4 injections (range, 1 to 7). 
There was also no significant difference (P = 0.25) in the number of injections between 
tumours with a successful outcome and those that were nonresponsive to 
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Table 1 - Treatment success rates for 614 sarcoids in 230 equids (200 horses, 24 ponies, and 6 
donkeys) in a retrospective study to evaluate outcomes following treatments selected according 
to a standardized protocol and to identify risk factors for sarcoid treatment failure in these patients. 
Variable No. of sarcoids  
(% of total for 
category) 




Treatment    
 Acyclovir 62 (10.1) 33 53.2 (41.0–65.1) 
 Imiquimod 61 (9.9) 44 72.1 (59.2–82.9) 
 BCG 48 (7.8) 28 58.3 (43.2–72.4) 
 ICS 23 (3.7) 12 52.2 (30.6–73.2) 
 Cryosurgery 67 (10.9) 43 64.1 (51.5–75.5) 
 Electrosurgery with ICB 34 (5.5) 23 67.7 (49.5–82.6) 
 Electrosurgery 319 (52.0) 277 86.8 (82.6–90.3) 
Multiple sarcoids present    
 Yes 386 (62.9) 269 69.7 (64.8–74.2) 
 No 228 (37.1) 191 83.8 (78.3–88.3) 
≥ 1 other sarcoid treated by an 
immunostimulating method*† 
   
 Yes 135 (22.0) 116 85.9 (78.9–91.3) 
 No 474 (77.2) 339 71.5 (67.2–75.5) 
Tumour location    
 Head 120 (19.5) 72 60.0 (50.7–68.8) 
 Neck 36 (5.9) 31 86.1 (70.5–95.3) 
 Axilla 81 (13.2) 67 82.7 (72.7–90.2) 
 Thorax 53 (8.6) 47 88.7 (77.0–95.7) 
 Abdomen 78 (12.7) 65 83.3 (73.2–90.8) 
 Inguinal region 228 (37.1) 168 73.7 (67.5–79.3) 
 Distal aspect of limb 18 (2.9) 10 55.6 (30.8–78.5) 
Sarcoid type†    
 Occult 83 (13.5) 60 72.3 (61.4–81.6) 
 Nodular 66 (10.7) 51 77.3 (65.3–86.7) 
 Verrucous 141 (23.0) 114 80.9 (73.4–87.0) 
 Fibroblastic 63 (10.3) 47 74.6 (62.1–84.7) 
 Mixed 125 (20.4) 82 65.6 (56.6–73.9) 
Patient sex    
 Sexually intact male 48 (7.8) 35 72.9 (58.2–84.7) 
 Castrated male 283 (46.1) 212 74.9 (69.4–79.9) 
 Sexually intact female 283 (46.1) 213 75.3 (69.8–80.2) 
Ulceration    
 Yes 142 (23.1) 102 71.8 (63.7–79.1) 
 No 472 (76.9) 358 75.9 (71.7–79.6) 
Recurrent tumour†    
 Yes 89 (14.5) 60 67.4 (56.7–77.0) 
 No 365 (59.4) 277 75.9 (71.2–80.2) 
 
Success was defined as full regression of the treated tumour without evidence of recurrence on follow-
up ≥ 6 months after treatment. Treatment success rates and 95% CIs are reported as percentages. 
Some patients underwent concurrent treatment of > 1 sarcoid by different methods. *Intratumoural BCG 
vaccine injection, cryosurgery, and topical imiquimod application were considered to have general 
immunostimulating effects. †Some animals with missing information were excluded from these 
analyses.  























Table 2 - Treatment types selected by use of a standardized protocol for 614 sarcoids in 230 equids (200 horses, 24 ponies, and 6 
donkeys), grouped according to anatomic location and type of sarcoid. 
 
Variable Treatment Total 
Acyclovir Imiquimod BCG ICS Cryosurgery Electrosurgery with ICB Electrosurgery 
Location         
Head 17 24 47 2 16 4 10 120 
Neck 1 10 1 0 4 0 20 36 
Axilla 7 5 0 4 8 6 51 81 
Thorax 5 4 0 0 8 1 35 53 
Abdomen 7 4 0 2 8 5 52 78 
Inguinal region 24 8 0 12 21 16 147 228 
Distal limb 1 6 0 3 2 2 4 18 
Type         
Occult 25 12 1 0 0 1 44 83 
Nodular 2 1 12 3 5 7 36 66 
Verrucous 10 21 5 1 14 3 87 141 
Fibroblastic 2 2 3 7 14 3 32 63 
Mixed 16 15 16 6 5 11 56 125 
Not recorded 7 10 11 6 29 9 64 136 
 See Table 1 for key.
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In the univariable analysis, treatment type (P < 0.001), presence or absence of multiple 
sarcoids (P < 0.001), whether another tumour on the same patient received any sarcoid 
treatment considered to have immunostimulatory effects (BCG vaccine injection, 
cryosurgery, or topical imiquimod application; P = 0.001), patient age at the time of 
treatment (P = 0.021), and anatomic location of the tumour (P = 0.10) met the criterion 
for inclusion in multivariable analysis, whereas patient sex, whether the treated 
tumours represented a recurrence of previous sarcoids, and whether ulceration was 
present did not (tumour type, although not meeting the criterion, was retained in the 
model as described).  
One hundred and forty-one sarcoids on 64 horses with missing data were excluded 
from the multivariable analysis. The quasi-likelihood under independence model 
criterion for the initial multivariable model was 508.72, and that for the final 
multivariable model (after removal of animal age, which was nonsignificant in the initial 
model) was 505.58, indicating that the final model fitted the data slightly better. In the 
final model, sarcoids that underwent topical acyclovir treatment, cryosurgery, and 
intralesional treatment with cisplatin- or carboplatin-containing emulsions had 
significantly higher odds of treatment failure, compared with those treated by 
electrosurgery (Table 3). Odds of treatment failure for tumours treated by topical 
application of imiquimod, BCG vaccine injection, or electrosurgery with intralesional 
placement of cisplatin-containing beads did not differ significantly from the odds for 
those treated by electrosurgery. The odds of treatment failure were significantly higher 
for tumours located in an equid with multiple sarcoids than for those in an equid with 
solitary lesions. These odds were also significantly higher for sarcoids where another 
tumour in the same equid did not receive immunostimulatory treatments than for those 
where another tumour did receive such treatment. Patient age at the time of treatment, 
sarcoid type, and anatomic location of the tumour were nonsignificant (P > 0.05 for 
each overall comparison) in the multivariable models.  
Separate analysis of occult and slightly verrucous sarcoids that succesfully underwent 
topical treatments revealed that a median treatment duration of 50 weeks (range, 3 to 
97 weeks) was required to obtain a successful result with acyclovir, compared with a 
median of 6 weeks (range, 2  to 40 weeks) for imiquimod. The observed difference in 
success rates between acyclovir-treated sarcoids and those treated with imiquimod 




(33/62 [53.2%] in 32 equids vs 44/61 [72.1%] in 43 equids, respectively) was not 
significant (P = 0.105). 
 
Table 3 - Results of multivariable analysis for risk factors associated with treatment failure for 
473 of the 614 sarcoids (in 166 of 230 equids) in Table 1. 
Variable Initial model Final model 
OR (95% CI) P value OR (95% CI) P value 
Treatment — 0.031 — 0.025 
   Acyclovir 3.89 (1.32–11.46) 0.014 4.05 (1.38–11.88) 0.011 
   Imiquimod 1.95 (0.68–5.59) 0.22 2.04 (0.72–5.79) 0.18 
   BCG 2.99 (0.81–11.03) 0.10 3.08 (0.84–11.31) 0.090 
   ICS 5.65 (1.37–23.30) 0.017 5.86 (1.43–24.09) 0.014 
   Cryosurgery 5.28 (1.66–16.77) 0.005 5.51 (1.70–17.89) 0.004 
   Electrosurgery with ICB 2.83 (0.93– 8.54) 0.066 2.92 (0.99–8.65) 0.052 
   Electrosurgery Referent Referent Referent Referent 
Multiple sarcoids present — <0.001 — < 0.001 
   Yes 4.16 (2.44 – 7.09) <0.001 4.13 (2.42–7.05) < 0.001 
   No Referent Referent Referent Referent 
≥ 1 other sarcoid treated by an 
immunostimulating method* 
— 0.030 — 0.041 
   Yes Referent Referent Referent Referent 
   No 2.58 (1.10–6.07) 0.030 2.51 (1.04–6.08) 0.041 
Patient age — 0.59 — — 
 
Independent variables with a P value ≤ 0.20 in univariable analysis were included in the multivariable 
analysis, except that anatomic location and sarcoid type were considered confounding variables for 
treatment and retained in the models. In the multivariable analysis, values of P ≤ 0.05 were considered 
significant. A significant effect indicates significantly greater odds of treatment failure, compared with 
that of the referent category. 141 sarcoids (64 equids) were excluded from the analysis because of 
missing data.  
— = Not applicable. See Table 1 for remainder of key. 
 
Discussion 
The overall success rate (460/614 [74.9%] sarcoids) found in the present study was 
comparable to those reported in the few earlier studies in which results for multiple 
sarcoid treatments in equids were evaluated (86/117 [73.5%] horses by Diehl et al. 
(Diehl et al., 1987) and 154/186 [82.8%] sarcoids by Martens et al. (Martens et al., 
2001b)). For the present study, the overall success rate was generally attributable to 
the high success rate obtained with electrosurgical excision (277/319 [86.8%]), which 
was the most commonly performed treatment. In previous reports (Diehl et al., 1987; 
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Scott and Miller, 2011), substantially lower success rates for surgical excision (ranging 
from 5/18 [28%] sarcoids to 9/14 [64%] horses) were reported, whereas the data from 
the present study were in agreement with findings in another retrospective study 
(Martens et al., 2001b) of sarcoid treatment in equids performed at our institution for 
the period 1995 through 1999. The high success rate of electrosurgical excision in the 
present study can be attributed to a careful tumour selection, the fact that all excisions 
were performed under general anaesthesia, and meticulous use of the electrosurgical 
instrument with a nontouching technique followed by wound flushing and primary 
wound closure. Although treatment of all equids under general anaesthesia may not 
seem necessary, it allows for positioning of patients in a way that provides optimal 
access to tumours and facilitates excision. Logically, the selection of cases for surgery 
inherently biased the sample population in our study, and it is clear that surgical 
excision is not a treatment that can or should be universally used for all sarcoids in all 
anatomic locations. At the distal aspect of the limbs, for example, there often is less 
skin available for closure, and electrosurgery would not be an ideal choice for some of 
these tumours. 
The prognosis for sarcoid treatment is often reported to be worse when the tumour has 
previously undergone unsuccessful treatment (Bogaert et al., 2008; Scott and Miller, 
2011; Bergvall, 2013), but to the authors’ knowledge, there is no evidence-based 
research on this topic. In the present study, whether or not the tumour was recurrent 
had no significant effect on treatment outcome. Nevertheless, information on previous 
treatment was unavailable for 160 of 614 (26.1%]) sarcoids (60/230 equids), which 
may have influenced the results. Further research may provide more information on 
the possible influence of previous treatment failures on prognosis for equids with 
sarcoids undergoing specific treatment protocols. 
Use of a carbon dioxide laser has been suggested to be a promising treatment for 
sarcoids in horses (Hawkins and McCauley, 2005). Success rates for laser surgery 
range from 37 of 60 (61.7%) to 48 of 59 (81.4%) of horses (Diehl et al., 1987; 
Carstanjen et al., 1997; Martens et al., 2001b; McCauley et al., 2002). Owing to the 
high cost of acquiring a CO2 laser system and the fact that it is cumbersome to use, 
some surgeons have used a diode laser instead, with similar results (successful in 
21/25 [84.0%] horses) (Compston and Payne, 2013). Considering that these reported 
success rates for diode or carbon dioxide laser surgery were comparable with the 




results of the present study, albeit that success rates were calculated on the sarcoid 
level in the present study, an advantage for more expensive laser surgery has yet to 
be proven. Laser surgery was not used for the patients in the present study because it 
was not available in the clinic at that time. 
Earlier reported success rates for cryosurgery range from 21 of 35 (60%) to 10 of 10 
(100%) horses (Lane, 1977; Fretz and Barber, 1980; Klein et al., 1986; Diehl et al., 
1987; Martens et al., 2001b). The success rate for treatment of sarcoids in the present 
study with this modality was  43 of 67 (64.1%) sarcoids, and sarcoids treated with 
cryosurgery had significantly greater odds of treatment failure, including recurrence 
(OR = 5.51), compared with those treated by electrosurgery. This was partly 
attributable to the fact that this treatment was primarily used for more complicated 
sarcoids that were ill-defined, inconveniently located, or strongly attached to underlying 
tissues. Similarly, the high odds of treatment failure for sarcoids that underwent 
intralesional injection of platinum-containing chemotherapeutic agents, relative to 
those for tumours treated by electrosurgery (OR = 5.86) in the present study were likely 
associated with the fact that these tumours were unamenable to surgical treatments 
owing to size, anatomic location, or both. 
Presently, there is only limited scientific information available on the topical treatment 
of sarcoids with acyclovir (Stadler et al., 2011) or imiquimod (Nogueira et al., 2006) in 
equids. The previously reported success rate for treatment of sarcoids with topical 
acyclovir administration (32/47 [68%] sarcoids) (Stadler et al., 2011) was higher than 
that found in the present study, whereas our results with imiquimod were more 
comparable to the previously reported success rate (9 of 15 [60%] sarcoids) (Nogueira 
et al., 2006). One factor that could have influenced the success rates found in the 
present study was that owners were responsible for applying the topical treatments; 
therefore, treatment compliance could not be verified. The success rate for imiquimod-
treated tumours in this study was apparently higher, compared with that for acyclovir-
treated tumours, but the difference was not significant. Whereas the number of 
sarcoids in each treatment group was almost identical, there were more animals in the 
imiquimod group than in the acyclovir group, which influenced the statistical outcome. 
The authors speculate that if the study design had been more balanced, as in a 
prospective study, significance might have been reached. Many questions still remain 
about the working mechanisms of acyclovir and the distribution of acyclovir and 
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imiquimod in the skin of equids, but on the basis of the present information, the authors 
believe that imiquimod application might still be a better choice for treatment of occult 
and slightly verrucous sarcoids in equids that tolerate the skin irritation, even though 
the observed difference between treatment results was nonsignificant in this study.  
In the present study, periocular sarcoids were all treated by BCG vaccine injection; 
given that the success rate for BCG treatment was low (28/48 [58.3%]), this may 
explain the low overall treatment success rate for tumours located on the head (72/120 
[60.0%]). Previously reported success rates for BCG vaccination for periocular 
sarcoids range from 36 of 61 (59%) to 31of 31 (100%) of equids (Lavach et al., 1985; 
Klein et al., 1986; Owen and Jagger, 1987; Vanselow et al., 1988; Knottenbelt and 
Kelly, 2000; Martens et al., 2001b). A possible explanation for the lower success rate 
of BCG vaccination in our study, compared with that in an earlier study at the same 
clinic (21/30 [70%] sarcoids) (Martens et al., 2001b), is that different commercially 
available BCG strains were used in the 2 studies. In earlier reports, authors warned 
that nonfatal or fatal anaphylactic shock could occur after BCG vaccination (strain not 
specified) (Landsheft and Anderson, 1984; Vanselow et al., 1988). Although equids 
were not premedicated with anti-inflammatory drugs, no such events were identified in 
the study reported here. Possible treatment alternatives for periocular sarcoids include 
interstitial brachytherapy and local chemotherapy with cisplatin, carboplatin, or 
mitomycin (Théon and Pascoe, 1994; Knottenbelt and Kelly, 2000; Byam-Cook et al., 
2006). However, specific instruments, skills, and infrastructure are needed to protect 
the operator and the environment for most of these treatments, and the results of 
mitomycin treatment have not yet been thoroughly described. 
Although the specific role of the immune system in the development and resolution of 
sarcoids in equids is not yet fully understood, it is likely to play an important role in this 
bovine papillomavirus–induced tumour. Autovaccination has been used to treat 
sarcoids (Kinnunen et al., 1999; Espy, 2008), and regression of untreated tumours in 
horses that had other sarcoids treated with cryosurgery has been previously described 
(Lane, 1977; Martens et al., 2001b). Spontaneous regression of sarcoids in untreated 
equids is generally considered to be rare, but it has been reported (Brostrom, 1995; 
Studer et al., 1997; Martens et al., 2001b). Results of the present study showed that 
the odds of treatment failure were significantly lower for a sarcoid on a patient that 
received concurrent immune-stimulating treatment (cryosurgery, BCG vaccine 




injection, or imiquimod application) for antoher tumour, compared with those for a 
sarcoid on a horse that did not, regardless of the primary treatment. This could suggest 
that the immune system has a role in resolution of these tumours and should not be 
neglected in future treatment development. 
To our knowledge, the present study was the largest published to date in which multiple 
treatments for different sarcoid types and locations in equids were compared. Although 
the minimum follow-up time of 6 months can be considered relatively short, compared 
with that used in other retrospective studies on the subject, the median follow-up period 
was > 2 years, which facilitates making conclusions for a long-term prognosis. Owing 
to the large sample size in this study and the fact that the analysis was not focused on 
a specific treatment or location, these results have a practical relevance for treatment 
of sarcoids in equids under clinical conditions. It should be noted, however, that the 
current study focused on a referral population and the results may not directly reflect 
the situation in ambulatory practice. Other weaknesses of the study included the fact 
that complications were not always recorded and that the decision regarding whether 
a treatment was successful was left to the owner in some cases. Nevertheless, during 
the telephone interview, very specific questions were asked to guide the owner in this 
process. 
With the treatment selection protocol used in the present study, most sarcoids in equids 
were treated successfully by electrosurgical excision under general anaesthesia; our 
results also suggested that use of immunostimulating treatments may improve the 
posttreatment outcome in some equids.
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Topical acyclovir application is an owner-friendly treatment for occult equine sarcoids, 
without the caustic side-effects other topical treatments have. Variable clinical success 
rates have been described, but it is not known to what rate and extent acyclovir 
penetrates in and through equine skin from a topical formulation. 
In the current study, an in vitro Franz diffusion model was used to determine the 
permeation parameters for a generic 5% acyclovir cetomacrogol cream for both 
healthy and sarcoid equine skin. The distribution of acyclovir between different layers 
of both skin types was also evaluated. 
While acyclovir penetrated through both skin types, significantly less acyclovir 
permeated to the deep dermis of sarcoid skin (197.62 ng/mm³) compared to normal 
skin (459.41 ng/mm³). Within sarcoid skin samples, significantly higher acyclovir 
concentrations were found in the epidermis (983.59 ng/mm³) compared to the 
superficial dermis (450.02 ng/mm³) and the deep dermis. At each sample point, 
significantly more acyclovir permeated to the receptor fluid through normal skin 
compared to sarcoid skin, which is reflected in the significantly higher permeation 
parameters of normal skin. 
Normal skin was found to be more permissive for acyclovir, but even in sarcoid skin, 
enough acyclovir reached the deep dermis to treat a Herpes simplex virus infection. In 
the case of equine sarcoids, the treatment is aimed at the Bovine papillomavirus and 
no information is available on the susceptibility of the DNA polymerase of this virus for 
acyclovir. Therefore, further research is needed to determine the efficacy of acyclovir 








Equine sarcoids are common Bovine papillomavirus (BPV) induced tumours of the skin 
of equids. BPV DNA is most often found in the superficial and deep dermis (Wobeser 
et al., 2012). Various invasive treatments have been described with relatively good 
results (Taylor and Haldorson, 2013), but they are often expensive, require a high level 
of commitment of the owner and can lead to patient discomfort. Therefore, a tendency 
towards topical treatment of the early stages of equine sarcoids exists, using different 
products ranging from bloodroot (Wilford et al., 2014) or mistletoe extracts (Christen-
Clottu et al., 2010) to AW-ludes (Knottenbelt and Kelly, 2000), imiquimod (Nogueira et 
al., 2006) and acyclovir-based creams (Stadler et al., 2011). In a retrospective study 
comparing the latter two, higher success rates for complete tumour regression were 
obtained with imiquimod (Haspeslagh et al., 2016). However, repeated imiquimod 
application can cause severe local adverse effects including erythema, oedema, 
scaling, ulceration and exudation (Nogueira et al., 2006), and owners therefore often 
prefer treatment with the non-irritating 5% acyclovir-based cream. This cream is 
applied once or twice daily until full tumour regression (Stadler et al., 2011; Haspeslagh 
et al., 2016). 
Acyclovir is an antiviral drug that has been developed for human medicine to treat 
lesions caused by the Herpes simplex virus (HSV) (Elion et al., 1977). The mechanism 
of action relies on metabolisation of the drug to its monophosphate form by a thymidine 
kinase specific to HSV (Elion et al., 1977). The monophosphate form is then further 
metabolized by cellular enzymes to a bi- and triphosphate form (Miller and Miller, 
1980). In its final triphosphate form, acyclovir inhibits the HSV DNA polymerase, thus 
preventing further virus replication. While BPV lacks the presence of this thymidine 
kinase and thus the ability to phosphorylate acyclovir (Baker and Howley, 1987), it has 
been shown that small amounts of acyclovir triphosphate are also formed in the 
absence of HSV thymidine kinase and certain viral DNA polymerases (for example 
from the Epstein-Barr virus) are highly sensitive to acyclovir triphosphate, hence an 
antiviral effect can still be obtained (Datta et al., 1980).  
To understand if and how topical acyclovir treatment can help to cure occult equine 
sarcoids, it is important to know the disposition of the drug in equine skin and if it 




reaches the dermis, where viral replication takes place. Topical delivery of acyclovir 
has been well-described in humans (Freeman et al., 1986; Parry et al., 1992), mice 
(Gonsho et al., 1990) and pigs (Wei et al., 2012), but nothing is known on topical 
delivery of acyclovir in horse skin, let alone equine sarcoids.  
The present study focusses on (trans)dermal delivery of acyclovir after topical 
application of a 5% acyclovir cetomacrogol cream in both sarcoids and normal equine 
skin using an in vitro design in Franz diffusion cells. 
Materials and methods 
Skin sample collection and storage 
Twelve occult equine sarcoids with intact epidermis were excised from the skin of ten 
different healthy adult warmblood horses that were presented for treatment to the 
Faculty of Veterinary Medicine of Ghent University. After owner consent, surgery was 
performed under general anaesthesia as described earlier (Haspeslagh et al., 2016). 
Care was taken not to include the surface of the sarcoids in the surgical preparation 
protocol. Twelve pieces of approximately five by ten centimeters of normal skin were 
collected from 12 different adult warmblood horses after euthanasia for unrelated 
reasons. The location of each piece of normal skin was matched to the location of a 
corresponding equine sarcoid. The skin was clipped prior to removal, avoiding damage 
to the epidermis. Immediately after excision all samples were pinned at their edges to 
a Styrofoam surface and all subcutaneous tissues were carefully removed using a 
scalpel blade, taking care not to damage the dermis. Skin samples were then rinsed 
with a sterile isotonic solution (0.9% NaCl, Baxter) and stored separately at -20 °C. 
Diffusion experiment 
Immediately before the start of the experiment, skin and sarcoid samples were thawed, 
visually inspected for damage and cut to circular pieces with a radius of approximately 
three centimeters for further use in the experiment. Leftover samples of the edges of 
sarcoid pieces were stored in 4% formalin, subsequently colored with hematoxylin – 
eosin stain and examined histologically to confirm sarcoid diagnosis. Twelve sarcoid 
and 12 matched normal skin pieces were mounted into static Franz diffusion cells 
(FDC-6, Logan) with an exposed area of 0.64 cm², with 5.0 ml 0.01 M PBS receptor 
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fluid (RF) at 32 ± 0.5 °C (Baert et al., 2010). Three-hundred µl of a generic 5% acyclovir 
cetomacrogol cream was carefully applied to the epidermal side of the skin, covering 
its complete surface. The donor compartment was covered with a paraffin film. 
At specific time intervals (2h, 6h, 12h, 18h, 24h, 31h, 36h and 48h), 200 µl of the 
receptor fluid of all cells was obtained and stored at -35 °C. Immediately after sample 
collection, all receptor chambers were refilled with 200 µl of fresh 0.01 M PBS. 
Immediately after taking the last sample, the remaining donor cream was removed 
from the skin by using cotton swabs slightly soaked in PBS, followed by dry swabs. 
The remaining receptor fluid was discarded and the exposed skin area (0.64 cm²) was 
cut out with a scalpel blade. All exposed skin samples were placed on microscope 
slides to ensure they were positioned completely flat and stored at -35 °C. 
Tissue collection and acyclovir quantification 
Frozen skin samples were embedded in cryotome gel (Cryocompound Frozen Tissue 
Medium, Klinipath), placed in a cryotome (CM1900, Leica Microsystems) and cut 
parallel to the skin surface in slices of 50 µm starting from the dermal side. The blade 
was cleaned between every skin sample. Slices were counted and kept in order while 
cutting. When the epidermis was reached, which could be visually determined by the 
operator by a change in color and texture of the sample, the slices already cut were 
equally divided into two subsets: the deep dermis (DD) and the superficial dermis (SD). 
The third subset, the epidermis (E), consisted of the remaining part of the sample. The 
sample was then cut further until slices became incomplete, indicating there was no 
more epidermis. These last incomplete slices were discarded to avoid any leftover 
donor solution influencing the results. Slices from the same subset of the same skin 
sample were combined for analysis. The number of slices in each subset was noted 
and the thickness of each subset was calculated by multiplying the number of slices 
by the slice thickness (50 µm). The tissue volume of each subset was calculated by 
multiplying the subset thickness with slice area (0.64 cm²). All subset samples were 
stored at -35 °C. 
The amount of acyclovir in skin sample subsets and RF samples was determined by 
validated ultra-performance liquid chromatography-tandem mass spectrometry 
(UPLC-MS/MS). Matrix-matched calibration curves were prepared in untreated skin 




subsets and RF by spiking with an appropriate amount of a working solution of 
acyclovir. All samples were also spiked with internal standard (ganciclovir) prior to 
analysis. Skin samples were left to equilibrate for 1 h at room temperature. Extraction 
from the skin subsets was performed by incubating with 200 µl of UPLC water for 15 
min at 60 °C in a warm water bath. Every 5 min the samples were vortexed for 10 sec. 
Skin samples were cooled down to room temperature and 200 µl of 1 N aqueous 
perchloric acid was added. The skin samples were vortexed and thereafter centrifuged 
for 10 min at 13225 g. Finally, the supernatant was filtered through a 0.2 µm Millex 
nylon filter (Merck-Millipore) and 5 µl was injected onto the UPLC-MS/MS instrument. 
RF samples were diluted with 1 ml of 0.1 N aqueous hydrochloric acid whereupon they 
were brought onto a mixed cation exchange - solid phase extraction column previously 
conditioned with 3 ml of methanol, 3 ml of water and 3 ml of 0.1 N hydrochloric acid. 
After the sample passed through the column, it was subsequently washed with 3 ml of 
0.1N aqueous hydrochloric acid, 3 ml of water and 3 ml of methanol. Acyclovir was 
eluted with 3 ml of 5% ammonia in methanol. The eluate was evaporated to dryness 
under a gentle nitrogen stream at 40 °C. The dry residue was dissolved in 150 µl of a 
0.1% aqueous acetic acid solution and 5 µl was injected onto the UPLC-MS/MS 
system. 
Chromatographic separation was performed on a UPLC HSS-T3 column (2.1 x 100 
mm, 1.8 µm, Waters). A gradient elution was applied with methanol and 0.1% acetic 
acid in water as mobile phases. The UPLC-MS/MS system consisted of an Acquity 
UPLC sample manager and autosampler in combination with a Quattro Premier XE 
triple quadrupole mass spectrometer operating in positive electrospray ionization mode 
(Waters). For quantification Masslynx software v. 4.1 was used at m/z = 226.02 > 
151.92 for acyclovir and m/z = 256.02 >151.98 for ganciclovir. 
The method was validated according to EU guidelines (EMEA/CVMP/573/00-FINAL; 
VICH GL49 (R)(MRK), 2015) and as described previously (Maes et al., 2009) for 
following parameters: linearity, accuracy, within-day and between-day precision, limit 
of detection (LOD), limit of quantification (LOQ) and stability in matrix; The LOD and 
LOQ were respectively determined at 0.16 ng/ml and 1 ng/ml for RF. For the skin 
subsets the LOD and LOQ were 0.20 ng/subset and 1 ng/subset, respectively. 
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The concentration of acyclovir in each skin subset was calculated by dividing the 
absolute amount of acyclovir detected by the subset tissue volume. The concentration 
of acyclovir in complete skin was calculated for each skin sample by first adding the 
absolute acyclovir amounts of DD, SD and E and dividing this total by the complete 
sample tissue volume 
Data analysis 
Permeation parameters were calculated from the curves of the cumulative amount 
permeated as a function of time. Steady state flux (Jss) was derived from the slope of 
the linear portion of the curve, divided by the exposed skin surface (0.64 cm²). Lag 
time was estimated by extrapolating the linear part of the curve to the time axis. The 
permeability coefficient (kp,v) was calculated as kp,v = Jss / Cv with Cv being the acyclovir 
concentration in the donor cream. Q48h was calculated as the cumulative percentage 
of the applied acyclovir dose that was found in the receptor fluid at 48 h. 
Statistical analysis was performed in SPSS 20 (IBM). Table 1 shows an overview of 
the different fitted models. A general linear model (GLM) approach was used. When 
multiple pairwise comparisons were performed post-hoc, a Bonferroni correction was 
applied. Significance was set at P ≤ 0.05. Normality of unstandardized residuals was 
tested for every model by a Kolmogorov-Smirnov test. When residuals did not show a 
normal distribution (P < 0.05) or when a large amount of heteroscedasticity was 
detected, a logarithmic transformation of the data was performed and variances and 












Table 1 - Overview of the fitted general linear models. N = normal skin; S = sarcoid skin; DD 
= deep dermis; SD = superficial dermis; E = epidermis; AC = acyclovir; RF = receptor fluid. 
Model 
number 
Independent variable(s) Covariate Dependent variable 
1 Type (N, S)  Complete skin thickness 
2 Type (N, S)  Skin subset thickness 
3 Type (N, S) Complete skin thickness AC in complete skin 
4 Type (N, S) Skin subset thickness AC in skin subset 
5 Skin subset (DD, SD, E) Skin subset thickness AC in skin subset 
6 Type (N, S) Complete skin thickness AC in RF by time 
7 Type (N, S) Complete skin thickness Jss 
8 Type (N, S) Complete skin thickness Q48h 
9 Type (N, S) Complete skin thickness Kp,v 
10 Type (N, S) Complete skin thickness Lagtime 
 
Results 
Equine sarcoid diagnosis was confirmed histologically for all sarcoid samples. One 
sarcoid was located on the neck, one at the level of the axilla, two on the abdominal 
wall, three at the inside of a hind leg and five around the praeputium or teats. One 
sarcoid sample was omitted from all calculations except for skin thickness because of 
reduction of the RF level during the experiment, indicating an artefact. 
Skin thickness 
Table 2 shows the mean thickness of complete skin and skin subsets for both normal 
and sarcoid skin, along with the associated F- and P-values. Sarcoid skin was 
significantly thicker compared to normal skin, due to the dermis of sarcoid skin being 
significantly thicker than normal dermis (Table 2). Because of these differences, skin 
or subset thickness was included as a covariate in further models comparing normal 
and sarcoid skin. 
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Table 2 - Thicknesses in mm of complete skin and skin subsets of normal and sarcoid skin 
along with associated F- and P-values. SE = standard error; DD = deep dermis; SD = superficial 
dermis; E = epidermis. * P ≤ 0.05. 
 
 Normal skin (n=12) 
Mean value (± SE) 
Sarcoid (n=12) 
Mean value (± SE) 
F- and P-values 
Complete 1.95 (± 0.12) 2.53 (± 0.16) F(1;17) = 9.07; P < 0.01* 
DD 0.58 (± 0.06) 0.85 (± 0.08) F(1;22) = 7.37; P = 0.01* 
SD 0.60 (± 0.06) 0.84 (± 0.08) F(1;21) = 6.12; P = 0.02* 
E 0.75 (± 0.11) 0.85 (± 0.12) F(1;21) = 0.80; P = 0.38 
 
Acyclovir in skin 
In Table 3, the concentrations of acyclovir and associated P-values are listed for 
complete skin and skin subsets of normal and sarcoid skin. While there was no 
significant difference between normal and sarcoid skin in the concentration measured 
in total skin, significantly lower concentrations of acyclovir were detected in DD of 
sarcoid skin compared to normal skin. 
In sarcoid skin, there was a significant difference between different skin layers for the 
concentration of acyclovir (F(2;29) = 15.06; P < 0.01), which was not present in normal 
skin (F(2;30) = 1.82; P = 0.18). Post-hoc tests revealed that in sarcoid skin, significantly 
higher concentrations of acyclovir could be measured in E compared to SD (P = 0.03) 
and DD (P < 0.01), and acyclovir concentration was significantly higher in SD 










Table 3 - Concentration of acyclovir in ng/mm³ for complete skin and skin subsets of normal 
and sarcoid skin along with associated F- and P-values. SE = standard error; DD = deep 
dermis; SD = superficial dermis; E = epidermis. * P ≤ 0.05. 
 
 Normal skin (n=12) 
Mean value (± SE) 
Sarcoid (n=12) 
Mean value (± SE) 
F- and P-values 
Complete 755.68 (± 122.71) 576.49 (± 92.40) F(1;19) = 1.28; P = 0.27 
DD 459.41 (± 73.48) 197.62 (± 25.11) F(1;20) = 10.01; P < 0.01* 
SD 664.03 (± 113.83) 450.02 (± 90.84) F(1;19) = 3.59; P = 0.07 
E 1031.97 (± 242.95) 983.59 (± 156.53) F(1;19) = 0.05; P = 0.83 
 
Acyclovir in receptor fluid 
Figure 1 shows the mean cumulative concentration (ng/ml) of acyclovir found in RF at 
each sample point for normal skin and sarcoid skin. At each time point, significantly 
more acyclovir had permeated through normal skin compared to sarcoid skin (P ≤ 
0.05). 
Acyclovir permeation parameters through normal and sarcoid skin are listed in Table 
4, along with the associated F- and P-values. All permeation parameters except lag 
time were significantly higher in normal skin compared to sarcoid skin. 




Figure 1 - Mean ± standard error (SE) acyclovir concentrations determined in the receptor 
fluid at each sampled time point for both normal and sarcoid skin. 
 
 
Table 4 - Permeation parameters for normal and sarcoid skin and the associated F- and P-
values. SE = standard error. * P ≤ 0.05. 
 
 Normal skin (n=12) 
Mean value (± SE) 
Sarcoid (n=12) 
Mean value (± SE) 
F- and P-values 
Jss (ng/cm²*h) 4958.56 (± 1735.39) 924.31 (± 147.54) F(1;19) = 4.83; P = 0.04* 
Q48h (%) 0.97 (± 0.34) 0.16 (± 0.03) F(1;19) = 5.36; P = 0.03* 
kp,v E-5 (cm/h) 9.90 (± 3.47) 1.8 (± 0.3) F(1;19) = 4.83; P = 0.04* 
Lag time (h) 3.54 (± 0.66) 6.8 (± 1.08) F(1;19) = 2.64; P = 0.12 
 





Sarcoid skin was thicker than normal skin and this difference was due to thickening of 
the dermis (Table 2). These findings can be related to the distinct proliferation of 
fibroblast-like cells in the dermis which occurs in all equine sarcoids (Martens et al., 
2000). While epidermal hyperplasia is not uncommon in equine sarcoids, the epidermis 
of equine sarcoid skin was not significantly thicker compared to normal skin in this 
experiment(Table 2). The mean normal skin thickness (1.95 mm) was in the lower 
spectrum of the reported range of equine skin thickness (1.0 – 7.7 mm) (Wong et al., 
2005; Scott and Miller, 2011). As normal skin samples were matched to the body 
location of sarcoid skin samples, this confirms earlier statements of sarcoids occurring 
more frequently at body locations where the skin is thinner (Pilsworth and Knottenbelt, 
2007). 
Less acyclovir penetrated to DD of sarcoid skin compared to normal skin. Within 
sarcoid skin, higher concentrations of acyclovir were measured in E than in SD and 
DD, and more acyclovir was present in SD than in DD (Table 3). In normal skin, no 
such differences could be found. Moreover, all permeation parameters, except for lag 
time, also indicated that the permeability of sarcoid skin was lower compared to normal 
skin. This filter effect of sarcoid skin is probably due to the thicker and more dense 
dermal layers and the presence of hyperkeratosis at the level of the epidermis (Martens 
et al., 2000). Nevertheless, a certain amount of acyclovir still reached the dermis, 
where viral transcription occurs and causes the fibroblastic proliferation typically 
present in equine sarcoids. 
The minimal acyclovir dose that leads to 50% inhibition of viral cytopathic effect of HSV 
is 0.35 – 0.79 ng/mm³ (Crumpacker et al., 1979; Declercq et al., 1980). In human 
epidermis (which is the target skin layer in humans), concentrations of 7 ng/mm³ were 
reported after topical acyclovir application (Parry et al., 1992). The mean concentration 
found in the sarcoid DD in this experiment was 197.62 ng/mm³ (Table 3), which would 
be sufficient to treat a HSV infection. Of course, the viral target in this case is BPV and 
to the author’s knowledge, no information is available on the susceptibility of the BPV 
DNA polymerase for acyclovir. 
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In humans it has been shown that more acyclovir was present in E after topical 
administration compared to oral administration, while in the deeper basal epidermis, 
the acyclovir concentration was 2 – 3 times higher after oral administration (Parry et 
al., 1992). Since the target region for treating equine sarcoids with acyclovir is located 
even deeper in the skin, oral acyclovir administration could increase the drug 
concentration at this target location. However, oral acyclovir administration resulted in 
low plasma concentrations and a low absolute oral bioavailability (< 5%) in adult 
horses, pointing to intravenous acyclovir administration or oral valacyclovir 
administration as better alternatives (Garré et al., 2007). Other techniques improving 
permeation of acyclovir through human skin (e.g. Solid Lipid Nanoparticles (Gide et al., 
2013) or iontophoresis (Volpato and Nicoli, 1998; Shukla et al., 2009)) could also be 
applied to horses. 
In conclusion, the results show that after topical acyclovir administration on sarcoid 
skin, concentrations in the deeper dermal layers were significantly lower compared to 
normal skin. Nevertheless, concentrations in the DD of sarcoid skin were still 
considerable. If BPV is susceptible for those acyclovir concentrations, a therapeutic 
effect at the level of the target skin region could be obtained after topical administration. 
To find out whether the obtained concentrations are sufficient to interfere with BPV 
DNA replication, a DNA polymerase assay can be carried out to test the susceptibility 
of the BPV DNA polymerase for the effects of acyclovir. Further, the question remains 
how much acyclovir is being triple phosphorylated in the equine dermis.





Baert, B., Boonen, J., Burvenich, C., Roche, N., Stillaert, F., Blondeel, P., van Bocxlaer, 
J., de Spiegeleer, B., 2010. A new discriminative criterion for the development of 
franz diffusion tests for transdermal pharmaceuticals. Journal of Pharmacy and 
Pharmaceutical Sciences 13, 218–230. 
Baker, C.C., Howley, P.M., 1987. Differential promoter utilization by the bovine 
papillomavirus in transformed cells and productively infected wart tissues. The 
EMBO journal 6, 1027–1035. 
Christen-Clottu, O., Klocke, P., Burger, D., Straub, R., Gerber, V., 2010. Treatment of 
clinically diagnosed equine sarcoid with a mistletoe extract (Viscum album 
austriacus). Journal of veterinary internal medicine / American College of 
Veterinary Internal Medicine 24, 1483–1489. 
Crumpacker, C.S., Lowell, E., Zaia, J. a, Myron, J., 1979. Growth Inhibition by 
Acycloguanosine of Herpesviruses Isolated from Human Infections. Antimicrobial 
agents and Chemotherapy 15, 642–645. 
Datta, A.K., Colbyt, B.M., Shawt, J.E., Paganotf, J.S., 1980. Acyclovir inhibition of 
Epstein-Barr virus replication. Biochemistry 77, 5163–5166. 
Declercq, E., Descamps, J., Verhelst, G., Walker, R.T., Jones, A.S., Torrence, P.F., 
Shugar, D., 1980. Comparative efficacy of antiherpes drugs against different 
strains of herpes simplex virus. Journal of Infectious Diseases 141, 563–574. 
Elion, G.B., Furman, P. a, Fyfe, J. a, de Miranda, P., Beauchamp, L., Schaeffer, H.J., 
1977. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) 
guanine. Proceedings of the National Academy of Sciences of the United States 
of America 74, 5716–5720. 
EMEA/CVMP/573/00-FINAL. Notice to applicants. Veterinary medicinal products: 
Establishment of maximum residue limits (MRLs) for residues of veterinary 
products in foodstuff of animal origin: Development and validation of a proposed 
regulatory method. Vol. 8. 
Freeman, D., Sheth, N., Spruance, S., 1986. Failure of topical acyclovir in ointment to 
penetrate human skin. Antimicrobial agents and Chemotherapy 29, 730–732. 
Garré, B., Shebany, K., Gryspeerdt,  a., Baert, K., Van Der Meulen, K., Nauwynck, H., 
Deprez, P., De Backer, P., Croubels, S., 2007. Pharmacokinetics of acyclovir after 
intravenous infusion of acyclovir and after oral administration of acyclovir and its 
prodrug valacyclovir in healthy adult horses. Antimicrobial Agents and 
Chemotherapy 51, 4308–4314. 
Chapter 7 – Topical acyclovir in vitro 
135 
 
Gide, P.S., Gidwani, S.K., Kothule, K.U., 2013. Enhancement of transdermal 
penetration and bioavailability of poorly soluble acyclovir using solid lipid 
nanoparticles incorporated in gel cream. Indian Journal of Pharmaceutical 
Sciences 75, 138–142. 
Gonsho, A., Imanidis, G., Vogt, P., Kern, E.R., Tsuge, H., Su, M.-H., Choi, S.-H., 
Higuchi, W.I., 1990. Controlled (trans) dermal delivery of an antiviral agent 
(acyclovir). I: An in vivo animal model for efficacy evaluation in cutaneous HSV-1 
infections. International journal of Pharmaceutics 65, 183–194. 
Haspeslagh, M., Vlaminck, L., Martens, A., 2016. Treatment of sarcoids in equids: 230 
cases (2008-2013). Journal of the American Veterinary Medical Association 249, 
311–318. 
Knottenbelt, D.C., Kelly, D.F., 2000. The diagnosis and treatment of periorbital sarcoid 
in the horse: 445 cases from 1974 to 1999. Veterinary Ophthalmology 3, 169–191. 
Maes,  a, Garré, B., Desmet, N., van der Meulen, K., Nauwynck, H., De Backer, P., 
Croubels, S., 2009. Determination of acyclovir in horse plasma and body fluids by 
high-performance liquid chromatography combined with fluorescence detection 
and heated electrospray ionization tandem mass spectrometry. Biomedical 
chromatography : BMC 23, 132–140. 
Martens, A., De Moor, A., Demeulemeester, J., Ducatelle, R., 2000. Histopathological 
characteristics of five clinical types of equine sarcoid. Research in veterinary 
science 69, 295–300. 
Miller, W.H., Miller, R.L., 1980. Phosphorylation of acyclovir (acycloguanosine) 
monophosphate by GMP kinase. Journal of Biological Chemistry 255, 7204–7207. 
Nogueira, S. a F., Torres, S.M.F., Malone, E.D., Diaz, S.F., Jessen, C., Gilbert, S., 
2006. Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot 
study. Veterinary dermatology 17, 259–265. 
Parry, G.E., Dunn, P., Shah, V.P., Pershing, L.K., 1992. Acyclovir bioavailability in 
human skin. The Journal of Investigative Dermatology 98, 856–863. 
Pilsworth, R.C., Knottenbelt, D., 2007. Equine sarcoid. Equine Veterinary Education 
19, 260–262. 
Scott, D.W., Miller, W.H.J., 2011. Structure and function of the skin, in: Scott, D.W., 
Miller, W.H.J. (Eds.), Equine Dermatology. Saunders, Maryland heights, MI, p. 2. 
Shukla, C., Friden, P., Juluru, R., Stagn, G., 2009. In Vivo Quantification of Acyclovir 
Exposure in the Dermis Following Iontophoresis of Semisolid Formulations. 
Journal of pharmaceutical sciences 98, 917–925. 




Stadler, S., Kainzbauer, C., Haralambus, R., Brehm, W., Hainisch, E., Brandt, S., 2011. 
Successful treatment of equine sarcoids by topical aciclovir application. The 
Veterinary record 168, 187–190. 
Taylor, S., Haldorson, G., 2013. A review of equine sarcoid. Equine Veterinary 
Education 25, 210–216. 
VICH GL49 (R) (MRK), Guidance for Industry, Studies to evaluate the metabolism and 
residue kinetics of veterinary drugs in food producing animals: validation of 
analytical methods used in depletion study. Revision at step 9, 2015. 
Volpato, N., Nicoli, S., 1998. In vitro acyclovir distribution in human skin layers after 
transdermal iontophoresis. Journal of controlled Release 50, 291–296. 
Wei, H., Wang, S., Xu, F., Xu, L., Zheng, J., Chen, Y., 2012. Topical bioequivalence of 
acyclovir creams using dermal microdialysis in pigs: a new model to evaluate 
bioequivalence for topical formulations. Drug Development and Industrial 
Pharmacy 38, 785–791. 
Wilford, S., Woodward, E., Dunkel, B., 2014. Owners’ perception of the efficacy of 
Newmarket bloodroot ointment in treating equine sarcoids. Canadian Veterinary 
Journal 55, 683–686. 
Wobeser, B.K., Hill, J.E., Jackson, M.L., Kidney, B. a, Mayer, M.N., Townsend, H.G.G., 
Allen, A.L., 2012. Localization of Bovine papillomavirus in equine sarcoids and 
inflammatory skin conditions of horses using laser microdissection and two forms 
of DNA amplification. Journal of veterinary diagnostic investigation 24, 32–41. 
Wong, D., Buechner-Maxwell, V., Manning, T., 2005. Equine Skin: Structure, 









Topical use of 5% acyclovir cream for the 
treatment of occult and verrucous equine 




M. Haspeslagh, M. Jordana Garcia, L. Vlaminck and A. Martens 
 
 
Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, 




Haspeslagh M., Jordana M., Vlaminck L. and Martens A. Topical use of 5% acyclovir cream 
for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-
controlled study (2017), BMC Veterinary Research 13, 296. 











Previous studies mention the use of topical acyclovir for the treatment of equine 
sarcoids. Success rates vary and since the bovine papillomavirus (BPV) lacks the 
presence of a kinase necessary to activate acyclovir, there is no proof of its activity 
against equine sarcoids. 
Twenty-four equine sarcoids were topically treated with acyclovir cream and 25 with a 
placebo. Both creams were applied twice daily during six months. Before the start of 
the treatment and further on a monthly basis, photographs and swabs were obtained. 
On the photographs, sarcoid diameter and surface area were measured and 
verrucosity of the tumours was quantified using a visual analog scale (VAS). The 
swabs were analysed by PCR for the presence of BPV DNA and positivity rates were 
calculated as the number of positive swabs divided by the total number of swabs for 
each treatment group at each time point. Success rates were not significantly different 
between both treatment groups. There was also no significant effect of treatment on 
sarcoid diameter, surface area or VAS score. For the swabs, a significantly higher BPV 
positivity rate was found for acyclovir treated tumours compared to placebo treated 
sarcoids only after one month of treatment and not at other time points. 
None of the results indicate that treatment with acyclovir yields any better results 













Acyclovir (acycloguanosine) is an antiviral drug developed for the treatment of herpes 
simplex virus (HSV) infections in humans (Elion et al., 1977). The drug relies on 
competitive inhibition of the viral DNA polymerase, but needs to be phosphorylated by 
a HSV specific thymidine kinase and then further by cellular enzymes to a triphosphate 
form to exert its action (Miller and Miller, 1980). Nevertheless, inhibition of viral 
replication also occurs for other viral species than HSV (Datta et al., 1980), suggesting 
phosphorylation of the drug may also occur in cells where the HSV thymidine kinase 
is not present, albeit to a lesser extent. 
Equine sarcoids are tumours originating in the dermal layers of equine skin. The 
pathogenesis is not entirely clear yet, but there is agreement in literature that the 
bovine papillomavirus (BPV) (mainly type 1 and type 2) most likely plays an important 
role in the development of these tumours (Nasir and Campo, 2008). Many treatments 
have been reported, but no universal treatment has been found to cure all sarcoids on 
all body locations. 
Topical treatment with acyclovir has been described to result in complete regression 
in 68% of occult, verrucous, nodular or mixed equine sarcoids (Stadler et al., 2011). In 
addition, a recent ex vivo study has shown that acyclovir concentrations reached in the 
dermal layers after topical administration on sarcoid-affected equine skin are high 
enough to possibly achieve an antiviral effect (Haspeslagh et al., 2016a). However, the 
thymidine kinase necessary for initial phosphorylation of the drug is missing in BPV 
DNA (Baker and Howley, 1987) and the susceptibility of the BPV DNA polymerase for 
acyclovir is unknown. A retrospective study further described complete regression after 
topical acyclovir treatment in only 53% of the cases (Haspeslagh et al., 2016b). 
The goal of the present study was to establish if topical treatment of occult equine 
sarcoids with a 5% acyclovir cream is more effective compared to the application of a 









Materials and methods 
Subjects 
A power analysis revealed that at least 15 unrelated sarcoids were needed in each 
treatment group to be able to show a difference between acyclovir and placebo 
treatments (power = 0.8; type-1 error = 0.05). Because multiple sarcoids on the same 
horse would be treated the same way, a minimum of 15 horses was necessary in each 
treatment group. 
All horses that were presented to the Department of Surgery and Anaesthesiology of 
the Faculty of Veterinary Medicine of Ghent University for the treatment of previously 
untreated occult or partly verrucous equine sarcoids were considered for inclusion in 
the study. Horses that had fibroblastic or nodular sarcoids in addition to the occult 
and/or partly verrucous tumours and horses that received concurrent medical 
treatment for other indications were excluded. The diagnosis of equine sarcoid was 
made by clinical examination by an experienced veterinarian. As a compensation for 
taking part in the study, the treatments and consultations were offered free of charge 
and sarcoids that would have been treated with placebo during the study would be 
treated afterwards without additional costs. When owners were willing to participate, 
an informed consent was signed in which the owners also committed to apply the 
topical treatment as instructed. 
Treatment and sampling 
Sarcoids were topically treated with either a generic 5% acyclovir cetomacrogol cream 
or a placebo consisting of the same cetomacrogol cream without active component. 
The choice between both treatments was made at random and owners were blinded 
to the treatment. Packaging of the creams was identical and the labels were coded. 
When multiple occult or partly verrucous sarcoids were present on the same horse, all 
tumours were treated with the same product. 
The sarcoids of both treatment groups were completely covered with cream twice daily 
by the owner. If cream remnants were still present, the lesion was cleaned with water 
and dried with a paper towel before applying more. Owners were instructed and 
demonstrated to beforehand how to apply the cream. Treatment continued for six 
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months or until the sarcoid had disappeared completely. The experiment was stopped 
if sudden aggressive growth of the sarcoid would occur. 
Before the start of the treatment (T0) and further at monthly intervals (T1 until T6), a 
close-up photograph of the sarcoid was taken with a ruler next to, but not covering the 
tumour. To gain more insight in the antiviral effect of acyclovir on BPV in equine 
sarcoids, a swab sample for BPV DNA analysis was taken at the same time as the 
photographs by rubbing a sterile cottontip swab soaked in sterile distilled water over 
the surface of the sarcoid (Martens et al., 2001). Swabs were stored in separate 
containers at -20 °C until further processing. When the horses were stabled too far 
away from the clinic, private practitioners were responsible for obtaining the swab 
samples and photographs and provide them to the clinic. When this was the case, the 
private practitioners received clear instructions on how to do this to ensure a high 
sample quality. 
All pictures and samples were processed together at the end of the experiment. 
Pictures were given a random coded file name and put in random order to ensure 
blinded processing. On all pictures, sarcoid maximal diameter and surface area were 
measured twice using image measuring software (ImageJ). The mean of two 
measurements was used for further analysis. Severity of the sarcoid was determined 
by three diplomates of the European College of Veterinary Surgeons. A visual analog 
scale (VAS) was used ranging from no visible abnormalities of the skin (score 0) to 
distinct skin verrucosity (score 1000) (Figure 1). The mean of three scores was used 
for further analysis. 
Swabs were examined for the presence of BPV DNA. DNA was extracted using a 
commercial kit (DNeasy Blood & Tissue Kit, Qiagen). Swabs were first incubated for 
12 hours in 180 µl buffer ATL and 20 µl proteinase K at 56 °C. The samples were then 
vortexed and 200 µl buffer AL was added. After vortexing again, swabs were removed 
from the vials and discarded. Further DNA extraction was continued as described in 
the manual of the kit, following the tissue protocol. After DNA extraction, real-time PCR 
analysis was performed using general BPV primers and BPV-1 and -2 specific TaqMan 
probes as described by Bogaert et al. (Bogaert et al., 2007). All samples were 
processed in duplicate and when quantification cycle values between repeats differed 
by more than one, the PCR was repeated. Positive controls consisting of a mixture of 





known BPV-1 and BPV-2 samples and negative controls consisting of distilled water 
were included in each run. All samples were also tested for the presence of equine 
interferon beta (IFNb) DNA to confirm successful DNA extraction (Haralambus et al., 
2010). Samples were considered positive when either BPV-1 or BPV-2 DNA was 
detected. Samples were only considered negative when IFNb DNA could be detected, 
but no BPV DNA. When no IFNb DNA was detected, samples were marked as missing 
data for further analysis. 
Statistical analysis 
All data analysis was performed using statistical software (SPSS 20, IBM). Statistical 
significance was set at P ≤ 0.05. To estimate the effect of treatment on the number of 
fully regressed sarcoids, a Fisher exact test was used. For all continuous data (sarcoid 
diameter, sarcoid surface area and VAS score), the effect of time and treatment on the 
dependent variables was determined by repeated measures ANOVAs with horse as a 
blocking factor. When sphericity could not be assumed, a Greenhouse-Geisser 
correction was applied. Additionally, a “change parameter” was calculated for 
continuous data from all sarcoids as the difference between the measurement at T0 
and the last measurement. The effect of treatment on this “change parameter” was 
estimated by a generalized linear model, corrected for follow-up time and with horse 
as a blocking factor. For each time point, the effect of treatment on the number of 
samples positive for BPV DNA was tested using a binary logistic regression with horse 
as a blocking factor. To test the effect of time on the number of samples positive for 
BPV DNA, a binary logistic regression with horse as a blocking factor was used for 
both treatments with T0 as the reference category. 
Results 
Twenty-eight horses and three ponies were included in the study. In total, 24 sarcoids 
on 15 individuals were treated topically with 5% acyclovir cream and 25 sarcoids on 
16 individuals were treated topically with placebo cream. Multiple sarcoids were 
present in four horses in the acyclovir group, and in five horses in the placebo group. 
For both groups, median treatment time was six months (min: one month, max: six 
months). The study was stopped early because of sudden aggressive tumoural growth 
in one horse, which was part of the acyclovir treatment group. For three placebo treated 
horses and one acyclovir treated horse, the study was stopped early because of 
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complete sarcoid regression. No side effects were observed in any of the treated 
horses. 
Complete regression during treatment occurred in two of the acyclovir treated sarcoids 
(8.3%; 95% CI: 1.0% - 27.0%), while this was the case in four (16%; 95% CI: 4.5% - 
36.1%) of the placebo treated sarcoid. This difference was not significant (P = 0.67). 
Figure 2 shows the mean measurements along with the 95% confidence interval of 
sarcoid diameter (A), sarcoid surface (B) and VAS score (C) at each time point for both 
treatment groups. The intraclass correlation coefficient of the raters for average 
measures of VAS was 77.0%. There was no significant effect of treatment or time on 
any of these variables. The mean calculated “change parameters” are listed in Table 
1 along with the P-values for the effect of treatment on them. A positive “change 
parameter” indicates a decrease in measurement between T0 and the last sample 
point whereas a negative change indicates an increase. The mean largest sarcoid 
diameter of acyclovir treated tumours increased during treatment, while it decreased 
for the placebo treated sarcoids (Table 1). Mean surface area increased during the 
treatment for both groups (Table 1). Mean VAS score decreased, indicating that 
sarcoids were found to be less verrucous towards the end of the treatment (Table 1). 
Differences in “change parameters” between both treatment groups were never 
significant. 
No genomic DNA was present on the swab in 15.9% of the samples in the acyclovir 
treated group and in 22.8% of the samples in the placebo group. Figure 3 shows the 
percentage of positive PCR samples in each treatment group at each time point. Only 
at T1, a significantly higher percentage of samples was positive for the presence of 
BPV DNA in the acyclovir group compared to the placebo group (P = 0.005). At all 
other time points, there were no significant differences between groups. In the acyclovir 
group, the percentage of positive samples was significantly higher at T1 compared to 
T0 (P = 0.004). At all other time points, the percentage of positive samples was not 
significantly different from T0. In the placebo group, the percentage of positive samples 
was significantly lower at all time points except for T1, compared to the percentage of 
positive samples at T0 (T2: P = 0.06; T3: P = 0.03; T4: P = 0.04; T5: P = 0.04; T6: P = 
0.04). 
 





Table 1 - Mean “change parameters” and  associated p-values for the difference between 
both treatment groups (SE = Standard Error; VAS = visual analog scale). 
Change Acyclovir (± SE) Placebo (± SE) p-value 
Diameter (mm) -6.10 (± 4.63) 2.02 (± 5.67) 0.52 
Surface area (mm²) -314.26 (± 203.44) -60.25 (± 247.67) 0.87 







Figure 1 - Example of how a slider bar was used to determine severity of a sarcoid on a visual 



















Figure 2 - Mean measurements along with the 95% confidence interval of sarcoid diameter (A), sarcoid surface (B) and visual analog scale (VAS) 




















Figure 3 - The percentage of samples positive for the presence of BPV DNA at each time point 
(months after start of the treatment)  and corresponding 95% confidence intervals. No fill: acyclovir; 
dotted fill: placebo. 
Discussion 
This is the first study on equine sarcoid treatment which is placebo controlled and 
double blinded. Results of this study are therefore valuable for treatment selection in 
practice. Because of the long study duration, the horses were cared for by their owners 
at home and this implicated that it was hard to check for treatment compliance. 
However, all owners signed a commitment to the experiment beforehand and were 
contacted regularly by phone to monitor the course of the study. Because the horses 
were stabled at home and this was in many cases too far away to allow for visits to the 
clinic, monthly visits were often performed by trusted private practitioners. While this 
implicates a possible variation in sample quality, practitioners received clear 
instructions on how to take pictures and swabs to maximize uniformity. A benefit of this 
was that the persons evaluating the pictures and analyzing the samples never saw the 
patients in real life, which enabled an unprejudiced evaluation. 
The success rate for acyclovir treatment was lower compared to previously reported 
success rates (Stadler et al., 2011; Haspeslagh et al., 2016b). The sample population 
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of the present study was smaller, which could explain the lower success rates. 
Moreover, acyclovir treatment was stopped after 6 months of treatment in the present 
study, while under normal clinical circumstances it is often continued longer when the 
tumour has not fully regressed yet, but a beneficial effect is observed. In both previous 
studies, a certain number of sarcoids have indeed been treated for over six months, 
which could have increased the success rate. In the study of Stadler et Al. (2011), 
some lesions were ablated before acyclovir treatment, which could have improved the 
results. The sarcoids that responded well to acyclovir treatment in that study were all 
smaller than 5 mm in diameter (Stadler et Al., 2011), which is a lot smaller compared 
to the lesions that were used for the present study (Figure 2). While the concentration 
of acyclovir in the cream used in the present study was the same as in all earlier studies 
(Stadler et al., 2011; Haspeslagh et al., 2016b), the constitution of the cream vehicle 
used in this and earlier studies by Haspeslagh et al. (Haspeslagh et al., 2016a, 2016b) 
differed from the one used by Stadler et al. (Stadler et al., 2011). The cream base was 
altered because sedimentation occurred when using the cream formulation of Stadler 
et al., which lead to a heterogeneous acyclovir concentration. 
Time and treatment type did not have a significant influence on mean sarcoid 
dimensions or mean VAS score. Mean “change parameters” were also not significantly 
different between treatment groups. Nevertheless, the mean VAS score decreased for 
both treatment groups during the study, indicating that equine sarcoids were found less 
verrucous towards the end of the treatment. Perhaps the previously observed benign 
effect is therefore not due to the application of acyclovir, but merely to the effect of a 
cream that keeps the skin hydrated, preventing the formation of a thick verrucous layer. 
Anti-keratotic creams have analogously been used to lessen the verrucosity of equine 
sarcoids prior to other treatments (Quinn, 2003). This hypothesis can be tested by 
including a third “no treatment” group, which was not done here due to ethical 
considerations towards the owners. The presence of a keratinous layer in equine 
sarcoids with a high degree of verrucosity could interfere with acyclovir penetration and 
the presence of highly verrucous tumours could have influenced the results. 
Nevertheless, the mean VAS score, based on verrucosity, was not very high at T0 and 
decreased during treatment. VAS scores at T0 did also not differ significantly between 
the acyclovir and placebo group, indicating that the comparison between both groups 
is valid. To evaluate the effect of a thick verrucous layer on acyclovir treatment, a 





similar experiment could be performed comparing treatment of strictly occult versus 
strictly verrucous tumours.  
In order to obtain a good indication of the BPV load in non-ulcerated equine sarcoids, 
a quantitative real-time PCR on tissue from a biopsy probably yields the most reliable 
results. However, this would have required the sarcoids to be biopsied prior to the 
study and further at each time point of evaluation, which could have influenced the 
outcome, as equine sarcoids often become more aggressive after being damaged 
(Knottenbelt et al., 1995; Bergvall, 2013). For this reason, swabs were obtained instead 
of biopsies. This also implies that histological examination to confirm the diagnosis of 
equine sarcoid could not be performed and that there is a chance that some lesions 
which regressed spontaneously were not actual equine sarcoids. Nevertheless, the 
clinical appearance of equine sarcoids is so typical that clinical examination by an 
experienced veterinarian should be sufficient to make a correct diagnosis (Knottenbelt 
et al., 1995; Bogaert et al., 2008) (chapter 4). While the presence of BPV DNA can be 
shown in up to 100% of swabs from equine sarcoids, this is only the case in ulcerated 
tumours where the dermis is exposed (Martens et al., 2001). As none of the tumours 
were ulcerated in the present study, the percentage of positive samples was lower and 
in range with the earlier reported positivity rate originating from occult sarcoids 
(Martens et al., 2001). Nevertheless, in the placebo group, a clear and significant 
decrease in the positivity rate could be seen over time, which was not the case for 
acyclovir treated tumours. No plausible explanation could be given for this observation. 
In conclusion, none of the results presented in this study indicate that topical treatment 
of occult or partly verrucous equine sarcoids with acyclovir yields any better results 
compared to treatment with placebo cream.
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Equine sarcoids are among the most common tumours in equids. Nevertheless they 
remain relatively unknown to the wider public and their repercussions on animal value 
and well-being are often underestimated. Because of the complexity of the 
pathogenesis of equine sarcoids, research in this field is difficult and advances at a 
slow rate only. In addition to the research which has been presented in the previous 
chapters of this work, the author had the opportunity to devote a significant amount of 
time to clinical work, treating over 250 equine sarcoid cases. Thanks to this unique 
immersion in all facets of the disease, a broader vision could be developed on what is 
necessary to advance equine sarcoid treatment. Many aspects of this disease remain 
uncertain and these shortcomings in our understanding form important bottlenecks for 
treatment or prevention of these tumours. Clearing all or even some of these 
bottlenecks would increase our knowledge of the disease pathways, and would give 
us new opportunities to interfere with those pathways or even disrupt them. This could 
lead to the discovery of new treatments, aimed directly at one or more aspects of the 
pathogenesis. Therefore, the final chapter of this work will be dedicated to addressing 
these bottlenecks and identifying opportunities for future research. 
Etiopathogenesis and disease transmission 
It is currently widely accepted that the bovine papillomavirus (BPV) is the main 
causative agent in equine sarcoid development (Nasir and Campo, 2008). As a 
consequence, equine sarcoids can be thought of as an infectious disease and some 
key elements are necessary for such a disease to develop. These key elements are 
transmission of the infectious agent and infection of the host, immune evasion, and 
cellular transformation. 
Transmission and infection 
As discussed in chapter 1, it is assumed that BPV infection in equids is abortive and 
the disease cannot spread from equid to equid. While this is still the main belief, 
evidence in favour of infectious virus production in equine sarcoids is accumulating 
and culminates in one electron microscopic picture of something what might be an 
infectious BPV virion in an equine sarcoid (Wilson et al., 2013). In the same publication, 
the authors however state that they do not believe that a substantial amount of 
infectious virus is being produced in equine sarcoids, but that further research, 
especially aimed at occult sarcoids, is needed to support this statement (Wilson et al., 
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2013). Electron microscopy would currently be the most efficient tool for detection of 
infectious virus in equine sarcoids, but since BPV DNA copy numbers in sarcoids can 
be as low as 0.001 copy per cell (Haralambus et al., 2010), there is an urgent need for 
a method to concentrate intact virus in equine sarcoid cell extracts. One way to achieve 
this would be through the use of antibody capture techniques, for example as described 
by Brandt et al. (2008b). During the past years, experiments with a technique involving 
microscopically small magnetic beads (Dynabeads, ThermoFisher) coated with 
antibodies against the capsid L1 protein were carried out at our department 
(unpublished data). The idea is that intact virus is being captured by the antibody 
coated beads, which in turn are concentrated by a magnet. Once suspended in a 
smaller volume, the antibodies can then be dissolved and the beads removed, leaving 
a concentrated virus suspension. While the first results were disappointing because no 
virus could be visualised, this could have been due to the contrast technique for 
electron microscopy. The magnetic bead technique could potentially be explored more 
thoroughly and prove to be an elegant way of achieving higher virus concentrations in 
samples. Combined with the quantitative PCR that was developed for chapters 3 and 
8, the technique could even be proof of presence of capsid associated viral DNA. 
Quantitative PCR could be carried out on paired samples, before and after 
concentration with the magnetic bead protocol. If after the protocol a sample contains 
a higher DNA concentration compared to before, this proves that the sample contains 
DNA in conjunction with viral capsid proteins. Other ways of concentrating virus 
particles in fluids include centrifugal ultrafiltration or polyethylene glycol precipitation, 
but both techniques require a very clean fluid sample free of debris, which is typically 
not the case with tumour samples. 
Regardless of whether equine sarcoids are productive sources of BPV, sudden onsets 
of sarcoid cases have been described in isolated, formerly sarcoid free, populations 
(Nel et al., 2006; van Dyk et al., 2009). This indicates that the virus is being transmitted 
in another way than by direct contact. In chapter 3, it was established that the stable 
fly (Stomoxys calcitrans) can become positive for BPV DNA in controlled conditions 
and the possible role of the stable fly in sarcoid transmission was discussed. There are 
however other insects (for example Haematobia irritans or different tabanid species) 
that are capable of disease transmission and have not been investigated yet. The 
methods established in chapter 3 can easily be adapted to accommodate other vector 
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research. When one or more possible vectors are identified, it will be important to 
define exactly how the disease is being transmitted. It is not because a certain insect 
is capable of becoming positive for BPV DNA that infectious virus will be present and 
that the insect is capable of actually inducing equine sarcoids. The possible advances 
in electron microscopy that were mentioned earlier can assist in identifying infectious 
virus in vectors and transmission experiments will be necessary to establish whether 
a biting vector is needed, or if skin lacerations need to be present in the case of a non-
biting vector. 
Immune evasion and cellular transformation 
The current knowledge on the pathogenesis of equine sarcoids is discussed in chapter 
1. Evasion of the immune system seems to be one of the key factors for the BPV to be 
able to infect and transform cells. A better understanding of the mechanisms involved 
in immune evasion could identify key pathways for the virus to escape the immune 
system and finally result in new ways to prevent equine sarcoid disease by interfering 
with these pathways. The predisposition of sarcoids to develop in horses carrying 
certain alleles of the equine leukocyte antigen (ELA) gene suggests that breeding 
associations could potentially be able to select against sarcoid susceptibility and even 
if heredity of sarcoid susceptibility would be proven to be polygenic this would still 
remain true, as a heritability of 21% on the liability scale has been demonstrated. 
(Christen et al., 2014). 
Transformation of fibroblasts is most likely mainly driven by viral E5 expression as 
discussed in chapter 1. While the effects of E5 expression are well understood in 
bovine epithelial cells, this is not the case in equine fibroblasts and in vitro experiments 
on equine fibroblast cell lines are needed to better understand the effects of E5 on 
cytokine expression and cell growth. Blocking the expression of viral oncogenes by 
using small interfering RNA (SiRNA) could be an innovative way to treat or even 
prevent sarcoid disease, although certain hurdles will need to be taken first (see 
treatment further in this chapter). 
Equine sarcoids are mostly believed to be the result of a localized BPV infection and 
recurrence after treatment is being chalked up to incomplete treatment of the affected 
tissues. If BPV infection occurs through insects as suggested in chapter 3, the 
occurrence of multiple sarcoids can be the result of individual de novo infections at 
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different body sites by the same vector. Another explanation for the fact that horses 
tend to have multiple sarcoids on different body sites is found in the discovery of BPV 
DNA in PBMCs of sarcoid affected horses (Brandt et al., 2008a). This has led some to 
believe that equids go through a viraemic phase before sarcoids develop (Hartl et al., 
2011) or that BPV persists in a latent form in PBMCs. Curiously, only E5 DNA  and no 
L1 DNA could be detected in equine PBMCs, suggesting an altered viral DNA at least 
in equine PBMCs (Brandt et al., 2008a). In cattle, BPV2 has been shown to reside in 
PBMCs as well, and E5 oncoprotein and L1 capsid protein were also detected in bovine 
PBMCs (Roperto et al., 2011). E5 expression was not tested in equine PBMCs and 
doing so could enhance our understanding of BPV infection in horses, as E5 
expression could induce transformation of PBMCs, which in turn could enhance 
immune-evasion by the virus. Using the same protocol as published earlier (Brandt et 
al., 2008a), it was at our facilities not possible to detect BPV DNA in PBMCs of any of 
the 7 sarcoid affected horse that were tested (unpublished data). This could indicate 
that the viraemic phase is short or viral latency in PBMCs does not always occur, which 
in turn could be related to equine immunity and genetics. 
Diagnosis 
In sarcoid research, a correct and reliable diagnosis is paramount: it needs to be 
certain that the lesions under investigation for an experiment actually are equine 
sarcoids. 
Histopathology remains the gold standard for equine sarcoid diagnosis, but even 
histologically, a correct diagnosis is not always easy to make and depends heavily on 
the experience of the pathologist. As discussed in chapter 1, typical histological 
properties of the equine sarcoid include picket-fence formation at the dermo-epidermal 
junction, long rete ridges and a cell-rich dermis of densely stacked fibroblasts in whorls 
or bundles. While these properties are indeed typical for equine sarcoids, they are not 
always present in all cases (Martens et al., 2000) and to make matters even worse, 
extensive ulceration or secondary inflammation in samples can make it even more 
difficult to come to a diagnosis (Wobeser, 2017). Combined with the fact that other 
(neuro)fibromas can closely resemble equine sarcoids both clinically and histologically, 
misdiagnosis is not uncommon, even by experienced pathologists. Therefore, there is 
a need for immunohistological markers that are discriminatory for equine sarcoids. The 
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combination of presence of BPV DNA and absence of S-100 protein in equine sarcoid 
tissue samples has been proposed to discriminate them from schwannomas (Bogaert 
et al., 2011), but further investigation revealed that the combination of these 
characteristics was not enough to positively identify equine sarcoids from other skin 
tumours in the horse (Epperson and Castleman, 2017). Because BPV interferes with 
ELA functionality in the host cells, it can be assumed that antigen presentation at the 
cell surface is limited and the search for specific markers should be aimed at 
intracellular antigens such as the early oncoproteins E5, E6 and E7. P38 is 
overexpressed in equine sarcoid cell lines (Yuan et al., 2011b), as is p53 (Finlay et al., 
2012), but overexpression of these proteins is not very specific for equine sarcoids. 
Recently, the complete transcriptome of equine sarcoid derived fibroblasts has been 
compared to that fibroblasts originating from healthy equine skin and over 900 
transcriptional differences were found (Semik et al., 2017). Perhaps the key to a 
sarcoid specific marker can be found there. 
Taking biopsies of suspected equine sarcoids is associated with risk of sudden growth 
(Scott and Miller, 2011) and it is therefore not always advisable to do so in cases where 
owners are not immediately willing to treat. In sarcoid research, when experimenting 
on clinical cases, a confirmed diagnosis is often needed. However, for reasons 
mentioned above, the act of taking a biopsy can in itself affect the outcome of such 
experiments and obtaining a histological diagnosis is therefore out of the question. For 
those cases, the detection of BPV DNA in superficial swabs (Martens et al., 2001) can 
be an elegant and reliable solution, although BPV DNA has also been detected in 
healthy equine skin (Bogaert et al., 2005) and sarcoid unrelated lesions (Brandt et al., 
2011). Besides, in non-ulcerated occult and nodular sarcoids, detection of BPV in 
superficial swabs is not always possible (Martens et al., 2001). In order to obtain a 
diagnosis for those clinical cases, fine needle aspirates of the lesions can be taken. 
Because equine sarcoids cannot be diagnosed histologically on fine needle aspirates, 
the samples can be analyzed for the presence of BPV DNA by PCR. Fine needle 
aspirates are far less invasive compared to biopsies and therefore, the risk of tumoural 
exacerbation is limited. By this method, 18 histologically confirmed sarcoids were 
positively identified and 9 histologically confirmed non-sarcoids were negatively 
identified (unpublished data). Of course, a higher sample number and more elaborate 
research protocol are needed to validate this diagnostic technique, but these 
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preliminary results are promising. Fine needle aspirates could be useful for diagnosing 
non-ulcerated lesions by PCR and at the same time prevent false positive results from 
non-sarcoid lesions contaminated on the surface by BPV DNA. 
Private practitioners and non-university clinics are not always aware of PCR 
techniques for sarcoid diagnosis, or do not opt for them for logistical reasons and are 
therefore limited to histological examination of the lesion. In cases where taking a 
biopsy is unwanted, there are no further diagnostic tools available and one has to rely 
on the clinical diagnosis. In chapter 4, the ability of veterinary professionals of different 
expertise levels and undergraduate students to correctly diagnose equine sarcoids 
was tested. Clinical diagnosis of equine sarcoids proved to be highly reliable, with an 
overall sensitivity of 83.3% and an overall specificity of 79.6%. Clinical diagnosis by 
equine sarcoid experts yielded an even higher sensitivity and specificity. While 
sensitivity and specificity were also high for other levels of expertise, there was room 
for improvement. Therefore, a tool to aid inexperienced veterinarians with equine 
sarcoid diagnosis was developed and tested. The results described in chapter 5 prove 
that the use of this tool significantly increases the performance of clinical diagnosis, 
especially for the least experienced veterinarians. The tool needs to be developed 
further and tested on more cases, but it has the potential to become a benchmark to 
make clinical diagnosis more objective. This will ultimately lead to clinical diagnosis 
being accepted as a validated diagnostic method in equine sarcoid research, 
especially when the diagnosis was made by veterinarians fulfilling the requirements to 
meet the equine sarcoid expert level, or when less experienced veterinarians use the 
diagnostic protocol, as explained in chapters 4 and 5. 
The current categorisation of equine sarcoids into 5 subtypes (occult, verrucous, 
nodular, fibroblastic and mixed (Pascoe and Knottenbelt, 1999)) is theoretically very 
straightforward, but sometimes difficult to apply on clinical cases. Especially for mixed 
sarcoids, it is not clear in the current nomenclature how the different aspects of the 
sarcoid are proportioned. In addition, most of the sarcoid cases have characteristics of 
more than one sarcoid type. This can lead to confusion when describing cases, both 
in research and in clinical practice. Figure 1 shows an example of such a case where 
categorizing the lesion can be confusing: by strict definition this would be a mixed 
nodular fibroblastic lesion, although the fibroblastic portion is very small and the lesion 
is actually of the nodular type. To streamline clinical descriptions and to avoid 
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confusion in communication on equine sarcoids, it could be helpful to avoid using the 
term “mixed equine sarcoid” altogether and instead to clearly describe the lesion using 
the remaining 4 clinical types. The example in Figure 1 would then be a nodular equine 
sarcoid with local ulceration in an area of 5 by 5 mm. The term “mixed sarcoid” can 
then be reserved for those cases where two or more sarcoid types are present in 
approximately equal proportions in the same lesion. 
 
In order to be able to develop preventive treatments (see treatment later in this 
chapter), researchers and clinicians could benefit from a method for early detection of 
BPV infection, before tumours develop. First steps in this direction have already been 
taken by the discovery of BPV DNA on the normal skin of unaffected horses living in 
contact with cattle or sarcoid affected horses (Bogaert et al., 2005) and in PBMCs of 
sarcoid bearing horses (Brandt et al., 2008a). Nevertheless, the importance of these 
findings and more specifically their role in tumour development are not understood. 
Prospective longitudinal studies focussing on the importance of such findings in 
predicting tumour development will be very difficult, because they imply that a large 
pool of BPV positive and BPV negative horses without lesions will need to be followed 
and screened for lesion development, possibly during multiple years. 
Figure 1 - Describing this lesion according to the classic 
nomenclature can be confusing. 




Treatment options for equine sarcoids are discussed in chapter 1. In chapter 6, a 
methodical approach for treatment selection is proposed and tested. Currently, most -
if not all- available treatments are curative: tumours are treated when they become 
aesthetically or functionally hindering. Ideally, treatments should evolve to become 
more of a preventive nature. As mentioned before, this necessitates a sound method 
to be developed for detection of horses that are at high risk of sarcoid development. 
This could be done on a genetic level, as an association seems to exist between 
sarcoid susceptibility and certain alleles of the ELA and possibly other genes (see 
chapter 1), but also on a molecular level, if the presence of BPV DNA in normal skin 
or PBMCs would prove to have a good predictive value for later sarcoid development. 
Alternatively, a prophylactic vaccine could be developed and administered to all horses 
without knowing if they are or will be susceptible for equine sarcoid disease. The 
current knowledge of the exact pathogenesis and mechanisms for immune-evasion is 
however insufficient to perform research aimed at specific key processes of sarcoid 
development and attempts of developing a prophylactic vaccine by trial and error with 
our current understanding is like playing darts in a dark room. 
Efforts have been made to produce a vaccine based on BPV-1 virus-like particles 
(VLPs) to prevent sarcoid formation (Hainisch et al., 2016). The results look promising 
and are certainly valuable in the greater light of the development of a preventative 
treatment. Nevertheless, the experiment suffers from a circle argument. VLP 
vaccinated horses were challenged with intradermal BPV inoculations, which are 
known to produce nodular lesions similar to equine sarcoids, but they are not actual 
equine sarcoids and disappear over time (Hainisch et al., 2009), likely due to 
spontaneous development of an immune response (Hartl et al., 2011). If we think of 
these artificially induced lesions as being localized BPV infections, not sarcoids, all that 
is achieved by VLP vaccination is that the immune response is being developed before 
intradermal BPV inoculation instead of after. As a logical result, the localized BPV 
infection is being prevented from developing in vaccinated horses, which does not 
necessarily mean that the vaccine is of any use for preventing actual sarcoid 
development. The big culprit here is the absence of a good disease model. There is 
no reliable and repeatable method to induce equine sarcoids in unaffected equids and 
as a result, there is no good way to challenge any preventive treatment, other than to 
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treat a large population and observe it over time for the development of sarcoids. Since 
epidemic outbreaks of sarcoids in isolated populations have been described (Nel et al., 
2006; Abel-Reichwald et al., 2016), preventive treatment of a number of unaffected 
animals in such a population could be a way to test said treatment. Nevertheless, 
research would greatly benefit from the development of a reliable sarcoid model, but 
again the development of this model will be very difficult without fully understanding 
the complete pathogenesis first. 
Until a preventive treatment can be developed, veterinarians are stuck treating the 
symptoms of the disease. The currently best available treatments require surgery, 
which is expensive, unpractical and often implies a risk of anaesthesia and recovery 
(see chapter 6). Therefore, and because the horse can be treated at home, topical 
treatments are popular among horse owners. Topical treatment with acyclovir had the 
potential of becoming popular (Stadler et al., 2011), because it is relatively cheap, easy 
to obtain and use, and free of undesired side effects. Nevertheless, in chapter 7 and 
8, it was proven that treating occult equine sarcoids topically with acyclovir did not lead 
to better results compared to a placebo treatment. Other topical treatments that have 
been described for the treatment of sarcoids (see chapter 1) have painful side effects, 
which are not always well tolerated in horses. Because of the demand for topical 
treatments without adverse effects, the value of other topical agents specifically 
targeting viral processes can be researched, but to date, none exist that target 
papillomaviruses. Potentially, the results of topical treatment with imiquimod could be 
improved by pre-treatment of the skin with a keratolytic cream containing tazarotene 
or salicylic acid. Treatment of equine sarcoids with 5-fluorouracil could be explored.  
Advances in biotechnology have led to the discovery of SiRNA  (Hamilton and 
Baulcombe, 1999; Agrawal et al., 2003). SiRNAs are small pieces of dual strand RNA 
which, once they enter a cell, divide into single strand RNA and form a complex with 
intracellular proteins, keeping them stable. These RNA-protein complexes (called 
RNA-induced silencing complexes) then bind to their complementary messenger RNA 
and inhibit its translation by degrading it. The final result is that expression of a gene 
is inhibited by disruption of the pathway to protein assembly. Artificial SiRNA is now 
widely used in genetic research as a gene silencer, but since this process is very 
specific, it seems to be a good candidate to treat viral diseases with minimal side 
effects to the host cell. In a mouse model for human papillomavirus induced cervical 
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cancer, SiRNAs targeting E6 and E7 successfully reduced tumour volumes (Jonson et 
al., 2008). In vitro experiments have demonstrated that BPV infected equine fibroblasts 
showed a lower viral load, slower and less invasive growth and more apoptosis after 
SiRNA treatment targeting E2, compared to non-treated cell cultures (Gobeil et al., 
2009; Yuan et al., 2010). SiRNAs targeting E6 were even more efficient at inhibiting 
cell proliferation (Yuan et al., 2011). SiRNAs targeting E5 were less efficient (Yuan et 
al., 2011), which is curious, because E5 is believed to be the main oncoprotein driving 
cellular transformation. These results are very promising, both because SiRNA 
targeting of specific BPV proteins can help us to understand the specific functions of 
these proteins and because blocking of key proteins could prevent or even revert 
transformation of the host cell. There are however some difficulties that need to be 
overcome before SiRNA can be applied as a routine in vivo treatment for equine 
sarcoids. Most importantly, the artificial SiRNAs need to be deposited intracellularly. 
This is in vitro most often achieved by a process called transfection, for which the 
SiRNA is bound to a carrier that easily crosses the cell membrane. The in vivo 
efficiency of transfection, however, is low (SABiosciences, 2009). Alternatively, SiRNA 
can be delivered into the cell by electroporation. This has already been applied to 
enhance intracellular delivery of cytotoxic drugs in equine sarcoids (Tamzali et al., 
2012; Souza et al., 2016), but it is difficult to separate the clinical effects of the 
electroporation itself from the effects of the drug being tested. A third way of getting 
SiRNA into a cell is by incorporating it in a viral vector (SABiosciences, 2009). 
Ultimately, this could lead to integration of the precursor of the SiRNA into the host 
genome. By doing so, the host cell would permanently produce the SiRNA and make 
itself resistant against the targeted viral influences. 
Conclusion 
The results of the research presented in this work have added important information to 
our knowledge and understanding of equine sarcoids. In chapter 3, it was 
demonstrated that airborne insects can play a role in BPV transmission. The protocol 
that was established to work with flies under controlled conditions can now easily be 
adapted to other insects and can be used to ultimately perform transmission 
experiments. In chapters 4 and 5, it was established that clinical diagnosis of equine 
sarcoids is reliable, and the foundation for a protocol for clinical sarcoid diagnosis was 
built. This means that clinical diagnosis should now be accepted as a valid tool in 
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experimental research where other diagnostic methods might interfere with the 
outcome. Ultimately, a guideline for equine sarcoid diagnosis will be developed, aiding 
equine practitioners in the decision whether or not to pursue further (invasive) 
diagnostics. The treatment selection protocol proposed in chapter 6 has proven to 
obtain a high overall success rate and can be applied in practice to improve treatment 
outcome and provide a realistic prognosis. In chapters 7 and 8, it was proven that 
topical acyclovir is not more effective to treat sarcoids compared to placebo treatment. 
Therefore, it is not recommended to continue with topical acyclovir treatment of equine 
sarcoids and for occult lesions, imiquimod can be used as a topical alternative. 
In the future, efforts in equine sarcoid research should be aimed at unravelling the 
mysteries surrounding BPV transmission, pathogenesis and immune-evasion as this 
knowledge is the key to all further treatment development. A broader understanding of 
these topics will lead to the prevention of BPV infection and the development of 
treatments specifically aimed at key processes in the transformation of fibroblast cells 
into sarcoid cells. A technique to reliably induce equine sarcoids in healthy animals is 
needed to challenge studies on genetic predisposition and prophylactic vaccine 
development. Finally, the possibilities of novel techniques like SiRNA integration in the 
host genome need to be explored. 
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Equine sarcoids are common tumours of the equine dermis which do not metastasize 
and are no immediate threat to the lives of affected animals. Nevertheless, they are 
often underestimated and can grow into large masses with severe implications for an 
animal’s welfare and value. Because equine sarcoids can have different clinical 
presentations and because there are no specific histological markers, diagnosis is 
often difficult for inexperienced veterinarians. It is now widely accepted that equine 
sarcoids are caused by the bovine papillomavirus (BPV), but the exact mechanisms 
that lead to disease spread, fibroblast infection, cellular transformation and tumour 
development are ill understood. Therefore, it should not come as a surprise that these 
tumours are notoriously difficult to treat. Many treatments have been described, but as 
of today, no universally successful treatment exists and selection of the optimal 
treatment for a given sarcoid is an erratic process. In this work, a research project is 
described, which aims to shed light on different aspects of the disease with the ultimate 
goal of improving clinical management of these tumours. 
In chapter 1, the current knowledge on equine sarcoids is reviewed. The chapter deals 
with the etiopathogenesis, epidemiology and transmission of the disease, as well as 
the clinical presentation, diagnosis and treatment. While certain of these aspects are 
well studied, clinical management of equine sarcoids would greatly benefit from further 
investigation of unexplored facets of the disease. This chapter serves to justify why 
this research project was undertaken and is the foundation for understanding the 
further chapters of this work. 
Chapter 2 describes the main ambitions of this work. The general aim was to improve 
clinical management of equine sarcoids. This was done directly by validating the 
clinical diagnosis of equine sarcoids against histopathology, by developing and testing 
a treatment selection protocol for equine sarcoids, and by formal testing of topical 
sarcoid treatment with acyclovir. The knowledge gained by looking into a theory for 
BPV spread indirectly adds to the general aim by opening the door for disease 
prevention. 
The often insinuated hypothesis that flies act as a vector for BPV transmission to 
equids was tested in chapter 3. The stable fly (Stomoxys calcitrans) was selected 






mouthparts which are ideal for BPV deposition at the level of the dermis. Bovine 
papillomavirus negative stable flies were live caught and exposed to equine sarcoid or 
bovine wart tissue. The BPV viral loads of exposed flies were measured every 24 hours 
by quantitative real-time PCR until 7 days after exposure. Viral loads raised 
significantly immediately after exposure to bovine wart tissue and equine sarcoid 
tissue, but were higher and remained high for a longer time in the latter group. This 
indicates that BPV transmission by Stomoxys calcitrans seems possible and more 
likely occurs from bovines to equids as opposed to between equids. Clinical 
transmission experiments are necessary to establish if transmission of BPV by stable 
flies can indeed cause equine sarcoids in formerly BPV negative horses. 
Histopathological diagnosis of equine sarcoids is not always feasible or wanted, 
because taking a biopsy comes with a risk of lesion exacerbation or because this 
interferes with the results of clinical trials. Clinical diagnosis would be a good 
alternative, but because its reliability has never been tested, it is not recognised as 
valid by the scientific community. This is remediated in chapter 4. Forty cases of 
different equine skin diseases were presented in an online examination to respondents 
of different expertise levels. The cases were carefully selected to realistically represent 
the distribution of equine sarcoids and other skin diseases in the population and 
respondents were asked to clinically diagnose them either as equine sarcoids or as 
not equine sarcoids. Clinical diagnosis of equine sarcoids proved to have a high 
sensitivity and specificity overall (respectively 83.3% and 79.6%) and the mean 
success rate for all respondents was 82.0%. Sensitivity and specificity were 89% and 
86% respectively for equine sarcoid experts, while lesser experienced respondents 
were significantly less able to correctly diagnose equine sarcoids. Clinical diagnosis 
should now be accepted as valid. For inexperienced respondents, there is room for 
improvement. 
To improve the ability of inexperienced respondents to correctly discriminate equine 
sarcoids from other skin lesions, in chapter 5, a diagnostic protocol was developed to 
assist them in making a correct clinical diagnosis. The diagnostic protocol was used 
by inexperienced respondents to diagnose the same 40 cases that were used in 
chapter 4 and their results were compared to the respondents who did not have access 
to the diagnostic protocol. Overall, respondents using the diagnostic protocol were 




protocol. Inexperienced respondents using the protocol scored on par with equine 
sarcoid experts and were more confident of their diagnosis compared to their peers 
who did not use the protocol, proving that the tool is a useful guide to help 
inexperienced veterinarians to correctly diagnose equine sarcoids. 
Equine sarcoids are very heterogeneous in clinical presentation and body location. 
This, combined with the fact that no universally successful treatment exists, makes 
adequate treatment selection for a given sarcoid on a given location difficult. In chapter 
6, a treatment selection protocol is described based on tumour type and location. 
Included treatments were topical administration of acyclovir or imiquimod, non-touch 
electrosurgical excision (with or without intralesional cisplatin), cryosurgery, Bacillus 
Calmette-Guerin vaccine injection, and intralesional injection of platinum-containing 
drugs. The treatment selection protocol was applied to 230 clinical cases (614 
sarcoids) and a follow-up at least 6 months after the last treatment was done. The 
overall success rate using this treatment selection protocol was 74.9%. Electrosurgical 
non-touch excision was performed most frequently and had the highest success rate 
(86.8%). Significantly lower success rates were obtained with topical administration of 
acyclovir, cryosurgery and intralesional application of platinum-containing drugs. When 
a sarcoid was located on a horse with multiple equine sarcoids, chances of success 
were significantly lower compared to when this was not the case. For sarcoids present 
on a horse that concurrently received immunostimulating treatment for another sarcoid, 
chances of successful treatment were significantly higher compared to when this was 
not the case. When a topical treatment was possible, owners could choose between 
acyclovir or imiquimod application. While significance was not reached, better results 
were obtained with imiquimod compared to acyclovir. 
Topical treatment of equine sarcoids with acyclovir has been proposed to achieve good 
results, without the side effects other topical treatments have, in a limited non-
controlled clinical trial. In chapter 7, it was tested in vitro how deep acyclovir penetrates 
into intact normal and sarcoid affected skin. Equine sarcoid skin samples were 
surgically removed and matched with normal equine skin samples, harvested from 
horses that were euthanized for unrelated reasons. After removal of the hypodermis, 
the samples were used in a Franz cell diffusion experiment, where they were exposed 
to a 5% acyclovir cetomacrogol cream on the epidermal side during 48 hours. At set 






performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). 
Afterwards, the skin was frozen and cut in a cryotome. Epidermis, superficial dermis 
and deep dermis were separated and the acyclovir concentration in the tissues was 
measured by UPLC-MS/MS. While acyclovir permeated through both skin types, 
normal skin was significantly more permeable for acyclovir compared to sarcoid 
affected skin. In sarcoid skin, significantly more acyclovir was present in the epidermis 
compared to the superficial dermis and deep dermis, which was not the case in normal 
equine skin. Nevertheless, acyclovir concentrations found in the dermis of sarcoid 
affected skin were still high enough to treat a Herpes simplex virus infection in humans. 
Because the acyclovir concentration which is needed to treat BPV infection in equine 
skin is not known, we can only assume that these concentrations are sufficiently high. 
If the BPV is susceptible for these concentrations, a beneficial effect of topical acyclovir 
application on occult equine sarcoids could be possible. 
In chapter 7 it was demonstrated that acyclovir is able to reach the dermis of equine 
sarcoid affected skin in considerable concentrations after topical application. This does 
however not proof that a beneficial effect can be expected when applied on equine 
sarcoids and in chapter 6, better results were obtained with topical imiquimod 
treatment. In chapter 8, a double blinded placebo controlled experiment was set up to 
test whether treating equine sarcoids topically with acyclovir yielded better results 
compared to a topical placebo treatment. Twenty-four sarcoids on 15 equids were 
treated twice daily topically with a 5% acyclovir cetomacrogol cream and 25 sarcoids 
on 16 equids with a placebo cream. Treatment selection was done randomly and 
treatment continued during 6 months, or until the sarcoid disappeared earlier. Monthly, 
a swab sample and a digital image were taken of the lesion. After completion of the 
study, the swabs were analyzed for presence of BPV DNA by PCR. Three diplomats 
of the European College of Veterinary Surgeons scored the images for sarcoid severity 
on a visual analog scale (VAS). The exact surface and widest diameter of the sarcoids 
were also measured on the images. There was no significant difference in lesion 
surface area, diameter and VAS score between acyclovir and placebo treated lesions 
at any time point, although the severity of the lesion decreased slightly over time for 
both treatment groups. There is no evidence that topical treatment of occult or partly 





In chapter 9, the ideas for the future of equine sarcoid research are presented, based 
on the clinical and scientific experience that was acquired during this project. Key 
topics that need to be better understood in order to develop new strategies to treat or 
even prevent equine sarcoid disease are BPV transmission, immune-evasion and 
sarcoid pathogenesis. The development of a reliable technique to induce equine 
sarcoids in healthy equids is needed to challenge newly developed treatments and 










Equine sarcoïden zijn veel voorkomende tumoren van de dermis van paardachtigen. 
Ze metastaseren niet en vormen geen onmiddellijke bedreiging voor het leven van 
aangetaste dieren. Ze kunnen echter wel uitgroeien tot grote massa’s die het 
dierenwelzijn en de waarde van het dier aantasten en worden daarom dikwijls 
onderschat in een vroeg stadium. Er bestaan verschillende vormen van equine sarcoïd 
met een verschillend klinisch uiterlijk. Daarom en omwille van het feit dat er geen 
histologische markers bestaan voor de aandoening is de diagnose voor onervaren 
dierenartsen vaak moeilijk te stellen. Het wordt momenteel aangenomen dat het 
boviene papillomavirus (BPV) een belangrijke rol speelt in het ontstaan van equine 
sarcoïden, maar de exacte mechanismen die leiden tot het verspreiden van het virus, 
infectie en transformatie van de fibroblasten van de dermis en verdere 
tumorontwikkeling zijn niet gekend. Het mag daarom geen verrassing zijn dat deze 
tumoren vaak erg moeilijk te behandelen zijn. Heel wat behandelingen zijn 
beschreven, maar tot op vandaag bestaat er geen behandeling die universeel met 
succes kan toegepast worden, en de keuze van de beste behandeling voor een 
bepaald sarcoïd is een proces dat dikwijls met tegenslag te kampen heeft. In dit werk 
wordt een onderzoeksproject beschreven waarin verschillende aspecten van deze 
aandoening verder uitgediept worden, met als uiteindelijk doel het klinisch 
management van de tumoren te verbeteren. 
In hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis van het equine 
sarcoïd. Er wordt dieper ingegaan op de etiopathogenese, epidemiologie en 
transmissie van de aandoening, evenals de klinische vormen, diagnose en 
behandeling. Sommige van deze aspecten zijn goed gekend, maar er rest nog heel 
wat onontgonnen gebied waar meer inzicht zou kunnen leiden tot het ontstaan van een 
betere klinische benadering. Dit eerste hoofdstuk verantwoordt waarom dit 
onderzoeksproject werd uitgevoerd en vormt de basis om de volgende hoofdstukken 
te begrijpen. 
Hoofdstuk 2 beschrijft de voornaamste ambities van dit werk. In de eerste plaats was 
het doel om het klinisch management van equine sarcoïden te verbeteren. Dit werd 
mogelijk door dieper in te gaan op de validatie van de klinische diagnose, door het 





sarcoïden en door het formeel onderzoeken van de topicale behandeling van de tumor 
met acyclovir. Het nader onderzoeken van een theorie voor het verspreiden van BPV 
droeg indirect bij aan het hoofddoel, door de deur voor preventie van de aandoening 
op een kier te zetten. 
De hypothese dat vliegen verantwoordelijk zouden zijn voor de overdracht van BPV 
werd getest in hoofdstuk 3. De stalvlieg (Stomoxys calcitrans) werd geselecteerd voor 
dit onderzoek omdat ze frequent voorkomt in de buurt van zowel paardachtigen als 
runderen en omwille van haar bijtende monddelen, die ideaal zijn om het virus te 
deponeren ter hoogte van de dermis. Stalvliegen negatief voor de aanwezigheid van 
BPV werden levend gevangen en blootgesteld aan weefsel afkomstig van equine 
sarcoïd of runderpapilloma. De virale BPV load van deze blootgestelde vliegen werd 
elke 24 uur gemeten door quantitatieve real-time PCR tot 7 dagen na de blootstelling. 
De BPV load steeg significant onmiddellijk na blootstelling aan weefsel afkomstig van 
sarcoïd en runderpapilloma, maar was hoger en bleef langer hoog na blootstelling aan 
die laatste. Dit wijst erop dat BPV overdracht door Stomoxys calcitrans mogelijk zou 
kunnen zijn en wellicht plaatsvindt van rund naar paard en niet tussen paarden. 
Verdere klinische transmissie-experimenten zijn nodig om vast te stellen of BPV 
overdracht via de stalvlieg ook echt kan leiden tot het ontstaan van equine sarcoïden 
bij BPV negatieve paarden. 
Omdat het nemen van een biopt gepaard gaat met een risico op plotse tumorale groei 
of een invloed kan hebben op de uitkomst van een experiment, is histologische 
diagnose van equine sarcoïden is niet altijd haalbaar of wenselijk. Klinische diagnose 
zou een goed alternatief kunnen zijn, maar is momenteel niet gevalideerd en wordt 
daarom niet aanvaard in de wetenschappelijke literatuur. In hoofdstuk 4 wordt de 
validatie van de klinische diagnose beschreven. Veertig gevallen van verschillende 
huidaandoeningen bij het paard werden in een online test beoordeeld door 
respondenten met verschillende expertiseniveaus. De gevallen werden zorgvuldig 
geselecteerd om een realistische steekproef te vormen van de prevalentie van equine 
sarcoïd in de populatie. Aan de deelnemers werd gevraagd om de aandoeningen te 
categoriseren als equine sarcoïd of geen equine sarcoïd. De klinische diagnose van 
de aandoening had een hoge algemene sensitiviteit en specificiteit (respectievelijk 
83.3% en 79.6%) en het percentage correcte diagnoses was 82.0%. Sensitiviteit en 




sarcoïd, terwijl minder ervaren deelnemers significant minder goed waren in het correct 
discrimineren van equine sarcoïden. De klinische diagnose van deze aandoening kan 
nu als volwaardig aanvaard worden, al is er voor onervaren respondenten nog ruimte 
voor verbetering. 
Om het klinisch herkennen van equine sarcoïden door onervaren personen te 
verbeteren wordt in hoofdstuk 5 een diagnostisch protocol voorgesteld en getest. Het 
protocol werd gebruikt door onervaren deelnemers om dezelfde 40 gevallen te 
beoordelen die in hoofdstuk 4 gebruikt werden en hun resultaten werden vergeleken 
met deze van de deelnemers die geen gebruik konden maken van het protocol. 
Deelnemers die over het protocol beschikten waren significant beter in het 
onderscheiden van equine sarcoïden in vergelijking met deelnemers die het protocol 
niet gebruikten. Onervaren deelnemers die het protocol gebruikten scoorden even 
goed als experten op het gebied van equine sarcoïden en waren ook zekerder van hun 
diagnose in vergelijking met onervaren deelnemers zonder protocol. Dit bewijst dat het 
protocol een goede hulp kan zijn voor de correcte klinische diagnose van een equine 
sarcoïd. 
Sarcoïden zijn erg heterogeen qua klinische presentatie en locatie op het lichaam. 
Omdat er daarenboven geen universele behandeling bestaat is het moeilijk een goede 
behandeling te kiezen voor een bepaald sarcoïd op een bepaalde lichaamslocatie. In 
hoofdstuk 6 wordt een protocol voorgesteld om op basis van het klinisch uiterlijk van 
de tumor en de locatie op het lichaam een behandeling te selecteren. De 
behandelingen die in het protocol werden opgenomen zijn topicale toediening van 
acyclovir of imiquimod, non-touch electrochirurgische excisie (al dan niet met 
intralesionaal gebruik van cisplatine), cryochirurgie, Bacillus Calmette-Guerin vaccin 
injectie en intralesionale injectie van chemotherapeutica op basis van platinum. Het 
selectieprotocol werd toegepast op 230 paarden met in totaal 614 sarcoïden en een 
follow-up werd uitgevoerd ten vroegste 6 maand na het uitvoeren van de laatste 
behandeling. Het slaagpercentage bij gebruik van het protocol was 74.9%. Non-touch 
electrochirurgische excisie had het hoogste slaagpercentage (86.8%). Significant 
lagere slaagpercentages werden bekomen met topicaal gebruik van acyclovir, 
cryochirurgie en intralesionale injectie van chemotherapeutica op basis van platinum. 
Wanneer een sarcoïd gelegen was op een paard dat nog andere sarcoïden had was 





sarcoïd behandeld werd op een paard dat tegelijk voor een ander sarcoïd behandeld 
werd met een immunostimulerende behandeling waren de slaagkansen significant 
hoger dan wanneer dit niet het geval was. Wanneer een topicale behandeling mogelijk 
was kregen de eigenaars de keuze tussen acyclovir of imiquimod. Hoewel niet 
significant werden betere resultaten bekomen met gebruik van imiquimod. 
Topicale behandeling van equine sarcoïden met acyclovir werd eerder beschreven in 
een beperkt, niet gecontroleerd klinisch experiment. Er werd een goed resultaat 
gerapporteerd zonder de ernstige bijwerkingen die andere topicale behandelingen 
hebben. In hoofdstuk 7 werd in vitro getest hoe diep acyclovir kan penetreren in 
normale paardenhuid en paardenhuid aangetast door sarcoïd. Equine sarcoïden 
werden chirurgisch geëxciseerd en normale huid van dezelfde lichaamslocatie werd 
bekomen van paarden die geëuthanaseerd werden omwille van losstaande redenen. 
Nadat de hypodermis verwijderd werd, werden de stalen gebruikt in een experiment 
met Franz diffusie cellen waarin ze aan epidermale zijde gedurende 48 uur werden 
blootgesteld aan een 5% acyclovir cetomacrogolcrème. Op verschillende tijdstippen 
werd de acyclovir concentratie van het receptormedium bepaald door middel van ultra-
performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Na 
afloop van het experiment werd de huid bevroren, gesneden in een cryotoom en 
verdeeld in epidermis, oppervlakkige dermis en diepe dermis. De weefselconcentratie 
van acyclovir werd ook in deze stalen bepaald door UPLC-MS/MS. Acyclovir werd 
teruggevonden in het receptormedium van zowel gezonde als aangetaste huid, maar 
in significant hogere concentraties bij gezonde huid. In de huid zelf werd meer acyclovir 
teruggevonden in de epidermis van sarcoid aangetaste huid dan in de oppervlakkige 
en diepe dermis. Dit was niet het geval bij normale huid. Desalniettemin waren de 
teruggevonden acyclovir concentraties in de diepe dermis van aangetaste huid nog 
voldoende hoog om een Herpes simplex virus infectie te bestrijden bij de mens. 
Aangezien de nodige acyclovir concentratie om BPV infectie te bestrijden niet gekend 
is kunnen we enkel veronderstellen dat de teruggevonden concentratie voldoende 
hoog is om equine sarcoïden te behandelen. Indien het BPV gevoelig is voor deze 
concentratie zou een gunstig effect van acyclovirbehandeling van equine sarcoïden 
mogelijk kunnen zijn. 
In hoofdstuk 7 werd aangetoond dat acyclovir na topicale toediening een aanzienlijke 




nog geen bewijs dat een gunstig effect op equine sarcoïden kan bekomen worden en 
in hoofdstuk 6 werden betere resultaten bekomen met topicale imiquimod behandeling.  
In hoofdstuk 8 wordt een dubbel blind, placebo gecontroleerd klinisch experiment 
beschreven om na te gaan of topicale behandeling van equine sarcoïden met acyclovir 
betere resultaten oplevert in vergelijking met een placebo. Vierentwintig sarcoïden op 
15 paardachtigen werden 2 keer per dag topicaal behandeld met een 5% acyclovir 
cetomacrogolcrème en 25 sarcoïden op 16 paardachtigen met een placebo. De 
selectie van behandeling gebeurde willekeurig en de behandeling werd voortgezet 
gedurende 6 maanden of tot wanneer het sarcoïd verdwenen was indien dit voor het 
einde van de behandelingsperiode gebeurde. Maandelijks werd een swab genomen 
en werden digitale foto’s van het letsel gemaakt. Nadat de studie afgelopen was 
werden de swabs geanalyseerd voor het voorkomen van BPV DNA door middel van 
PCR. Drie gediplomeerde leden van het European College of Veterinary Surgeons 
beoordeelden de foto’s op hoe uitgesproken het letsel was op een visueel analoge 
schaal (VAS). De oppervlakte en grootste diameter van de letsels werden ook gemeten 
op de foto’s. Op geen enkel tijdpunt was er een significant verschil in een van de 
gemeten parameters (oppervlakte, diameter en VAS score) tussen de behandelingen, 
hoewel de letsels voor beide behandelingen wel minder uitgesproken werden 
naarmate de behandelingstijd vorderde. Er kon geen enkel bewijs gevonden worden 
dat het topicaal behandelen van equine sarcoïden met acyclovir betere resultaten zou 
opleveren dan een placebobehandeling. 
In hoofdstuk 9 worden ideeën besproken voor toekomstig onderzoek naar het equine 
sarcoïd, gebaseerd op de klinische en wetenschappelijke ervaring die opgedaan werd 
tijdens dit project. De belangrijkste domeinen waarbinnen meer inzicht zal leiden tot 
het verbeteren van behandeling en preventie zijn BPV transmissie, evasie van het 
immuunsysteem en pathogenese van het sarcoïd. Daarenboven is het noodzakelijk 
een betrouwbare techniek te ontwikkelen om equine sarcoïden te induceren bij 
paardachtigen zodat nieuwe behandelingen getest kunnen worden en inzicht 
verworven kan worden in de invloed van paard-specifieke genetische parameters op 
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